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Abstract 
A major challenge in tissue engineering is overcoming the low diffusion limit of oxygen 
and nutrients in engineered tissue such as cardiac patches. In this study, the design team aimed to 
design and develop microengineered vasculature within a fibrin hydrogel capable of being 
perfused to maintain the viability of seeded C2C12 cells. A novel microengineered vascular 
network with tunable dimensions was created using a gelatin sacrificial mold that was 
continuously perfused at physiologic flow rates for up to twenty-four hours. Additionally, a 
bioreactor system with a custom microfluidic chamber was developed to provide perfused 
culture conditions and allow the study of small molecule diffusion and the interactions between 
microvasculature and adjacent tissue constructs. The system maintained cell viability and 
morphology of cells seeded on top of the perfused fibrin hydrogel for twenty-two hours at least 
1200 μm from the edge of the perfused channel. This project suggests that microvascular 
networks formed using gelatin sacrificial molds and cultured in a custom microfluidic chamber 
have the potential to be used in the formation and culture of a tissue engineered cardiac patch.  
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Chapter 1: Introduction 
In the United States alone, approximately 610,000 people die every year due to heart 
disease, making it the leading cause of death for both men and women (CDC, 2015). Forms of 
heart disease include arrhythmia, congestive heart failure, and myocardial infarction. Annually, 
approximately 735,000 Americans suffer a myocardial infarction, commonly known as a heart 
attack (Mozaffarian et al., 2014). During such an event, the cardiac muscle stops receiving 
oxygen and nutrients due to a blockage in an artery. If blood flow is not restored quickly, a 
section of the heart tissue begins to die. Possible causes of a blockage in the coronary artery are 
an embolism or coronary heart disease, both of which cause blockages. Such a blockage in the 
coronary artery can cause a myocardial infarction (Vlaar, 2008). 
The main goals of immediate treatments are to restore blood flow to the damaged area, to 
minimize the damage on the myocardium, and reduce the risk of having another myocardial 
infarction. Unfortunately, the current methods do not regenerate the patient's tissue or regain 
functionality of the starved myocardium. After a myocardial infarction, the myocardium is 
replaced by scar tissue and no myocardial regeneration occurs (Poss, Wilson, & Keating, 2002). 
Currently, the only long term treatments for myocardial infarctions are whole heart transplants. 
However, this procedure has associated risks which include failure of the donor heart, 
complications from medication, infection and negative immune response (Lindenfeld et. al, 
2004). During the transplant operation, patients are given immunosuppressant drugs that reduce 
the activity of the immune system. This leaves the body prone to disease, cancer, other 
malignancies, and infection (Lindenfeld et al., 2004). Because the proposed methods do not 
restore the patient's heart functionality, a method of regenerating the patient's native tissue must 
be developed.  
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Researchers have begun to develop methods aimed at regenerating damaged myocardial 
tissue. Scientists have been researching and testing the use of cells on a scaffold to grow tissue 
patches. In humans, the size needed to repair an average myocardial infarction is at least one cm 
thick. However, oxygen and nutrients can only diffuse about 200 μm (Carmeliet & Jain, 2000; 
Novosel, Kleinhans, & Kluger, 2011). These issues have sparked a need for engineers to develop 
a microvascular layer of myocardial tissue which can be incorporated into a larger cardiac patch 
in order to replace all the damaged tissue. The vascular layer is needed to provide nutrients to a 
thick layer of tissue or many layers of stacked tissue. The patch could be used to replace the scar 
tissue formed after a myocardial infarction and regenerate the structure and functionality of 
cardiac tissue at the site of injury. The vascularization of the patch would promote angiogenesis 
and assist with the integration of the construct into the surrounding native tissue.  
The need for tissue regeneration to restore damaged tissues can only be accomplished 
with the use of bioreactors. They are research and development tools that allow the study of 
interactions between all components within the system. Bioreactors facilitate the growth of cells 
and tissue constructs for biological applications that may be clinically effective and safe while 
maintaining tissue viability in addition to culturing cells for months through continuous 
perfusion of fresh medium. The bioreactor must maintain an environment with very specific 
parameters that promote the growth of tissue. These parameters include flow rate, temperature, 
sterility, and specific sizing that accommodates the needs of the client. The ultimate goal is that 
bioreactors can contain scaffolds within them and can monitor and control the conditions of the 
tissue to ensure they are suitable for long term implantation with minimal rejections.  
For the completion of the Major Qualifying Project (MQP) at Worcester Polytechnic 
Institute (WPI), the team was tasked with creating a perfusion bioreactor and a microvascular 
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network within a hydrogel. After interviewing clients Dr. George Pins, Megan O’Brien, and 
Meagan Carnes, specific needs and constraints were identified and the team began working 
towards completing the desired objectives and functions. The construct had to maintain cells in a 
layer with dimensions of 1 cm wide by 1 cm long by 300 µm thick for up to three weeks in vitro 
in addition to supporting a layer composed of fibrin threads and cardiomyocytes. The bioreactor 
needed to allow for viewing the sample at all times in addition to maintaining a sterile 
environment and continuous perfusion throughout the system.  
To ensure the completion of this project, a project strategy was created with detailed 
milestones and deadlines. The first step of the project strategy was to design and develop a 
bioreactor. Research was conducted, design ideas were brainstormed, suitable materials were 
explored, computer-aided design (CAD) designs were fabricated, and feasibility testing was 
conducted. Next, methods to create a single channel microvascular system were explored and 
tested to ensure that they were reproducible in addition to methods for creating bifurcations 
within the hydrogel. Continuous perfusion was accomplished first through the use of a peristaltic 
pump and then improved with the use of a syringe pump. Diffusion rates within the 
microvascular network were characterized through biochemical and biological assays and 
compared with physiologically relevant values. Next, a cell viability assay was developed and 
performed to test the survival of cells on top of the microvascular layer.  
The first step in the project strategy was to select a method to fabricate the proposed 
microvascular network with physiologically relevant dimensions. To create microengineered 
vasculature with sizes on the order of arterioles, the final method selected for this was using a 
gelatin hydrogel as a sacrificial material. This method employed gelatin molds as temporary 
molds, which were cast into fibrin gels, then melted and flushed out. This left behind an empty 
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network of channels matching the initial mold geometry. Once a microvascular network 
fabrication method was selected, the team moved onto designing a bioreactor and a microfluidic 
chamber, which would assist in the microvascularization formation and hold the developed tissue 
construct. In order to meet the clients’ and users’ requirements for the functions of the 
bioreactor, the team selected a syringe pump to achieve physiologically relevant flow rates that 
match those of arterioles in vivo. The team then moved to design a microfluidic chamber, which 
would be compatible with the microvascular network fabrication method, while allowing for 
imaging, sustaining a cell culture over an extended period of time, and maintaining a sterile 
environment.  
In order to quantify the success of the selected final design the team performed three 
main validations. The first test was establishing continuous perfusion through the fabricated 
microvascular network. The second was to study the diffusion of nutrients and metabolites 
through the gel construct. The third validation was to determine the microvascular and bioreactor 
system’s ability to sustain cell viability. Each one of these major validation steps study the 
efficiency of a number of elements of the final design. The purpose of these assays and 
experiments was to determine the feasibility of applying the microvascular network and 
bioreactor system to assist in the fabrication of a multilayered cardiac patch. 
In the following chapters, the team summarizes past research in the field of tissue 
engineered vasculature and bioreactor systems from available literature, describes the project 
approach with goals and objectives set by the clients, and proposes a functional final design 
select from various alternatives. 
The team developed a protocol for creating a microvascular network that mimics native 
blood vessel size and designed a bioreactor system to sustain cell viability in a 3D gel construct. 
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This 3D cell culture creates an environment that more closely resembles that in vivo than a 2D 
cell culture and would allow for improved study of cell interactions. In this project, the focus was 
to create a microvascular network specifically for a fibrin cardiac patch. However, the 
fabrication approach could be adjusted and reapplied to vascular network fabrication for other 
organs as well.  
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Chapter 2: Literature Review 
Chapter 2: Literature Review provides an overview of heart disease, including its 
associated types and current treatments. With an understanding of the current treatments, the 
need for a vascularized cardiac tissue replacement construct becomes clear. This chapter reviews 
current strategies within cardiac tissue engineering and microvasculature fabrication as well as 
the advantages and disadvantages to current approaches. It provides the necessary background 
for the development of a microvascular network and the need for an endothelial layer. Lastly this 
chapter defines bioreactors, explains the need for them, and what can be found on the market. 
2.1 Heart Disease 
Heart disease is the leading cause of death in the United States. Each year, about 610,000 
people succumb to the illness, making up 25% of all deaths in the United States (Lloyd-Jones, 
2010). Heart disease includes arrhythmia, congestive heart failure, and myocardial infarction. 
Myocardial infarction, also known as a heart attack, is the most common form of heart disease. 
(Lloyd-Jones, 2010).  
2.1.1 Myocardial Infarction 
Myocardial infarctions occur when the flow of blood to the heart suddenly becomes 
blocked. Coronary arteries deliver oxygenated blood to the heart muscles and if one of these 
arteries become blocked, the corresponding portion of the heart is deprived of oxygen. If the 
muscle is starved for too long due to the high metabolic demand, myocardial infarction occurs, 
which is death of heart muscle. The major cause of myocardial infarctions are blood clots, also 
known as thrombi. Over time, the arteries can narrow from a buildup of plaque. When the plaque 
in arteries rupture, the inflammatory response creates a blood clot which can partially or 
completely block flow of blood through the coronary artery (Figure 1).  
25 
 
Figure 1: Heart with arterial plaque build-up. (A) Shows the dead heart muscle (darker area) caused by a blockage 
(highlighted area) in the coronary artery. (B) A cross-sectional image of a coronary artery showing a blood clot caused by 
plaque buildup (White & Chew, 2013). 
The severity of a myocardial infarction is judged by the volume of heart muscle 
damaged, known as the infarct size. In Figure 1 above, the infarct is labeled as the ‘dead heart 
muscle’. An average infarct size is about 8 cm3, which is approximately 12% of the left ventricle 
muscle (Kawel et al., 2013, Miller et al., 1995). Depending on the infarct size and the condition 
of the patient, different treatments might be suggested by the doctor (Zafari, 2015). The most 
common medical treatments are percutaneous coronary intervention and coronary artery bypass. 
These treatments aim to restore the blood flow to the damaged heart section. This enables the 
tissue to regain some structural morphology, but not functionally, since it only reforms as scar 
tissue. This creates the need to develop a treatment that addresses the restoration of myocardium 
function. Current treatments only recover blood flow to the damaged areas created by the 
infarction and prevent recurrent myocardial infarctions from happening. The reduction in the 
myocardial function, however, leads to further complication to the patient’s health. 
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2.1.2 Current Treatments 
Currently, immediate treatments for a myocardial infarction include clot-busting 
medications and percutaneous coronary intervention (PCI). These are immediate treatments 
because their purpose is only to reestablish blood flow to the heart. Long-term treatments are 
coronary artery bypass surgery and whole heart transplant. The goals of these treatments are to 
prevent the occurrence of another myocardial infarction. Except for whole heart transplant, none 
of the other three treatments address the reduction in functionality of the damaged heart region 
(Bauer et al., 2006). 
Clot busting drugs have been approved to treat coronary artery blockages and limit the 
damage by breaking up and dissolving clots in the arteries that have restricted the blood flow to 
the heart. The most prevalent risk is excessive bleeding which can lead to death, since the clot 
busting drugs also act as blood thinners (Antman, 2011). Percutaneous Coronary Intervention 
(PCI) is a minimally invasive procedure that uses a catheter to place a stent into a blocked blood 
vessel and widen it creating a passage. Fifteen to forty percent of the time following surgery, the 
body considers the stent to be a foreign object, causing an inflammatory reaction and resulting in 
restenosis of the artery, possibly leading to another heart attack (Sakr, 2015). 
Bypass surgery is performed by taking a section of a blood vessel, typically from the leg 
or chest, to graft around the affected artery, bypassing the clot. This lowers the chance of having 
recurring heart attacks by improving blood flow. Limitations include stroke, excessive bleeding, 
infection, and death (Serruys et al., 2009). A heart transplant is the only method that replaces 
damaged and diseased heart muscle and is only used when all other treatments have failed. There 
are many complications and risks associated with this procedure which include a long waitlist, 
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infection, organ rejection, immunosuppressive medication response, long recovery period, and 
high cost (Lindenfeld et al., 2004). 
Most of the treatments currently available do not repair damaged heart muscle or recover 
functionality. In addition, they have significant drawbacks. Whole heart transplant is not a 
reliable treatment due to the extremely long wait list. As such, there is a need for an off-the-shelf 
treatment to restore functionality which addresses these challenges. The most promising 
approach is through cardiac tissue engineering applications that have the ability to replace and 
regenerate damaged heart muscle, restoring the myocardium function while being readily 
available. 
2.2 Cardiac Tissue Engineering 
The purpose of cardiac tissue engineering is to create and develop a viable and efficient 
approach to treating heart failure. The field addresses the need through the de novo fabrication of 
implantable biocompatible scaffolds with cardiomyocytes and a functional vasculature, which 
can metabolically support the construct. 
2.2.1 Clinical Need 
The limited ability of cardiac muscle to regenerate after a myocardial infarction and the 
difficulty to find heart donors clearly suggests a need for new methods of restoring the damaged 
myocardium (Emmert, 2013). Cardiac tissue engineering is a field of engineering that has been 
heavily researched in recent years, specifically focusing on creating biocompatible scaffolds, 
finding abundant sources of cardiomyocytes, and fabricating functional microvascular systems 
(Dilley, 2014). None of the current treatments regenerate the damaged myocardium. As 
mentioned in Section 2.1.2 Current Treatments, whole heart transplant is the only treatment that 
can restore functionality; the process for this treatment, however, is difficult due to the long wait 
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list, risk of rejection, and complications following the initial procedure. Cardiac tissue 
engineering is a favorable alternative to current treatments; as such constructs would be more 
readily available, have minimal chance of rejection, and could potentially restore the structure 
and functionality of the patient’s damaged tissue (Radisic, 2013).  
2.2.2 Current Approaches 
Within the field of cardiac tissue regeneration there are a few different approaches. Cell 
therapy, in which cells are injected into the damaged site of the heart, is a possible option. 
Studies done in the field have shown minimal functional improvement with little to no 
phenotypic differentiation into myocardial cell lines. Researchers have attributed this to the poor 
targeting and survival rate of the injected cells (Emmert, 2013; Dilley, 2014). Implantable 3D 
scaffolds have shown more promising results, so the majority of current research in the field 
focuses on studying possible materials for the construct fabrication, cardiomyocyte sourcing, and 
microvasculature fabrication (Dilley, 2014).  
Currently there are two main approaches to introducing the scaffold to the damaged 
cardiac tissue for therapeutic use. The first is injectable hydrogel constructs. This approach 
allows for the materials to be introduced through a catheter and the 3D system to be built in vivo. 
This removes the need for surgery and general anesthesia (Radistic, 2013). The drawback of this 
approach is that there is no control over the cell and biomaterial organization, which has a 
significant effect on the tissue properties and function.  
The second approach is to fabricate the scaffold in vitro and implant it at a later time. 
This requires an invasive surgical procedure, as the 3D construct needs to be placed on the heart. 
This approach to cardiac tissue engineering gives the researcher a greater variety of possible base 
materials and cells to use for scaffold fabrication. Researchers have used alginate, collagen, and 
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fibrin hydrogel scaffolds as the base material to support the seeded cardiomyocytes. (Emmert, 
2013). Along with more freedom to choose different combinations, the in vitro scaffold 
fabrication approach allows for more control over the structure and properties of the scaffold and 
seeded cells, which can potentially improve the material’s regenerative capabilities. This 
approach, however, also requires a bioreactor system to sustain and grow the tissue construct in 
vitro (Emmert, 2013).  
2.2.3 Limitations 
Although there are many advantages to various myocardial tissue engineering 
approaches, some limitations exist. Use of a hydrogel scaffold ensures that the desired cells reach 
the infarct area in addition to providing support mechanically. A disadvantage includes that the 
implantation procedure would be invasive and requires open chest surgery. A significant amount 
of research must be done to ensure the most appropriate cell type and biomaterial is chosen, in 
order to match the chemical and mechanical properties of the native tissue. Another major 
limitation is the perfusion and diffusion of nutrients through the 3D construct’s microvascular 
networks, a vital part of maintaining life of any tissue (Ikada, 2006). 
There have been major advances in the field of cardiac tissue engineering over the past 
ten years. These advances have been made in the fields of cardiac cell biology, stem cell, and 
biomaterials. The main reason tissue engineering in this field has not been able to advance as 
rapidly is due to the current vascularization techniques, which have lagged behind significantly. 
Due to the current vascularization methods and the diffusion limit of oxygen, which is 
approximately 200 μm, there is a limit on the volume of tissue created in vitro. This makes it 
challenging to apply the advances of cardiac tissue engineering into scaffolds of clinically 
relevant sizes (Dilley, 2014; Novosel, Kleinhans, & Kluger, 2011).  
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2.2.4 Cardiac Tissue Engineering in Pins Lab 
In order to overcome the current challenge microvascularization is presenting, Pins Lab is 
designing a novel fabrication method for cardiac tissue constructs that allow for myocardial 
regeneration. The approach involves a layer-by-layer fabrication process. By alternating 
myocardial tissue layers, approximately 300 μm, with microvascular network layers, 
theoretically, a patch of clinically relevant thickness, approximately 1 cm, can be created.  
The layer-by-layer approach allows for precision and accuracy in the fabrication of each 
layer, as well as for multi-functionality incorporation. Pins Lab has identified the microvascular 
network and the myocardial layers as critical for a functional cardiac tissue patch (Bornstein, 
Gagnon, Moutinho, & Reyer, 2015). The myocardial layer is loaded with fibrin microthreads and 
seeded with cardiomyocytes. This layer provides the contractile functionality and the mechanical 
support of the cardiac patch. The microvascular network layer, on the other hand, provides the 
nutrients and gasses necessary for the metabolic function of a whole patch. 
This MQP focuses on developing a functional microvascular layer and creating a 
bioreactor to maintain whole tissue constructs. The microvascular network layer and bioreactor 
designs would play a vital role in the development and sustainability of a finalized cardiac patch 
with a clinically relevant size. 
2.3 Vascular Tissue Engineering 
2.3.1 Need for Vascular Engineering 
Vascularization is required for the delivery of oxygen, nutrients, and clinically, the 
delivery of drugs, as well as the removal of carbon dioxide and other waste products as depicted 
in Figure 2. One cause of the low amount of clinical applications is the diffusion limit of oxygen 
and nutrients through the bulk of a material (Rouwkema, Rivron, & Van Blitterswijk, 2008). The 
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diffusion limit of oxygen is 200 μm and due to this reason, mammalian cells are typically located 
within 200 μm of blood vessels in vivo (Carmeliet & Jain, 2000; Novosel, Kleinhans, & Kluger, 
2011). As a result, the size of engineered tissue is limited to approximately 400 μm. Without a 
method to provide cells with the required oxygen and nutrients past 200 μm, there is a need to 
research the creation of microvascular networks within 3D tissue constructs (Laschke et al., 
2006). For tissues to be created of clinically relevant sizes, vascularization must be achieved. 
 
Figure 2: Schematic description of diffusion and transport processes in vascularized tissues in vivo (Novosel, Kleinhans, 
& Kluger, 2011) 
The need for vascularization in engineered cardiac tissue is particularly strong as seen 
with the highest ratio of blood vessels to cells and due to the high metabolic demands of heart 
tissue (Post, Rahimi, & Caolo, 2013). It has been found that the physiological density of cells in 
engineered cardiac tissue can only survive 128 μm from a static oxygen source and that media 
flow significantly increased oxygen concentration within the tissue engineered construct (Radisic 
et al, 2006). 
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2.3.2 Microvasculature Design Parameters 
When designing a microvascular network there are many parameters that must be 
assessed. Studies have shown channels ranging from 10 µm to 1000 µm in diameter using 
different methods (Bertassoni et al., 2014). Most channels however, were not endothelialized. 
Endothelialized channels, although more accurately depict in vivo condition, proved more 
difficult to produce at small diameters in recent studies. The most successfully endothelialized 
channels were 250 µm, 500 µm and 1000 µm. The studies with the smaller diameter channels 
encountered issues when perfusing because the needles used were difficult to insert correctly into 
the channels to facilitate flow (Bertassoni et al., 2014).  
Among the different size of channels there are a few different geometries that have been 
tested. As previously stated, studies using photolithography mostly fabricated rectangular 
channels. These rectangular channels were endothelialized with some difficulty. The corners of 
the channels produce flow stagnation which lowers the shear stress acting on the endothelial 
cells, which prevents them from adhering and producing extracellular matrix (ECM) proteins 
(Abdelgawad et al., 2011). Studies have used sacrificial layers, such as gelatin, to create rounded 
channels with diameters as small as six micrometers. Even though these channels were not 
endothelialized they still demonstrated a more physiologically relevant shape than the square 
channels (Golden & Tien, 2007).  
Once channels are formed in hydrogels perfusion can then be performed. The most 
common method is continuous perfusion (Dagenais, Rousselle, Pollack, & Scherrmann, 1999). 
Two metrics used to characterize perfusion are volumetric flow rate as well as pressure drops 
across a vascular network. The normal pressure of capillaries in the body between 10.5 and 22.5 
mmHg (Shore, 2000). In order to characterize the transport rates of perfusate through a hydrogel 
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using channels, a study was conducted in 2007 using a variety of pressures and flow rates. The 
first rate was lower than physiological conditions at 5.88 mmHg and 0.0008 mL/min. The second 
flow rate was at the end of the range at 22 mmHg and 0.0024 mL/min. Their final rate was 36.7 
mmHg and 0.005 mL/min. These flow rates gave the authors a clear view of how the rate of 
perfusion affects the rate of transport of rhodamine and bovine serum albumen (BSA) throughout 
the hydrogel. As the flow rates increased so did the rate of transport of these molecules (Golden 
& Tien, 2007). 
2.3.3 Vascularization Methods 
Vascularization can be achieved in engineered tissues through the use of microfluidic 
technologies which are systems with geometries on the scale of tens to hundreds of microns 
involving transport of fluids. There are additional advantages of microfluidics in tissue 
engineering beyond delivery of oxygen and nutrients and removal of waste including promoting 
flow-induced cell signaling, controlling spatial relationships between cells, and introducing 
chemical gradients, all of which help to better reproduce the in vivo microenvironment (Inamdar 
& Borenstein, 2011). 
There are two main methods utilized for developing vascularization in engineered tissues, 
the first of which is angiogenesis or vasculogenesis, the ability of endothelial cells to form new 
blood vessels from existing ones or the process by which cells form new blood vessels during 
embryonic development (Hasan et al., 2015). A second method which will be discussed is 
engineering microvascular networks which involves the formation of pre-vascularized scaffolds 
(Hasan et al., 2015; Novosel, Kleinhans, & Kluger, 2011).  
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2.3.3.1 Angiogenesis and Vasculogenesis 
Angiogenesis and vasculogenesis in engineered tissues are processes promoted by 
seeding endothelial cells as well as other cell types such as myoblasts or fibroblasts and adding 
angiogenic growth factors such as vascular endothelial growth factor (VEGF), basic fibroblast 
growth factor (bFGF), and hepatocyte growth factor (HGF) (Rivron et al., 2006). Some examples 
of applications of this technique include directing angiogenesis and endothelial cell growth along 
micropatterned hydrogels (Koroleva et al., 2012; Nikkhah, Edalat, Manoucheri, & 
Khademhosseini, 2012). Additionally angiogenesis has been induced by functionalizing 
biomaterials with angiogenic biomolecular cues such as VEGF and angiopoietin-1 (Chiu & 
Radisic, 2010; Ito & Tada, 2013). A third method, and perhaps the most common, is the use of a 
growth factor gradient within a hydrogel, as endothelial cells will form vascular structures from 
regions of low to high growth factor concentrations (Hao et al., 2007, Kaully, Kaufman-Francis, 
Lesman, & Levenberg, 2009; Silva & Mooney, 2010). However, two main drawbacks of these 
techniques are that they are not rapid enough to immediately supply oxygen to tissue scaffolds 
developed in vitro and there is somewhat limited control of the resulting vascularization 
(Laschke et al., 2006).  
2.3.3.2 Microengineered Vascular Networks  
A second approach to microvascular engineering is the formation a microvascular 
network. The goal of such a microengineered vascular network is to provide nutrients and waste 
removal to cells in an engineered construct with precise geometry by artificially, pre-developing 
the microvascular network. One common strategy of designing engineered microvascular 
networks is to mimic the vessel structure of the cardiovascular system (Prabhakarpandian et al., 
2013). In vivo, almost all tissues are supplied with oxygen and nutrients via a highly branched 
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network of blood vessels. The greatest distance between capillaries is typically 200 μm which 
correlates to the previously mentioned diffusion limit of oxygen (Kannan, Salacinski, Sales, 
Butler, & Seifalian, 2005). 
It should be noted that though the scope of this project has been narrowed and focused on 
cardiac applications, the development of a microvascular layer could be applied to many 
different tissue types. Currently, many methods exist that are under investigation for the creation 
of microvascular networks. Each method will be presented with highlighted advantages and 
limitations. 
2.3.3.2.1 Cylindrical Rod Extraction 
One simple method of creating engineered microvasculature is by encasing a cylindrical 
rod such as a needle or wire in a hydrogel (Chrobak, Potter, & Tien, 2006). A needle was 
encased in a collagen or fibrin hydrogel and after polymerization was complete, the needle was 
drawn back leaving a channel with a diameter of 120 μm (Chrobak, Potter, & Tien, 2006). A cell 
suspension of both human umbilical vein endothelial cells (HUVECs) and human dermal 
microvascular endothelial cells (HDMECs) was adhered and grown to a confluent monolayer in 
the channel (Chrobak, Potter, & Tien, 2006). An advantage of the cylindrical rod extraction 
method is the simple, low-cost procedure. A limitation of this method is the limitation of straight, 
single channels in addition to possible adherence between the hydrogel and the rod. 
2.3.3.2.2 Laser Created Channels 
A parallel array of channels were created in poly(glycerol sebacate) (PGS) using a laser 
cutting/engraving system. These elastomer scaffolds contained channels that mimic a vascular 
network. The scaffolds were seeded with neonatal rat ventricular cardiomyocytes (nRVCMs) 
which formed constructs that synchronously contracted upon electrical stimulation (Radisic, 
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Marsano, Maidhof, Wang, & Vunjak-Novakovic, 2008). Advantages of this method include 
channels with well-defined geometry and the ability to create multiple channels. The main 
limitation of this method is being limited to straight, non-branching channels. 
2.3.3.2.3 Silicon Micromachining/Soft Lithography 
A series of trenches that mimic the architecture of small blood vessels was created on 
silicon wafers and after rat lung microvascular endothelial cells were seeded directly onto the 
wafer, they formed a monolayer. This monolayer was able to be lifted off the wafer and then 
folded into a compact three-dimensional (3D) scaffold (Kaihara et al., 2000). 
Researchers describe the development of a microvascular network created via silicon 
wafer micromachining. Multiple layers of tissue formed from the network are created to stack 
and provide filtration function similar to that of liver/kidney via a semipermeable membrane 
(Borenstein et al., 2013).  
Soft lithography, refers to the technique of creating a soft mold out of a material such as 
polydimethylsiloxane (PDMS) from the hard photolithographed master (Kim et al., 2008). A 
group from Tokyo Women’s Medical University used soft lithographic techniques to create a 
hyaluronic acid hydrogel. Cell sheets, one being HUVECs, were then placed on either side of the 
gel and over time formed capillary-like structures via cell movement around the gel 
(Sugibayashi, Kumashiro, Shimizu, Kobayashi, & Okano, 2013).  
The advantages of microvascular networks created via photolithography or soft 
lithography allow for finer control over the geometry and structures of the network, which can 
include branches and bifurcations. One limitation of most microvascular networks formed via 
photolithography is non-circular channels. A method was developed to create cylindrical 
microfluidic channels using soft lithography. Two PDMS molds with semi-circular cross 
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sections were created and could be stacked together to form cylindrical molds which overcome 
the limitation of photolithographic techniques of only being able to create rectangular features. In 
addition, computational models were used to calculate shear stress and pressure distributions 
within the microvascular network (Huang, Li, Martins-Green, & Liu, 2012). 
Soft lithography has also been used to form microchannels in silk scaffolds. One silk 
scaffold was molded with the PDMS reverse mold and a second, flat silk scaffold was adhered to 
the first to form the rectangular or circular cross-section channels. Human microvascular 
endothelial cells (hMVECs) were grown to confluence within the channels (Wray, Konstantinos, 
Gi, Omenetto, & Kaplan, 2013). 
2.3.3.2.4 Sacrificial Molds 
Another heavily researched method of microvascular network formation is through the 
use of sacrificial molds. Sacrificial molds use a material that can be dissolved, or melted after a 
hydrogel is formed around them. The removal of the material leaves a negative space used as 
channels of the microvascular network. Many materials have been used as sacrificial molds for 
the formation of microvascular networks and a review is described here. 
2.3.3.2.4.1 Gelatin 
Using gelatin as a sacrificial element, researchers created microfluidic networks in both 
collagen and fibrin hydrogels with channels as narrow as six micrometers. One advantage to 
using gelatin is that it is able to be melted at 37°C which avoids denaturation of protein scaffolds 
such as fibrin or collagen. It was also shown that human microvascular endothelial cells could 
attach, spread, and proliferate in microfluidic channels (Golden & Tien, 2007). 
38 
2.3.3.2.4.2 Carbohydrate glass 
Researchers developed perfusable engineered microvascular networks using a sacrificial 
mold made of carbohydrate glass, a material made of sucrose, glucose, and dextrans. A 3D 
filament network was created that resulted in cylindrical microvascular networks that could be 
lined with endothelial cells. Perfusion was successful with high-pressure pulsatile flow and the 
method was compatible with multiple cell types (Miller et al., 2012). One downside to this 
method is a relatively complex sacrificial element fabrication process that must be completed at 
high temperatures. 
Another group further developed carbohydrate glass as a sacrificial molding technique 
using 3D-printed isomalt, a sugar alcohol. Like other methods, this procedure creates a 
dissolvable sacrificial mold that creates a network of cylindrical channels. Improvements 
minimized bleeding of the carbohydrate and casting at low temperatures. This group also showed 
that carbohydrate glass can be printed from existing filaments or can end in free space and that 
the diameter can be controlled. The glass is able to be dissolved in a few different ways, via still 
water immersion for thirty-six hours, sonication in 41°C water for 16 hours, or immersion in 
boiling water for three hours (Gelber & Bhargava, 2015). 
2.3.3.2.4.3 Pluronic F127 
Pluronic F127, a triblock copolymer of polyethylene oxide and polyphenylene oxide was 
used as a sacrificial mold because of its lower critical solution temperature (LCST) in that it is a 
liquid below the LCST but forms a gel above the LCST (Müller, Becher, Schnabelrauch, & 
Zenobi-Wong, 2013). At a proper concentration, around 20 wt%, Pluronic F127 is a gel at room 
temperature and can be removed by cooling in 4°C water. Microvascular networks were 3D 
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printed in 1-, 2-, and 3-dimensions and were endothelialized with HUVECs (Kolesky et al., 
2014). 
2.3.3.2.4.4 Polyvinyl Alcohol (PVA) 
Polyvinyl alcohol (PVA) is a water soluble, hydrophilic polymer and these properties 
have led PVA to be used in many different applications. One study used PVA to create 
micromolds. The authors made a PVA and water solution and spin coated a plate used to create a 
PDMS mold. When the PVA was dissolved it left grooves in the PDMS (Ferrell, 2007). Another 
study used PVA to create a film on a glass plate. The study used the plate to create 3D 
microstructures. When these structures were formed they needed to be detached from the plate so 
the PVA layer was dissolved in water and the microstructures were released (Guan, 2005). 
Additionally, once a scaffold with a microvascular layer is implanted, it must continue to 
receive oxygen and nutrients and thus must connect with systemic circulation in vivo (Lokmic & 
Mitchell, 2008). It has been shown that microvascular networks developed in vitro can be 
implanted and maintained in vivo via spontaneous connection of endothelialized channels to 
systemic circulation (Koike et al., 2004, Levenberg et al., 2005) 
2.4 Hydrogels for Engineered Microvascular Networks 
Within our project, we will be creating a thin hydrogel scaffold containing a 
microengineered vascular network. The purpose of this hydrogel is to facilitate the perfusion and 
diffusion of necessary gases and nutrients into the surrounding scaffold. The microvascular 
hydrogel will be alternating with multiple fibrin layers to create a scaffold which could serve as a 
patch to replace damaged myocardial tissue. In order to ensure that our hydrogel will support 
additional layers above and below it, we must consider carefully what material we choose to use 
by analyzing its mechanical and bioactive properties. 
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Hydrogels are important for tissue engineering applications as scaffolds for cells to 
adhere, proliferate, and differentiate. In tissue regeneration when a wound is present, a scaffold 
must be created to allow cells to develop new tissue. Cells would be taken from the damaged 
tissue surface and placed onto the hydrogel so that they can be supported and create a viable 
layer of new tissue.  
2.4.1 Hydrogel Properties 
There are many relevant properties to be considered in selection of a hydrogel in tissue 
engineering applications. When selecting a hydrogel material for the microvascular layer, we 
must select one that encompasses the following qualities: biocompatible, allow for cell 
attachment, differentiation, proliferation, and should degrade appropriately with the rate of tissue 
regeneration in vivo. It should provide a scaffold until the cells can repair the damaged area and 
create a new extracellular matrix. It should also allow for nutrients to be delivered to the cells 
within the scaffold. The hydrogel material must allow for integration with the host tissue in vivo 
and degrade at an applicable rate that allows for tissue to regenerate as the scaffold is degrading 
(Dumitriu, 2013). Additionally, the creation of the hydrogel scaffold should be reproducible 
(Chen et al., 2008). 
2.4.2 Natural vs. Synthetic Hydrogels 
Both natural and synthetic hydrogels have advantages and drawbacks. It is important to 
consider the specific application of the scaffold. Some advantages of natural hydrogel materials 
include that they are typically biocompatible, biodegradable, and have fewer immunogenic 
issues. Some disadvantages include that they can have poor mechanical properties, poor 
processability, and there is the possibility of disease transfection. Synthetic materials can be 
advantageous in that they can have good processing characteristics, are more readily available 
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and predictable, and can be more easily manufactured. However, some disadvantages of 
synthetic materials include that inflammatory reactions and erosion can occur in addition to there 
being potential difficulty with tissue integration. The clients’ constraints typically help determine 
which qualities to keep in mind when selecting a material to use. For example, a main constraint 
for this project is that it that all materials that come into contact with the scaffold or 
microvascular layer must be completely biocompatible. This would narrow down possible 
material options. 
In addition to characterizing natural and synthetic materials, it is necessary to research the 
qualities of various hydrogel materials, as many differ. Below, Table 1 presents the properties of 
various materials that could be used when creating a hydrogel. The following information was 
gathered from various articles cited below. 
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Table 1: Characteristics of some natural and synthetic hydrogel materials (Chen et al., 2008; Hasan et al., 2013). 
Natural 
Fibrin  Origin: Plasma 
 Pro-angiogenic 
 Serves as a provisional scaffold in the coagulation cascade and 
wound healing 
 Good cell adhesion properties 
Collagen  Origin: Tendons, ligaments, ECM of skin, bone, and cartilage 
 Good biocompatibility 
 Strong cellular activities 
 Thermal reversibility  
 Possible immunogenic response 
Alginate  Origin: Cell walls of brown algae 
 Originally developed for drug delivery 
 Controlled release of basic fibroblast growth factor microspheres 
enhance vascularization of the scaffold 
 High biocompatibility 
 Low cost 
 Limited long term stability 
 Non-thrombogenic properties  
Gelatin  Origin: derivative of collagen 
 Good fabrication control 
 High biocompatibility 
 Promotes vascularization through growth factor release 
Synthetic 
Polyethylene Glycol 
(PEG) 
 Biocompatible 
 Hydrophilic 
 FDA approved for multiple biomedical applications 
 Does not cause immune response 
 Low toxicity 
Polyvinyl Alcohol 
(PVA) 
 Produced through hydrolysis of polyvinyl acetate 
 Elasticity allows it to be used as a matrix 
 Can connect to biological molecules 
 Minimal adhesion properties 
 Strong mechanical properties 
Polyphosphazene  Controlled biodegradability 
 Can be modified to be thermoresponsive 
 Useful for drug delivery 
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2.5 Endothelialization 
The endothelium, a thin layer of epithelial cells, lines the interior of blood vessels and 
lymph vessels. The purpose of the endothelium is to act as a boundary between the flowing 
fluids and the surrounding tissues. As a barrier, the layer controls diffusion of nutrients, oxygen, 
and wastes. Along with that, the endothelium plays a vital role in regulating the state of the 
blood. The endothelial cells control clotting and the dissolution in the blood vessels (Aird, 2007). 
Creating a functional endothelial layer on the interior of our designed channel would help ensure 
that perfusion of blood is possible, because it would provide the necessary surface and molecules 
to keep blood flowing and prevent clotting inside the designed vascular network.  
2.5.1 Endothelial Structure 
Blood vessels consist of three different layers. The outermost layer is called ‘tunica 
externa,’ the middle layer is ‘tunica media,’ and the innermost layer is known as ‘tunica interna.’ 
The endothelial cells are directly anchored to the basement membrane. The basement membrane 
is made of connective tissue and smooth muscle cells, more specifically pericytes (Félétou, 
2011). The different extracellular matrices of the layers enhance the mechanical strength and 
elastic properties of the channel. For our project, the goal is to create a microvascular network 
with properties similar to the coronary arteries, so that we can promote angiogenesis and native 
tissue integration. By mimicking coronary arteries, the vascular network assist in the 
differentiation and proper alignment of the surrounding tissues by providing mechanical and 
chemical signals.  
There are three main types of endothelial linings depending on their structure (Félétou, 
2011). The classes of endothelial linings are continuous endothelium, fenestrated endothelium, 
44 
and discontinuous endothelium. The different endothelial linings are determined by the vessel’s 
location and its function. The continuous endothelium, shown in Figure 3, can be found in most 
large arteries, veins, and capillaries in the brain, skin, heart, and muscle. In the fenestrated 
endothelium, the cells are characterized by the presence of wide transcellular pores with 
diaphragms which can seal the pore. These cells are often found in sites of increased exchange 
between the tissues and the blood, or locations of elevated filtration. The discontinuous 
endothelium is characterized by the presence of large fenestrations with no diaphragms and this 
layer can be found in sinusoidal vasculature that can be seen in the liver, spleen, and bone 
marrow (Aird, 2007). Since the project is focusing on the myocardial vasculature, an ideal lining 
would be a continuous endothelium.  
 
Figure 3: Endothelial cells of a blood vessel. 3D projection of a confocal Z-stack of vessel lining, fluorescent stained with 
PECAM-1 (green) and DAPI (blue) (Wong, Searson 2014) 
In capillaries, the endothelial cells are generally about 0.1 μm thick, and they are large 
and elliptical in shape. Endothelial cells express a large number of clathrin-coated vesicles, 
multivesicular bodies, and lysosomes and these components point to the endothelial cells’ 
endocytotic function. Other function specific components seen in endothelial cells are caveolae 
and vesiculo-vacuolar organelles. The transcytotic function of the organelles, the small thickness 
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of the cells, and the cellular structure of endothelium support the idea that a major function of the 
endothelial layer is to facilitate the molecular exchange between the blood and the surrounding 
tissues. 
2.5.2 Endothelial Function  
Endothelial cells have several primary functions that they perform. The functional 
heterogeneity is expressed by the difference in dominance between functions. A primary 
function of the endothelium is to control the state of the blood, as all endothelial cells regulate 
hemostasis, the process by which the body stops bleeding and keeps the blood within the 
damaged vessel. The endothelium maintains blood in fluid form, but also promotes localized 
blood clotting if there is breach in the vessel. Endothelial cells work closely with the platelets to 
control the state of the blood. The endothelium releases specific signaling proteins which act as 
anticoagulants and coagulants depending on their interaction with the platelets (Aird, 2007). 
Additionally, endothelial cells are also responsible for the process of fibrinolysis which is the 
opposite process to hemostasis, the dissolving of clots. Along with controlling the state of blood, 
endothelial cells act as the permeable barrier to the interstitial tissues. 
The two major functions of interest for the project are the endothelium’s controlled 
permeability and its control over the hemostasis. Controlled diffusion is crucial for the network 
to function properly, so that it can accomplish its primary purpose as a vascular system, which is 
to facilitate the delivery of nutrients and oxygen and the extraction and removal of wastes. The 
endothelial layer would also ensure that the perfusion of blood through the fabricated channels is 
possible. The endothelial layer is responsible for the anti-coagulant molecules which reduce the 
viscosity of blood, preventing it from clotting.  
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Understanding the structure and functions of endothelium would be beneficial to our 
project because a microvascular network is being constructed, which will sustain blood flow, 
facilitate perfusion of nutrients and gasses to the surrounding cells and tissues, and promote 
angiogenesis in vivo. 
2.5.3 Engineered Vascularization 
Currently, in the field of biomedical engineering, there is a need to develop an effective 
way of vascularizing 3D scaffolds and tissues in vitro and in vivo. Major challenges arise from 
the difficulty of properly forming the network, perfusion through capillaries, diffusion 
limitations, and ineffective integration in vivo (Lovett et al., 2009). Past studies have focused on 
two main aspects of vascularization. Some researchers focused on studying what factors affect 
vascularization while others are developing methods of integrating vascularization into 3D 
scaffolds. Endothelialization plays a crucial role in the vascularization process, as the proteins 
released from endothelial cells dictate the growth and development of vessels and channels. In 
past studies, a variety of endothelial cells have been used to test the different scaffold designs. 
The most commonly used types of primary line endothelial cells are human umbilical vein 
endothelial cells (HUVEC), human pulmonary artery endothelial cells (HPAEC), and human 
dermal microvascular endothelial cells (HDMEC) (Alberts, 2002). 
Primary cell lines generally have an average lifespan of ten cell culture passages and can 
be kept for up to five months (Bouis et al., 2001). Over that time limit, cells enter senescence and 
soon after undergo cell death. This means that long term experiments are difficult to be done 
with primary endothelial cells. Depending on the source site of the cells, their behavior differs 
significantly. Most studies use HUVECs because of their proliferation potential; however, when 
doing regeneration studies targeted at specific organs and tissues, it is recommended to use 
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endothelial cells from blood vessels similar to the ones found in the original tissue. This is 
because these endothelial cells will function optimally in that tissue environment (Alberts, 2002). 
Primary endothelial cell cultures grow slowly in vitro compared to immortalized cells, but the 
benefit of using a primary cell line is that their behavior in vitro is similar to their behavior in 
vivo. 
2.6 Bioreactor for Microvascular Network Perfusion  
A bioreactor is a research tool to observe and characterize interactions of cells and tissues 
throughout experimentations. The bioreactor consists of three major parts: a pump, a 
microfluidics chamber, and a collection reservoir. The pump provides the perfusion of media and 
nutrients to the microfluidic chamber. The microfluidic chamber is the part of the bioreactor that 
holds and interacts with the tissue construct being studied. The collection reservoir is used to 
collect the media that has passed through the system for disposal.  
2.6.1 Clinical Need 
There is limited capacity for self-repair and restoration of original tissue once damaged. 
Most common treatments involve implantable medical devices with many associated limitations 
such as time-span and implant failure. Today, there is a large demand for providing an 
alternative to these previous means of restoring severely damaged tissues when needed and 
bioreactors are vital in the development of such treatment. Bioreactors allow cells and tissue 
constructs to be used towards biological applications that are clinically effective and safe. A 
traditional bioreactor can be defined as “a device that uses mechanical means to influence 
biological processes” (Darling & Athanasiou, 2003). Bioreactors maintain tissue viability by 
providing physical or biochemical signals and can culture cells for months by continuously 
feeding the cells with fresh media. A perfusion system delivers the fresh media through a porous 
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scaffold to maintain cell viability while removing waste media. Bioreactors allow for a safe, 
reproducible, and controlled environment for the creation of a tissue construct. A bioreactor, 
which delivers nutrients and oxygen and removes wastes, should allow for biological processes, 
such as cell proliferation, growth, and differentiation, while maintaining sterility and generating 
reproducible results (Zhao & Griffin, 2016). The bioreactor must maintain an environment with 
very specific parameters that promote the growth of tissue. These parameters include flow rate, 
temperature, and specific sizing that accommodates our clients’ needs. The ultimate goal is that 
bioreactors can contain scaffolds within them and can monitor and control the conditions of the 
tissue to ensure they are suitable for long term implantation with minimal rejections. Like most 
bioreactors, the design should be based on a comprehensive understanding of the biological and 
engineering aspects of the application. 
2.6.2 Microfluidic Chamber Models 
 Microfluidic chambers are diverse as there are many types that can be used and each is 
tailored to a specific need. An example microfluidic chamber from a study from 2008 was a 
cylinder that consisted of three chambers with a single perfusion channel in each one, as seen in 
Figure 4 (Chang, 2008). 
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Figure 4: Simple three chambered bioreactor with hydrogel (Chang, 2008) 
The center chamber contained a hydrogel seeded with rat fat microvessel fragments 
(RFMF). The system was perfused through each of the three chambers. This allowed the 
RFMF’s to align into a microvascular network (Chang, 2008). This microfluidic chamber, 
although simple, maintained the viability of the construct while allowing the fragments to align.  
C. Williams, Ph.D. and T. Wick, Ph.D. designed a Perfusion Bioreactor for Small 
Diameter Tissue-Engineered Arteries in 2004. Their microfluidic chamber allows for dynamic 
sequential seeding of smooth muscle and endothelial cells and monitoring of tissue growth. Cells 
are seeded onto porous scaffolds and cultured in the bioreactor under pulsatile flow. The 
bioreactor is cylindrical, flanked by two head plates made from hand-blown glass. Scaffolds 
were mounted on the two glass tubes within the chamber where perfusion is performed. The head 
plates, which can be seen in Figure 5 below, have a precision formed groove that allows the plate 
to form a tight and secure seal by compressing a gasket with clamps.  
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Figure 5: Cylindrical three-module bioreactor. The image shows the inlet and outlet, as wells as some of the components 
of the bioreactor chamber (Williams & Wick, 2004) 
The head plates are closed off at one end and the other end as a small port to allow flow 
through the construct for nutrient delivery. This study also designed a bioreactor that allowed 
simultaneous perfusion of multiple constructs (Williams & Wick, 2004). 
Another study from 2009 designed and developed a bioreactor system for tissue 
engineering of bone that enables cultivation of up to six tissue constructs simultaneously. The 
microfluidic chamber addressed several key design aspects including the use of multiple 
scaffolds, imaging capabilities, and direct perfusion. The chamber has the dimensions of a ten 
centimeter glass Petri dish. Below in Figure 6, the bioreactor system as well as schematic of the 
microfluidic chamber can be seen.  
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Figure 6: Bioreactor system. a) Schematic of the microfluidic chamber, b) Schematic of the bioreactor system setup; c-d) 
Compete bioreactor setup (Grayson et al., 2008) 
The glass cover of this dish serves as the removable cover enabling access to scaffolds as 
well as the use of traditional cell culture techniques for media changes. The microfluidic 
chamber was machined from polycarbonate plastic with silicone gaskets separating the 
individual parts. Scaffolds were placed into the six wells which are arranged radially within the 
microfluidic chamber. Media entered the chamber through a central port and flowed to the center 
of the chamber and evenly distributed to the six channels. A peristaltic pump was used to perfuse 
the media through the system (Grayson et al., 2008). 
A study from 2010 took a different approach from the previous bioreactor explained. This 
microfluidic chamber perfused a small set of scaffolds. It utilized a glass coverslip in a steel 
casing to maintain sterility. The microfluidic chamber utilized an insert with grooves to facilitate 
perfusion across the scaffolds with a gasket to prevent leakage, seen in Figure 7.  
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Figure 7: Microfluidic chamber components. Disassembled view of the microfluidic chamber showing of all chamber 
components (Fröhlich et al., 2010) 
The top and bottom plates provide support and use screws to compress the assembly 
enough to ensure there were no fluid leaks and sterility was maintained. A low profile was 
maintained so that the microfluidic chamber fit under a microscope. A gasket was used to ensure 
a tight seal between the plates. Holes on each end of the gasket allowed fluid to flow from 
channels in the top plate into the perfusion chamber. The channels were made from medical 
grade clear silicone and UV-transparent polycarbonate plastic. Lastly, the coverslip was clear 
providing optical efficiency when being imaged (Fröhlich et al., 2010).  
2.6.3 Microfluidic Chamber Fabrication  
The microfluidic chamber of the bioreactor system contained small features that can be 
sometimes hard to fabricate. There are many ways to fabricate chambers with these small 
features such as 3D printing, milling, injection molding, and soft lithography.  
2.6.3.1 3D Printing 
3D printing, also known as rapid prototyping, can be used to quickly create models 
designed to test and validate features and means. This can be done to allow testing of a single 
feature or to validate a means quickly and cost effectively. One of the two most common 
materials used is polylactic acid (PLA). The melting temperature of PLA is 160-220°C and can 
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be extruded at, or higher than melting temperature (Nampoothiri, Nair, & John, 2010). A 
common method of printing is Fused Deposition Modeling (FDM). This method heats, melts 
plastic, and lays down the melted plastic with each pass of the extruder. The next layer of plastic 
fuses to the layer below. This creates the model layer by layer fusing each layer to the next. 
There are a few limitations with FDM printing. The resolution on this type of printer settles 
around 0.1 mm. This means the printer can print layers as small as 0.1 mm accurately. Another 
limitation is the tolerances of the printer. The tolerances on the FDM printers are difficult to 
adjust, therefore some dimensions of prints were not as tight fitting as needed (Hossain, Espalin, 
Ramos, Perez, & Wicker, 2014). 
2.6.3.2 Milling 
Milling machines are used with metals, woods, and other solid materials. Mills remove 
material bit by bit from a large piece of material to leave the desired part. Mills such as the 
Bridgeport 3 axis can be accurate within the 1/1000 of an inch (Shah, 1998). This means mills 
can produce much smaller features than FDM printing. This is because mills remove small 
amounts of material while FDM deposits material based on the size of the extruder size. Because 
of the better resolution, the small scale of a microfluidics device could be fabricated more easily 
than with FDM. The tool heads used to cut the material come in a range of sizes and although 
small features are possible, they can be difficult to achieve.  
2.6.3.3 Injection Molding 
Plastic injection molding is the analog to die casting for metals. Injection molding has a 
high production rate and large control over dimensions. This method uses molds to cast melted 
plastic into complex patterns. A granulated plastic is heated and forced, at a high pressure, 
through and nozzle into a mold (Oktem, Erzurumlu, & Uzman, 2007). However, small 
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imperfections in the plastic or changes in the manufacturing process can have undesired results. 
These adverse effects include warping and feature shrinking of the cooled plastic (Jain, Kumar, 
& Kumawat, 2012).  
2.6.3.4 Soft Lithography 
Soft lithography is a fabrication technique that can be used to form microfluidic 
chambers from soft materials such as PDMS. Lithography uses a mask to cover the desired areas 
of materials. UV light or chemicals are used to remove the material not covered by the mask. 
This method is used to quickly create chambers and networks in materials that can be used in a 
microfluidic chamber. However, soft lithography requires a pre-made mold and a clean room to 
operate in. Also the cost of obtaining small features is variable, ranging from $40-1500 
(Mandenius, 2016). This makes fabricating intricate features needed in microfluidic chambers 
time consuming and expensive.  
2.7 Summary 
A myocardial infarctions results in death of a patient’s myocardium which is replaced 
with scar tissue, leading to a decrease in heart function. Current treatments either are not readily 
available or only serve to prevent further damage. Importantly, there is no current clinical 
treatment to regenerate a patient’s myocardium. Cardiac tissue engineering has the potential to 
fulfill this need but is limited by its inability of oxygen to passively diffuse greater than 200 μm 
into tissue. To develop a cardiac tissue construct of clinically relevant thickness, 
microvascularization is needed. There exist many methods to develop vascularization in 
vitro each with advantages and limitations. 
To develop vascularized tissue in vitro, a bioreactor is needed. A bioreactor is a research 
and development tool that used to study of interactions between tissue components. There is a 
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need for bioreactors that facilitate the growth of cells and tissue constructs which allow for 
biological applications that are clinically effective and safe. The bioreactor must maintain tissue 
viability and culture cells for months by continuously perfusing with fresh media. The field of 
cardiac tissue engineering could be greatly accelerated with the development of a clinically 
relevant microvascular construct. 
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Chapter 3: Project Strategy 
This chapter encompasses the project strategy the team used to drive the design process. 
The team followed an approach for the engineering design process described by Clive Dym and 
Patrick Little (Dym, Little, Orwin, & Spjut, 2009). The ultimate goals of the project were to 
design a microengineered vascular network and a bioreactor system with a microfluidic chamber, 
in which the microvascular network and a cardiomyocyte seeded fibrin layer could be sustained. 
This chapter presents an overview of the project strategy from the initial client statement and 
client interviews to the project objectives, constraints, revised client statements, and overall 
project approach. 
3.1 Stakeholders 
Dym and Little specify that keeping the stakeholders in mind at all times is a must for a 
successful design (Dym, Little, Orwin & Spjut, 2009). For this project, stakeholders include the 
client and users. Their opinions should be highly regarded as they have funded the project and 
will ultimately be using the device. The design team is the third party involved in the design 
process. It is imperative that the design team considers the constraints of the project and designs 
with the clients’ and users’ desired objectives in mind.  
As shown in Figure 8 one can see the designer-client-user triangle is a cyclical process 
demonstrating that the client, users, and design team are all integral parts of the design process 
(Dym, Little, Orwin, & Spjut, 2009). 
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Figure 8: Dym & Little designer-client-user triangle 
For this project, the clients and users overlap. The client was Dr. George D. Pins, while 
Megan O’Brien and Meagan Carnes acted as both clients and users. The design team consisted of 
Kevin S. Ackerman, Jamal J. Akid, Amanda M. Baltazar, Do M. Duc, and Stephanie R. Fariello. 
Dr. George D. Pins approached the team with the objective of engineering a microvascular 
network within a microfluidic chamber, capable of keeping multiple scaffold layers viable for a 
two to three week time period. The microfluidic chamber is part of a larger bioreactor system 
that contains a pump and collection flask as well. Megan O’Brien and Meagan Carnes are two 
WPI graduate students working in Dr. Pins’ lab. Megan O’Brien is currently working on the 
development of a cardiac patch and the team’s device would assist her with stacking and 
sustaining of multiple scaffold layers. Since the vascular network the team created can be used 
with multiple tissue types, it could also aid Meagan Carnes in the future with her research that is 
currently focused on skeletal muscle. The goal of the design team is to provide the users with a 
reproducible, functional bioreactor system and a microvascular network that could assist them in 
their research. 
3.2 Initial Client Statement and Clarification 
The initial client statement was presented as follows: 
Design, develop, and characterize a bioreactor that provides continuous flow to a thin fibrin 
scaffold containing a microengineered vascular network.  
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Upon the initial analysis of the client statement the design team determined there were 
two main aspects to the project: a microengineered vascular network and a bioreactor system. 
This meant the team needed to assess objectives and constraints for each design. The team first 
focused on the microengineered vascular network. The interpretation of the client statement 
indicated that the vascular network must sustain the viability of cells surrounding the vasculature 
by providing continuous access to nutrients and oxygen. 
Next, the team turned to the bioreactor system. After an initial review of the client 
statement, the team determined there were two elements that needed to be covered: a bioreactor 
system and a microfluidic chamber. The microfluidic device is necessary to contain and maintain 
the entire hydrogel scaffold, consisting of the microvascular network and hydrogel layers seeded 
with cardiomyocytes. This meant the microfluidic chamber needed to facilitate the perfusion of 
the microvascular network and to maintain the viability of the cells in the entire scaffold while 
being inside an incubator.  
In order for the team to better understand the clients’ needs and wants, in addition to 
conducting preliminary literature research, the team interviewed the clients. Many design 
attributes were ascertained and were recorded without being sorted by importance. The 
attributes, or needs and wants, from the initial client meetings for the microvascular network and 
the bioreactor are listed and organized below separately: 
Microvascular network: 
1) Mimics physiological vascular network 
a) Physiological dimensions 
i) Channel diameter 
ii) Cross-sectional geometry 
b) Physiological flow rates 
c) Physiological shear stress 
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2) Allow for perfusion 
3) Diffusion of gases 
a) Diffusion of nutrients 
4) Easy to manufacture 
a) Reproducible 
i) Accuracy and precision 
5) Aid in patch formation 
a) Stackable 
i) Layers of cell / hydrogel scaffold 
ii) Layers of microvascular network hydrogel 
6) Size 
a) 1 cm x 2 cm x 300 μm 
Bioreactor: 
7) Maintain cell viability 
a) Sustain endothelial cells in microvascular network 
b) Sustain cardiomyocytes in adjacent layer 
8) Sterilizable 
9) Cost effective 
a) Reusable 
b) Easy to manufacture 
c) Cheap to manufacture 
d) Minimize waste 
10) Easy to use 
a) Set up 
b) Transport 
11) Microscopy compatibility 
a) Transparent 
i) Allows visual monitoring 
ii) Allows imaging 
b) Size 
12) Incubator compatibility 
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a) Size 
b) Compatible with conditions inside the incubator 
Through the meetings with the clients the team expanded the attributes to encompass the 
full project. The design team used these attributes to establish the objectives, what the design 
needed to achieve. In addition the team established the constraints, what limits the design space 
within which the team can work. The objectives of the two components of the project and the 
constraints are listed below in Table 2. Once all objectives and constraints were compiled, the 
team ranked the objectives and identified sub-objectives. 
Table 2: Objectives and Constraints 
Objectives 
Bioreactor 
 Control Gas Permeability 
 Ease of Use 
 Cost Effective 
 Reproducible 
 Allow for Multiple Samples 
Vascular Network 
 Physiologically Relevant Dimensions 
 Physiologically Relevant Flow 
 Stackable 
 Reproducible 
 Easily Produced 
 Endothelializable 
Constraints 
 Sterilizable 
 Biocompatible 
 Size of Bioreactor 
 Size of Microfluidic Chamber 
 Timeline 
 Budget 
 Incubator Conditions 
 Microscope Compatibility 
 
3.3 Objectives and Sub-Objectives 
To organize the design process, the project was structured into two major parts. As seen 
in Figure 9 and Figure 10 respectively, the first component was to produce a microvascular 
network within a thin layer able to be integrated into a larger construct to support a cardiac patch. 
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The second component was to create a bioreactor to support and maintain a thin microvascular 
hydrogel layer with an adjacent cardiomyocyte layer in vitro. The design team, in conjunction 
with the clients, developed objectives and sub-objectives for each component. 
 
Figure 9: Vascular network layer objectives and sub-objectives 
As seen in Figure 9, the first portion of the project focused on the formation of the 
microvascular network. The first objective was that the microvascular network should have 
physiologically relevant flow that provides shear forces that mimic those found in vivo. Next, the 
network layers needed to be stackable with others to increase the thickness of a patch. Another 
objective was to be reproducible both in terms of the network dimensions and integrity of the 
channels. The network needed to be formed with physiologically relevant dimensions, so the 
seeded cells were in an environment that closely resembled in vivo conditions. Another objective 
for the vascular network was to be endothelialized. The channels needed to create capillary 
channels inside the hydrogel scaffold, in order to allow for blood perfusion and protect the 
surrounding cells and ECM from the shear forces from the flowing fluid. Finally, the production 
of the network needed to be cost effective with as little wasted material as possible.  
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Figure 10: Bioreactor objectives and sub-objectives 
The second portion of the project was to design and develop the bioreactor system. The 
objectives for the bioreactor can be seen in Figure 10 above. The first objective of the bioreactor 
was the ability to control gas permeability. Under most circumstances the bioreactor had to be 
gas permeable while keeping the tissue sterile and allowing diffusion of oxygen through the 
walls of the microfluidic chamber. However, the client also wanted the bioreactor to be gas 
impermeable to assess the effectiveness of the vascular system in delivering nutrients and 
oxygen. Therefore, the bioreactor needed an element to control the gas permeability. Another 
objective for the bioreactor was that it needed to be reproducible. The bioreactor needed to 
minimize variation between systems in production and the functions during experiments. It 
needed to allow for scaffold stacking and flow that could be replicated, while allowing the user 
to control the flow rate. The next objective for the bioreactor was to allow for multiple samples. 
Multiple samples needed to be perfused simultaneously in separate environments preventing 
cross contamination. Another objective of the bioreactor was ease of use. Sub-objectives for ease 
of use included that the system needed to be easy to transport, easy to set up, and allow for easy 
fluid control. In order for the system to be effective for our clients, it needed to work properly 
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while being assembled in the shortest amount of time and simplest way possible. Finally, the last 
objective was for the system to be cost effective. It needed to be reusable and cheap to produce, 
so that the overall cost of fabrication was manageable for users.  
3.4 Quantitative Analysis of Objectives 
To quantitatively analyze and order the objectives in terms of importance, the team 
created pairwise comparison charts (PCC) for the bioreactor and the microvascular network as 
seen in Table 28and Table 29 in Appendix B: Decision Matrices. A PCC is a method used to 
compare design objectives in pairs and to determine their relative importance. Each pair of 
objectives was discussed in detail, and the team came to agreement regarding the order of 
importance of the objectives for the success of this project. In the PCC, the objectives are listed 
as both rows and columns. The objectives in the first column are the initial objectives matched 
against each column. Moving across the row, if the objective in the row was more important than 
the objective in the column, the objective receives one point. If the team decided two objectives 
matched importance, the objective would get 0.5 points. The objective with the most points was 
ranked as the most important objective. This method allowed the team to properly allocate the 
necessary resources and effort to objectives that ranked highest.  
Appendix B: Decision Matrices shows all the decision matrices the team used. The team 
asked all users and clients to create a PCC. The client PCCs can be seen in Table 30 and Table 
31 in Appendix B: Decision Matrices. Each user PCC can be seen in Table 32 through Table 35 
also in below. A finalized PCC was created using the input from all parties. The team created a 
weight averaged PCC based on the clients’, users’, and the team’s original PCC. This was done 
by weighing the client and users’ scores as twice as heavily as the teams’ scores, therefore 
putting more weight in the opinions of the clients and users. Table 3 shows the final scores of the 
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microvascular network and Table 4 shows the final scores of the bioreactor. The PCCs were 
created after the discussion with the three clients. Initially, the team and clients had different 
understandings of what each objective entailed but once all parties agreed on the significance and 
meaning of each, the team was able to complete the following PCCs. 
Table 3: Final pairwise comparison chart of high-level project objectives for microvascular network 
 
Table 3 shows the PCC results for the microvascular network. For the microvascular 
network, physiologically relevant flow and stackable ranked as the two most important 
objectives. The microvascular network needed to sustain continuous perfusion at a physiological 
flow rate and allow for diffusion through the hydrogel. This objective is important, because in 
order for the finalized scaffold to be implantable, the microvascular network needed to withstand 
the in vivo conditions. The cardiomyocyte and microvascular layers needed to be stackable in 
alternating sequence for the microvascular network layers to provide nutrients and oxygen in an 
efficient manner to the cell seeded adjacent layers. The next objective was reproducibility of the 
system which included the output results and the network fabrication. Obtaining physiologically 
relevant dimensions was ranked next to allow future implantation and angiogenesis around the 
65 
cardiac patch. Next, the microvascular network needed to allow for endothelialization to occur 
and maintain the viability of the seeded endothelial cells. Cost effectiveness was ranked last 
because it was much more important for the project to be successful rather than reducing the 
cost.  
Table 4: Final pairwise comparison chart of high-level project objectives for bioreactor 
 
Table 4 shows the PCC results for the bioreactor. The most important objective of the 
bioreactor, specifically the microfluidic chamber, was its ability for gas permeability to be 
controlled. This was most important because it allowed the team to understand how the perfusion 
system was contributing to the cell viability, independently of external environmental factors. 
Without proper perfusion from the microvascular channels, the cells would not be viable. The 
second most important objective was reproducibility. Reproducibility has two meanings in this 
context. First, the environment the microfluidic chamber creates needed to be the same between 
experiments. Along with that, all fabricated microfluidic chambers needed to have the same 
dimensions. The ability to accommodate multiple samples in the bioreactor was ranked as the 
third objective. Having multiple samples to be tested and studied simultaneously was crucial for 
experimental reproducibility and experimental control. Ease of use was identified as the fourth 
most important objective. As such, later iterations of the project could address and improve the 
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assembly method and ease of use over the system. Finally, cost effective was last on the ranking 
of importance because, although it was important to keep price in mind, it was determined the 
price should not impair the effective performance of the system.  
3.5 Quantitative Analysis of Sub-Objectives 
After completing our analysis of the primary objectives the team began to analyze our 
sub-objectives through background research and client discussions. This analysis allowed the 
design team to quantitatively rank which sub-objectives were most important. When three or 
more sub-objectives were identified, a PCC was used to rank the relative importance of each. 
When there were only two sub-objectives for a given objective, no PCC was required and the 
design team decided which sub-objective had the greatest importance. The sub-objectives for the 
microvascular network were assessed first. 
3.5.1 Microvascular Network 
The design team analyzed the sub-objectives for the microvascular network component 
of this project, the objectives of which are presented in Figure 9. 
3.5.1.1 Reproducible 
Two sub-objectives were determined for the objective reproducible: network dimensions 
and network patency. The design team decided that reproducible network patency was the most 
important sub-objective. A reproducible and consistent network patency integrity would ensure 
the pressure in the microvascular network remain at the intended level. If one portion of the 
microvascular network were to collapse, the pressure in the other portions would increase, which 
would create an inconsistency in the network. Allowing for reproducible network dimensions 
was ranked second. This would ensure that the seeded cells are exposed to the same environment 
across samples.  
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3.5.1.2 Stackable 
Two sub-objectives were identified for the stackable objective. The first is the 
stackability of multiple microvascular layers and the second is the stackability of a microvascular 
layer and a cardiomyocyte layer being developed by Megan O’Brien. The design team 
determined that the stacking of a microvascular layer and a myocardial layer was most important 
because the purpose of the microvascular layer is to maintain cell viability of the adjacent layer.  
3.5.2 Bioreactor 
The design team analyzed the sub-objectives for the bioreactor component of this project, 
the objectives of which are presented in Figure 10. 
3.5.2.1 Reproducible 
Three sub-objectives were evaluated under the reproducible objective: reproducibility of 
dimensions, flow, and stacking of multiple layers with both accuracy and precision, seen in 
Table 37, Appendix B: Decision Matrices. The team determined that the highest priority sub-
objective was the reproducibility of flow. The client needed to be able to achieve the same flow 
rate conditions throughout the bioreactor system over multiple iterations of the experiments. The 
next most important sub-objective was that the bioreactor, specifically the microfluidic chamber, 
needed to be reproducible in dimensions. The fabrication process of the microfluidic chamber 
needed to produce devices with the same dimensions and characteristics. Lowest priority was 
given to the stacking of multiple layers because the team determined that at the current stage of 
the project, the device needed to be able to support two layers. At later stages of the project, this 
sub-objective has the potential to rise in importance, once the multilayer system becomes 
scalable to larger sizes.  
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3.5.2.2 Allow for Multiple Samples 
Two sub-objectives were identified for the allowance of multiple samples: prevent cross-
contamination and modularity. Prevention of cross-contamination was determined to be more 
important by the design team. It was crucial for the device to prevent issues of contamination and 
cross-talk between samples in experiments, because that could cause skewing of the collected 
data or failure of the experiment. Modularity would allow the number of samples to be adjusted 
depending on the experiment's need as opposed to allowing for a single pre-set number of 
samples. 
3.5.2.3 Ease of Use 
The team determined three sub-objectives of the higher level objective ease of use, which 
were as follows: ease of transport, ease of set-up, and ease of flow rate control. Using the PCC 
seen as Table 36, Appendix B: Decision Matrices, the design team decided that ease of transport 
was the most important sub-objective. Since the client had specified the device should be able to 
be moved from its location in an incubator to a microscope for visualization and imaging during 
the courses of a two to three week experiment, it was decided that ease of transport should be the 
first priority. Because the clients desired to use the device over multiple weeks, it was decided 
that the second most important sub-objective was the ease of fluid flow control. Since the device 
needed to be set up only once per experiment, this sub-objective had the lowest priority.  
3.5.2.4 Cost Effectiveness 
Two sub-objectives were identified under the cost effectiveness objective. The first sub-
objective was for the bioreactor to be reusable and the second sub-objective was to be 
inexpensive to produce. Upon analysis, it was decided among the design team and clients that the 
sub-objectives would have equal weight since if only one sub-objective could be achieved, either 
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would be sufficient. If the device was reusable, the cost would be limited to a one-time purchase 
or infrequent purchases over extended periods of time. On the other hand, if the device was 
cheap to produce, purchases could be made more frequently, and the user could save on time and 
resources trying to maintain the device.  
3.6 Constraints 
The team along with our clients formulated a list of constraints as seen in Table 2, in 
Section 3.2 Initial Client Statement and Clarification, for the microvascular network and 
bioreactor, as well as a list of constraints that are applied to the project as a whole. The 
constraints that applied to the microvascular network were biocompatibility, sterility, and size. 
The materials used for the microvascular network had to be biocompatible, since the 
microvascular network needed to sustain cells seeded around the channel. Along with that, the 
materials used for the microvascular network needed to be sterilizable in order to provide the 
seeded cells with a clean and safe environment. The clients and users set another constraint of 
the material chosen for the microvascular network. The fabrication material needed to be 
compatible with fibrin, since that would be the material used to make the cardiomyocyte seeded 
layers, which would be stacked on the engineered microvasculature. The microvascular network 
layer needed to be 1 cm by 1 cm in area, while being less than 1 cm thick, because that is the 
desired thickness of the final scaffold.  
The constraints for the bioreactor system were size, biocompatibility, sterility, 
transparency, and integrity in the incubator environment. Size wise, the whole bioreactor system 
needed to be compact enough to fit inside the incubator and the biosafety cabinet. More 
specifically for the microfluidic chamber, the size needed to be small enough to allow for 
imaging with a microscope, while having enough internal space to fit both the microvascular 
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network and a cardiomyocyte seeded gel layer, which is approximately 1 cm x 1 cm x 300 μm. 
The whole bioreactor system needed to allow for sterilization. This was important to protect the 
seeded cell culture from possible contamination, which would cause failure of the experiment. It 
was determined that the microfluidic chamber needed to have a transparent element, which 
would allow for microscope imaging. This was important for the users, so that the condition of 
the seeded cells could be observed, and adjustments to the experiment could be made if 
necessary. The last constraint for the whole bioreactor system was that it needed to sustain its 
structural and chemical integrity at 37°C temperature, 5% CO2 concentration, and 95% humidity, 
since this is the environment inside the incubator. 
Constraints that were placed on the project as a whole were time and budget. The first 
constraint was the timeline. The team was given twenty-eight weeks to complete the assigned 
project. In order to address this, the team planned guided timelines, which are described in more 
detail in Section 3.11.2 Project Management. The team followed the Gantt chart, as seen in 
Figure 111, Appendix A: Timelines, as a model. The second project constraint was the budget 
imposed through the official MQP guidelines. Each member of the team was given a budget of 
$156 adding up to a total of $780 for the entire project. 
3.7 Functions 
Based on the ranked objectives set by the design team, the users, and the clients, 
functions for the engineered microvascular network and the bioreactor were determined. The 
functions of the fabricated microvascular network were to imitate native vascular tissue, in order 
to create an environment that resembles in vivo conditions for cells to be cultured in. This could 
be achieved by recreating physiologically relevant dimensions of the channels and a 
physiologically relevant flow through the network, both of which are described in more detail in 
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Section 3.8 Specifications. The second function of the microvascular network was to sustain the 
cell viability of the cells seeded in the whole stacked system. This implied that the diffusion of 
the perfused nutrients and oxygen needed to reach and be sufficient for the cells seeded in the 
adjacent layer, representing the cardiomyocyte layer of the cardiac patch.  
Once the functions of the microvascular network were defined, the team moved onto the 
bioreactor. A large focus of the whole bioreactor system was the microfluidic chamber, since the 
team needed to design the device to be compatible with the fabrication method of the 
microvascular network. The first function of the bioreactor system was to sustain continuous 
perfusion at a physiologically relevant flow rate, which could be adjusted based on the user’s 
need. The second function of the bioreactor system was to maintain a sealed system that would 
limit the gas permeability, while maintaining a sterile environment. A specific function for the 
microfluidic chamber was that it needed to mold the microvascular network. Along with that the 
device needed to hold the multilayer construct, consisting of the cell seeded and microvascular 
network layers. All of these functions lead to the higher level function of the bioreactor system, 
which was to sustain the cell viability of a 3D cell culture construct.  
After defining the functions of the microvascular network and the bioreactor system, the 
team needed to define specifications in order to achieve the set objectives and functions, while 
remaining within the constraints. 
3.8 Specifications 
Specifications are specific metrics that assist and guide the design process. These 
statements and ranges limit the design space and help set a bar through which the team can 
measure the success of alternative designs and assist with selection of a final design. 
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A major aspect of the microvascular network design was that it needed to resemble the 
native tissue. From literature, the team determined the range of diameters of blood vessel types 
and their corresponding flow rates, as shown in Table 5 below. For the project, the team aimed to 
imitate arterioles, which range from 11 μm to 1000 μm, as the focus of the design was to create a 
fabrication method, rather than refine a pre-existing protocol. In order for the microvascular 
network design to be successful, the team needed to be able to fabricate channels within the set 
diameter range. These diameters and flow rates are seen in Table 5. 
Table 5: Average diameter ranges and flow rates in human blood vessels (Freitas, 1999) 
Blood Vessel Type Diameter Range (μm) Flow Rate (mL/min) 
Arteries 1000 - 6000 96.0 - 342.0 
Arterioles 11 - 1000 0.0015 - 0.21 
Capillaries 8 - 11 4.5 *10-6 
Veins 5000 - 10,000 240.0 - 720.0 
 
Another specification that was defined based on the objectives for the microvascular 
network was the diffusion distance. The microvascular network needed to promote diffusion to a 
distance sufficient to sustain an adjacent 300 μm thick layer. This sets the lower limit the of 
diffusion distance for the engineered microvascular network.  
Specifications for the bioreactor are specific to each component. The main purpose of the 
bioreactor system was to sustain a cell culture, and in order to do this efficiently, the microfluidic 
chamber, which holds the sample, needed a favorable environment for cell culture. The generally 
accepted environment for cell culture is 37°C, 5% CO2, and 95% humidity, since this closely 
resembles the in vivo conditions in the human body. These conditions are recreated inside 
incubators, so it was decided that the whole bioreactor system needed to fit inside the incubator, 
so that there was a minimized chance of contamination. The incubator at Pins Lab is 0.47 m x 
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0.47 m x 0.83 m, which means the whole assembled bioreactor system needed to be smaller than 
that. Since one of the objectives was for the system to recreate physiologically relevant flow, the 
pump needed to produce a flow in the range of 0.0015 - 0.21 mL/min, since that is the average 
range of the flow rate found in arterioles as described in Table 5. The users wanted to be able to 
observe the cell culture in the microfluidic chamber so the chamber needed to fit on a 
microscope stage. Based on the measurements from the microscopes available to Pins Lab, it was 
determined that the microfluidic chamber profile needed to be lower than 19.5 mm. The user 
desired to use the created bioreactor system for an extended period of time. The necessary time 
for the cell culture to proliferate and differentiate is two to three weeks, so the bioreactor system 
needed to be able to sustain the tissue construct for up to three weeks.  
3.9 Standards 
For any commercial product, especially when being used for medical purposes, strict 
standards must be followed. ISO International Standards ensure that products are safe, reliable 
and of good quality. The most important standard for the team's application is ISO 10993: 
Assessing the biocompatibility of medical devices and materials. This is necessary for any 
medical devices that come in contact with the human body and is in place to determine potential 
toxicity that could result from contact of the device's material with the body (ISO 10993, 2009). 
This is examined by testing the biocompatibility of the material used, in the team's case, 
Polytetrafluoroethylene (PTFE) and polyoxymethylene (POM). An agar diffusion assay can be 
used to determine the biocompatibility of each material by placing the test material on top of an 
agar layer, followed by incubation of the cells. Cytotoxicity of the material is indicated by 
formation of zones containing degenerative or lysed cells under and around the test material 
(Nemani, Moodie, Brennick, Su, & Gimi, 2013). Next is ISO 11737: Sterilization of Medical 
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Devices. This standard is in place to determine the amount of microorganisms that might be on 
the product, test the sterility, and to validate/maintain the sterilization process (ISO 11737, 
2006). ISO 13022: Medical products containing viable human cells are the next standard that the 
team must adhere to. This standard has been put into place as an application of risk management 
on the manufacture of medical products utilizing viable human material (ISO 13022, 2012). To 
test sterility, the device could be sterilized and filled with media. The device is left for five days 
in an incubator, and then examined under a microscope to determine microbial growth. The final 
standard that applies is ISO 16792: Technical product documentation using CAD. CAD is being 
used to design the bioreactor. Any devices that are created through CAD must adhere to this 
standard which outlines specific methods on documenting design drawings (ISO 16792, 2015).  
3.10 Revised Client Statement 
By meeting with the clients frequently, the team was able to keep them updated regarding 
the progress of the project and continually receive their feedback. By clarifying the client 
statement, quantitatively analyzing and ranking our objectives, and defining constraints and 
functions, the team developed a more detailed, revised client statement: 
 
Design, develop, and characterize a microengineered vascular network as well as a 
bioreactor that provides continuous perfusion through a thin hydrogel scaffold 
containing the microengineered vascular network. The bioreactor must allow for 
imaging under a microscope, be easy to use and cost effective, allow for 
reproducible stacking and flow, be sterilizable, and maintain an environment at 
37°C, 5% CO2, and 95% humidity because these are the widely accepted 
environmental conditions for cell culture in vitro. The microvascular network must 
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mimic physiologically relevant dimensions and sustain physiologically relevant 
flow. The microvascular network layer must also be endothelializable, stackable 
with other hydrogel layers, and cost effective. The entire system must maintain cell 
viability of an anisotropic, contractile myocardial tissue layer of 1 cm x 1 cm x 300 
μm in vitro for two to three weeks. 
 
The revised client statement contained more details and helped clarify the ultimate goal 
of the project. By incorporating significant objectives and specifications, project details were 
highlighted. The client statement was referenced by the design team during the entirety of the 
engineering design process. 
3.11 Project Approach 
3.11.1 Technical 
In order to keep the project on track, the team created five project strategy steps that were 
wanted to ensure were accomplished. The order in which they were placed follows the order in 
which the team strived to fulfill the milestones and keep up with the design strategy. The project 
strategy is shown below in Figure 11: 
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Figure 11: Project strategy steps 
The first step was to design and develop the microvascular network. Research of current 
approaches and techniques employed for channel formation was complete and based on that an 
original protocol for the vascular network fabrication was developed. Modifications to the 
protocol were made in order to match the objectives, constraints, and functions defined for the 
project. Once a single channel system was fabricated, the team moved on to form a bifurcated 
system. Once both processes were successful, the team moved onto designing and developing the 
bioreactor. 
A major element of the bioreactor system design process was the selection of 
components. Since specifications were defined, elements for the bioreactor were selected so that 
they could match the set operational ranges. Special attention was paid to the design of the 
microfluidic chamber, since this was the component that directly molded the microvascular 
network and held the tissue construct. After preliminary research was completed, the team 
created a concept design. After performance testing, modifications were made to the design to 
ensure the bioreactor system achieved the determined objectives.  
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The next step in the project strategy is to establish continuous perfusion through the 
fabricated microvascular network. This meant that the bioreactor pump component needed to 
provide a continuous flow through the microfluidic chamber, and the vascular network needed to 
sustain its patency and the provided flow. Once continuous flow was established, it was 
necessary to determine the performance of the microvascular network. 
The primary function of the vascular network was to sustain the viability of cells. The 
first characteristic that needed to be determined was the diffusion distance of nutrients. This was 
necessary to ensure that the fabricated microvascular network was feasible to provide nutrients to 
the adjacent layer. The last step of the project was to test the viability of these cells. Based on the 
proposed project strategy, a timeline with deadlines was created to keep the team on track and 
finish with the given time period.  
3.11.2 Project Management 
The team created a Gantt chart to highlight deadlines for various portions of the project 
beginning in A term and ending in D term. Every aspect from report writing to prototype 
production can be found with a deadline of completion. The yearlong Gantt chart can be seen in 
in Appendix A: Timelines. As the project progressed and tasks were completed, the team marked 
them off as complete, allowing the team's efforts and time to focus on the next tasks. If the team 
experienced problems or difficulty completing a set task during the project, the Gantt chart at 
times would be modified and adjusted appropriately to allow for enough time to complete the 
task thoroughly. Figure 111 in Appendix A: Timelines displayed a Gantt chart for A term and 
Figure 112, Figure 113, and Figure 114, and show Gantt charts for B, C, and D Term, 
respectively. These contain more details on the task deadlines than Figure 111. These Gantt 
charts can be seen in Appendix A: Timelines. 
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Each week, the team met with the advisors and clients to update them on the progress and 
direction of the project. During these meetings, the team gave presentations that highlighted the 
milestones completed the previous week, the goals of the coming week, and any problems the 
team might have encountered. Our advisor and clients challenged the team each week to think 
differently about certain tasks to ensure that alternative designs were considered and the best 
final design could be chosen. 
3.11.3 Financial 
A constraint of the project was the team's budget. Each member was allotted $156.00 
giving the team an accumulative budget of $780.00. The significant portion of the team’s budget 
went to purchasing materials for the microvascular network media, and growth factors. Before 
the end of A term, about 70% of our budget had been spent on those materials. The budget that 
was left went towards having allocated lab space in Goddard Hall 006, and materials necessary 
to run the proposed validation experiments.  
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Chapter 4: Design Process 
In this chapter, different design alternatives for the microvascular network and the 
bioreactor are described and evaluated to understand how well each would accomplish the 
project's objectives, functions, and specifications. The team specifically designed the 
microfluidic chamber component of the bioreactor system. This chamber is the interface between 
the bioreactor and the microvascular network. The team started by brainstorming and creating 
simplified conceptual designs. Based on the ideas proposed during these sessions, multiple 
possible alternative designs were created. The potential performance of each design was 
analyzed. Based on how well the design matched the set objectives, functions, and specifications, 
a final design was chosen. In Sections 4.2 Microengineered Vascular Network and 4.3 Bioreactor 
and Microfluidic Chamber, the design considerations and process are described respectively for 
the microvascular network and the bioreactor system.  
4.1 Design Concept 
After formulating the project approach, the team created a conceptual design of the 
project including the microvascular network, bioreactor system, and more specifically, the 
microfluidic chamber. With an understanding of the functions, objectives, constraints, and 
specifications, the following design concept was made in Figure 12. A design concept is the 
underlying basis for creating alternative designs for the entire project. 
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Figure 12: Design concept of the project. The design shows the completely assembled bioreactor system with the 
microvascular network 
The design concept shows a crude representation of what the final project setup will look 
like with general components. This figure shows a pump that provides continuous perfusion at 
physiologically relevant flow through a microfluidic chamber which contains a microengineered 
vascular network in a sterile environment. The microengineered vascular network replicates 
physiologically relevant dimensions and sustains cell viability through diffusion of perfused 
nutrients. The perfused media then flows through the outlet into a collection flask. The 
microfluidic chamber needs to allow for imaging, so it was designed to fit on the microscope 
stage with a viewing window.  
4.2 Microengineered Vascular Network  
4.2.1 Needs analysis 
Based on the objectives, described in detail in Chapter 3: Project Strategy, the team 
analyzed which elements of our project are needs and which are wants, based on our clients and 
users’ input. For the microvascular network it was determined that the system needed to sustain a 
physiologically relevant flow ranging between 0.0015 - 0.21 mL/min and the fabricated channels 
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needed to have a diameter within the physiologically relevant range of 11 - 1000 μm. Along with 
that the microvascular network needed to maintain its patency. In order for statistically relevant 
studies performed on the system, the microvascular network fabrication needed to be 
reproducible and give reproducible results when tested under the same conditions. 
Wants defined for the microvascular system were that it should be endothelializable and 
cost effective. In order to be endothelializable, the network needed to be made from a material 
that promotes cell adhesion to the inner wall of the channel and angiogenesis. In order to be cost 
effective, the microvascular network fabrication method should minimize waste, and allow for 
tools to be reused for the process after being washed thoroughly.  
4.2.2 Feasibility studies 
This section contains the feasibility studies for methods of creating the microengineered 
vascular network. Each feasibility study was conducted to determine whether the method could 
result in the formation of a single channel. 
4.2.2.1 Cylindrical Rod Extraction 
In order to determine the feasibility of the cylindrical rod extraction method as a 
technique for microvascular network fabrication, three factors were evaluated. The first aspect 
was the rod’s geometry, which needed to be uniform without damaging the channel. The second 
factor taken into account was the mobility and assembly of all the tools necessary to fabricate the 
channel. The third aspect evaluated was the ability to produce an empty perfusable channel.  
The idea of this method came from previous work of an earlier MQP project: “Fibrin-
based Microvascular Network for the Modular Design of a Cardiac Patch.” Small rectangular 
frames glued to glass slides were used as wells for the fibrin gel, as seen in Figure 13.  
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Figure 13: The well frames with attached tubing for channel fabrication 
The frames had two openings on opposite walls, which acted as the inlet and outlet for 
fluid perfusion. Initially, the method employed a thin 30G needle, which was inserted through 
the openings. Once the needle was in place, fibrinogen and thrombin solutions were cast into the 
well to produce the fibrin gel. Once the gel was fully polymerized, the needle was extracted, 
which left behind a small cylindrical channel, which can be seen in Figure 14. Using bright field 
microscopy, the channels were characterized. 
 
Figure 14: Channels fabricated using cylindrical rod extraction method. Three straight single channels fabricated using 
needles in the same gel. The channels were not structural uniformity both along the same channel and between different 
channels. 
Even though the channel produced had imperfections and defects, such as some 
deformation along the walls, it clearly connected the two ends of the gel, allowing for perfusion 
to occur. This simple method allowed for the fabrication of single straight channels in a fibrin 
gel. Since the technique successfully covered all aspects of the feasibility test, it was determined 
that this was an adequate method to produce the microvascular network.  
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4.2.2.2 Sacrificial Mold  
To assess the feasibility of a sacrificial material to ultimately be used to develop a 
microvascular network, the team determined the ability of a sacrificial mold to produce a single 
channel. Three criteria were assessed: the production of a sacrificial mold with adequate 
geometry, the ability to transfer the mold, and the ability to form an empty channel. 
4.2.2.2.1 Pluronic F127 
The feasibility of Pluronic F127 as a sacrificial material was assessed. A 24.5% solution 
of Pluronic F127 in phosphate-buffered saline was prepared due to its unusual thermoresponsive 
properties. The material exists as a gel at room temperature and liquid at 4°C and it is this 
property that allows the Pluronic to be used as a sacrificial material. The phase diagram showing 
these properties is shown in Figure 15. 
 
Figure 15: Phase diagram of Pluronic F127 (Müller, Becher, Schnabelrauch, & Zenobi-Wong, 2013) 
Extrusion of Pluronic Cylinders  
Pluronic sacrificial molds were produced by extruding the gel at room temperature to 
form cylinders. Various sized cylinders were produced by extruding out of a 1 mL syringe using 
various sized needles as seen in Figure 16.  
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Figure 16: Multiple sizes of Pluronic cylinders extruded from 1 mL syringe (left) and 23G needle (right). 
Mold Transfer 
As a gel, the Pluronic cylinders are not structurally sound and are unable to be transferred 
to another location. To overcome this property, the cylinders were dehydrated on the bench top 
for at least one hour. The dehydrated Pluronic cylinders were then stiff enough to be picked up 
and moved into place in a mold, as can be seen in Figure 17.  
 
Figure 17: Dehydrated Pluronic cylinder a) resting against acetyl slide to show stiffness and b) placed in PDMS mold. 
Channel Formation 
To form a channel in fibrin, a dehydrated Pluronic cylinder was placed in a PDMS mold 
and secured with laboratory tape. After the addition of fibrin components in a method as found in 
Appendix D: Protocols: Fibrin Gel Preparation Protocol, the cylinder rehydrated, as seen in 
Figure 18. 
   
Figure 18: Observed Pluronic cylinder rehydration (passage of time left to right) during fibrin polymerization. 
After fibrin polymerization was complete, the scaffold was placed in water at 4°C to 
liquefy the Pluronic sacrificial mold. After the sacrificial material was fully removed, blue food-
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colored water was perfused into the channel to show successful channel formation, as seen in 
Figure 19. 
  
Figure 19: Channel formation from Pluronic sacrificial mold. Empty channel after Pluronic liquefying (left) and after 
brief filling with blue food-colored water (right). 
Through this feasibility study, it was shown that sacrificial molds could be created with 
Pluronic F127 which could be transported to a PDMS mold, liquefied, and forms a channel that 
could be filled. 
4.2.2.2.2 Gelatin 
The feasibility of gelatin as a sacrificial material was assessed. A 10% w/v solution of 
gelatin was created using a protocol originally adapted from Golden & Tien, found in Appendix 
C: Client Meetings. The crucial sacrificial material property for gelatin is its gel transition 
temperature, between 20°C and 35°C depending on concentration, as seen in Figure 20. This 
sacrificial material is heated above the melting temperature, formed in a mold, and cooled below 
its gelation temperature. Once in place in a fibrin gel, created using the protocol found in 
Appendix D: Protocols: Fibrin Gel Preparation Protocol, the material can again be heated above 
its melting temperature and flushed out, leaving behind a channel. 
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Figure 20: Concentration-temperature phase diagram of aqueous gelatin sample showing the transition temperatures for 
melting (upper) and gelation (lower). The gelation line depends on cooling rate, which was 0.5 K min-1 here (Parker & 
Povey, 2012). At a concentration of 10%, gelatin exists as a gel at room temperature and a liquid at 37°C. 
Gelatin sacrificial molds were fabricated by melting the gelatin solution and then filling 
PDMS molds, both cylindrical and a half bifurcation, as seen in Figure 21. 
  
 
  
Figure 21: Straight and y-shaped gelatin molds. Straight gelatin channel molds and y-shaped structure formed in PDMS 
mold after gelation (A & C) and after drying overnight (B & D). 
A B 
C 
D 
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Gelatin sacrificial molds were also fabricated via extrusion of gelatin in its gel state. 
Gelatin was heated while submerged in water on a hot plate to melt. Liquid gelatin was then 
pulled into a one milliliter syringe and let cool for approximately 15 - 20 minutes. The gel was 
then extruded out of the syringe directly or through a 20G needle. The result was successful 
fabrication of sacrificial mold cylinders via extrusion of solid gelatin, as seen in Figure 22. 
 
Figure 22: Fabrication of gelatin sacrificial mold cylinders via extrusion of solid gelatin. 
After gelation, the sacrificial materials were able to be transported as a gel. It was noted 
that upon dehydration of the gelatin sacrificial molds, a qualitative decrease in size was 
observed. In addition to a decrease in diameter, this property would allow for easy transport of 
the sacrificial mold to another location.  
A channel was formed, as seen in Figure 23, using a dehydrated gelatin cylinder which 
was encased in fibrin and heated at 37°C. This whole process was completed in a Box Mold  
   
Figure 23: Channel formed from gelatin sacrificial material. a) gelatin cylinder in Box Mold, b) gelatin after filling mold 
with fibrin, and c) channel after gelatin flushing, viewed under 20X magnification. Arrows indicate channel edges. 
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This feasibility study showed that sacrificial molds could be created from gelatin that 
could be transported to a mold, liquefied, and formed into a channel. 
4.2.2.2.3 Polyvinyl Alcohol 
The feasibility of polyvinyl alcohol (PVA) as a sacrificial material was assessed. PVA is 
a water soluble synthetic polymer with high dependency on the humidity of its surroundings. 
Higher humidity means that more water is absorbed. A potential method of channel formation 
included placing a PVA cylinder inside the mold, casting the fibrin layer, and seeing if the PVA 
would dissolve, thus creating a channel. To determine the feasibility of PVA as a sacrificial 
material for vascularization, a 0.4 mm PVA cylinder was 3D printed. Next, the PVA was 
carefully placed into the indentations on the base of the two piece mold. Then, the top piece was 
placed onto the sacrificial material, making sure the pieces were aligned carefully and that the 
material was secured. A binder clip was used to keep the two pieces together. This would ensure 
the top and bottom piece would not separate during the experiment and can be seen in Figure 24 
and Figure 25 below. 
 
Figure 24: Two Piece Mold with Base with PVA channel before adding fibrin 
Next, the fibrin gel, prepared using the protocol found in Appendix D: Protocols: Fibrin 
Gel Preparation Protocol, was cast within the mold. This was done by adding a mixture of 
89 
fibrinogen, thrombin, CaCl2, and PBS. After about ten minutes, the PVA began to dissolve into a 
viscous substance as seen below in Figure 25.  
 
Figure 25: Two Piece Mold with PVA channel and fibrin scaffold forming 
After waiting fifteen more minutes, the team attached tubing and tried perfusing water 
through the system. However, the PVA was too thick and the water could not dissolve 
thoroughly or push the PVA through the channel. Another issue that arose included that the PVA 
began to sink to the bottom of the mold. This could be a result of the weight of the PVA, in 
addition to the possibility of the indentations of the mold being too small. It is possible this did 
not allow the PVA to expand as necessary within the water. As a result of this experiment, the 
possibility of using PVA as a sacrificial material to create a channel within the fibrin layer was 
eliminated. 
4.2.2 Microengineered Vascular Network Verification Tests 
Once the feasibility studies for cylindrical rod extraction and sacrificial molds were 
complete, verification tests were performed. These tests were completed to determine any key 
limitations or additional factors to consider before choosing the method of forming the 
microengineered vascular network for the final design.  
4.2.2.1 Cylindrical Rod Extraction 
As described earlier in the chapter, this method initially employed a thin 30G needle as 
the channel molding tool. The needle was placed in the gel mold through the inlet and outlet 
needles, and fibrin gel was cast around it, using the protocol in Appendix D: Protocols: Fibrin 
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Gel Preparation Protocol. Once the polymerization process was complete, the needle was 
removed leaving behind a channel inside the gel. In order to perfuse through the system, 
polyethylene tubing was connected to the inlet and outlet needles. This attachment of the 
perfusion tubing often caused damage to the fibrin gel. The inlet and outlet needles were not 
glued so that they could be cleaned and replaced periodically. An external force was exerted on 
the outside of the mold needles while trying to connect the tubing, causing the needles to 
dislocate inwards. This was an undesirable result, since by dislocating inwards, the mold needles 
made it difficult to connect the perfusion tubing and damaged both the gel and the channel. In 
order to prevent this dislocation of the inlet and outlet needles, the polyethylene tubing needed to 
be attached to the needles prior to the fibrin gel casting. This allowed for the tubing to be secured 
properly and the inlet and outlet needles to be readjusted as needed.  
By pre-attaching the polyethylene tubing, it became impossible to use the 30G needles, 
since they were too short. In order to overcome this obstacle, thin steel wires were employed. 
The wires were cut to a length that would allow them to be threaded into the perfusion tubing 
and through both the inlet and outlet needles, as seen in Figure 26. 
 
Figure 26: Cylindrical rod extraction method setup 
The tubes are attached prior to the wire being introduced through the inlet and outlet. 
Once in place, the fibrin gel is cast. In the same manner as in the needle extraction method, the 
wires were removed once the fibrin gel polymerized leaving behind a single channel. 
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Unfortunately, due to the adhesive nature of fibrin, a problem occurred during the extraction 
process. The fibrin adhered to the wire, which caused channel to lose uniformity, and in more 
serious cases, the whole gel to be malformed, as shown in Figure 27. 
 
Figure 27: Channel damage in cylindrical rod extraction. Gel damage occurring due to the adhesion of the fibrin to the 
steel wire during extraction 
The method needed to be adapted in order to reduce the adhesion of the fibrin gel to the 
steel wire. In order to do so, the steel wires were coated with Pluronic F127. With the Pluronic 
coating, the adhesion of fibrin to the wire was significantly reduced allowing for channels to be 
properly formed.  
In some cases, even after applying the Pluronic coating, serious tears along the walls of 
the channels were observed. Due to the manner of cutting, defects formed on the tips of the wire. 
These defects acted as “hooks,” which caused tears and damage along the wall of the channels. 
In more serious cases, the damage would be enough to compromise the integrity of the channel 
and then pierce the gel. In order to prevent these tears, the tips of the wires were filed using fine 
diamond files. The smoothened tips are shown in Figure 28. Using the filed wires, while coated 
with Pluronic, straight single channels were fabricated uniformly and with minimal damage as 
seen in Figure 29.   
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Figure 28: Filed tip of the steel wire. As it can be seen, the cutting artefacts were removed, as the edges were filed with a 
diamond file. 
 
Figure 29: Cylindrical rod extraction channel. Channel in fibrin gel fabricated through cylindrical rod extraction method, 
using filed and Pluronic coated wire 
One of the major challenges the microvascular network faced was perfusion. Even 
though the channel was properly formed, perfusion had been temporarily unsuccessful because 
of a blockage which formed from trapped air as fluid was being pumped into the channel. The 
blockage formation is shown in Figure 30.  
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Figure 30: Air bubble blockage. Image of the air bubble blockage that forms when using the cylindrical rod extraction 
method, obstructing perfusion 
One procedure that proved to be successful was air perfusion. Once the needle was 
extracted, leaving behind a channel in the gel, air was perfused through at a low rate. This initial 
perfusion indicated possible blockages in the channel, which could be opened by reinsertion of 
the wire and removed. This step ensured that the channel is empty, and allowed for fluid flow.  
4.2.2.2 Sacrificial mold – Pluronic F127 
After the Pluronic feasibility study was complete, Pluronic bifurcated channels were 
created on acetyl plastic using the hand-printed extrusion production method as seen in Figure 
31. 
 
Figure 31: Pluronic bifurcations via hand-drawn extrusion 
 Though bifurcated sacrificial materials were created, the Pluronic adhered to the 
surface of the acetyl plastic. Multiple surfaces were tested for Pluronic adherence. Pluronic 
printing on polystyrene, glass, and vellum paper all resulted in adhered Pluronic material. 
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However, Pluronic was found to not stick on PDMS surfaces. A bifurcated Pluronic material was 
printed on PDMS and shown to be non-adhered as seen in Figure 32. 
 
Figure 32: Pluronic bifurcation printed on PDMS and lifted to show non-adherence. 
A Pluronic cylinder was placed and enclosed in a two-part PLA mold to test perfusion. It 
was observed however that after fibrin components were added, the cylinder malformed over 
time as seen in Figure 33. Fibrin gel was formed via the protocol found in Appendix D: 
Protocols: Fibrin Gel Preparation Protocol. After fibrin polymerization was complete, the 
sacrificial material was removed and a channel formed.  
 
Figure 33: Pluronic mold channel fabrication. a) Pluronic cylinder across lower PLA mold, b) with top mold attached, c-f) 
channel malformation during fibrin polymerization, g) channel formation after sitting in 4°C water. 
It was hypothesized that the Pluronic cylinder swelled during rehydration after the fibrin 
precursors were added to the mold. Since the cylinder was actually clamped on either side by 
misalignment of the top and bottom molds, the middle portion of the cylinder likely swelled but 
had no room to expand in the inlet and outlet holes. To test if a Pluronic mold resting in an open 
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mold would exhibit the same effects; a bifurcated Pluronic sacrificial mold was created and 
placed in an open PDMS mold. Swelling and malformation were again observed, as seen in 
Figure 34. It was observed that the ends of the Pluronic did not rehydrate. The ends did not shift 
as the Pluronic malformed and they appeared to stick to the PDMS, causing malformation of the 
Pluronic within the mold. 
 
Figure 34: Pluronic bifurcation channel formation. a) Pluronic bifurcation in PDMS mold, b-d) Pluronic bifurcation over 
time (~15 minutes) after addition of polymerizing fibrin. 
To model the change in size of the Pluronic the diameter of cylinders (n=4) were 
measured during dehydration at time points of 5, 30, and 240 minutes, as seen in Figure 35. The 
results were inconclusive as some samples had increases in diameter at early time points between 
five and thirty minutes after extrusion, while there was little change in diameter after thirty 
minutes. There was some time after extrusion before images were first taken so it is possible that 
changes in diameter went unrecorded. If Pluronic was chosen as a sacrificial material, further 
tests could have focused on the change in diameter in this initial time point that was not captured. 
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Figure 35: Change in diameter of Pluronic F127 in PBS over time. Note the initial increase in diameter of samples 1 and 4 
from 5 to 30 minutes post-extrusion. 
One hypothesis for the swelling as well as observed brittleness of the Pluronic was salt 
crystallization from the phosphate-buffered saline (PBS) in which the Pluronic polymers were 
dissolved. A new Pluronic solution was created using the same protocol, replacing PBS 
deionized water. It was hypothesized that though there may not have been a change in diameter, 
a change in length during dehydration may have been observed. As seen in Figure 36, a decrease 
in length was observed for all cylindrical (n=5) and bifurcated (n=2) samples at time points of 5, 
10, 20, 55, 70, and 78 minutes. The average decrease in length was 9% and 10% for cylindrical 
and bifurcated samples respectively. However 5 minutes passed after fabrication of the sacrificial 
molds before images were taken. Since there was an observed sharp decrease in length in the 
first ten minutes recorded, it is possible the actual decrease in length was much greater than 9%. 
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Figure 36: Change in length of Pluronic F127 in deionized water over time. Note the overall and immediate decrease in 
length. C = cylinder, B = bifurcation 
4.2.3 Alternative Designs  
This section contains alternative designs pertaining to the microengineered vascular 
network. Presented are methods of forming a microengineered vascular network followed by 
sacrificial mold fabrication methods, and sacrificial mold loading methods. 
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4.2.3.1 Microvascularization Strategies 
Table 6: Means chart for the creation of a microvascular network 
 
Function – Create microvascular network of physiological dimensions 
Means Advantages Limitations 
Angiogenesis / 
Vasculogenesis 
Cells create own vasculature 
Only 1 hydrogel required 
Physiologically relevant size 
Time consuming 
Cannot perfuse immediately 
Difficult channel formation at 
input / output of microfluidic 
chamber 
Bonding of Pre-
Vascularized Hydrogels 
Well-defined geometry 
Complex geometry 
capabilities (bifurcations 
possible) 
Fills effectively via capillary 
action 
Difficult sealing backflow of 
fluid around inserted needle 
2 Hydrogels required - leads to 
problems adhering multiple gels 
Some difficulty aligning channel 
w/ inlet & outlet 
Cylindrical Rod 
Extraction 
Simple set-up, channel 
formation 
Channels always line up w/ 
input & output 
Multiple channels possible 
Limited to straight, non-
bifurcated channels 
Non-uniform geometry 
Hydrogel damage due to shear 
upon extraction 
 
Sacrificial Mold Only 1 hydrogel required 
No attachment nor adhesion 
problems 
Bifurcations possible 
No damage due to shear 
Proper sealing at input & 
output 
Potential for unwanted residue 
along the channel 
 
Table 6 shows the advantages and disadvantages of methods to create the microvascular 
network. One commonly used method of creating a microvascular network is through the natural 
processes of angiogenesis or vasculogenesis. The advantages of this method are that endothelial 
cells produce the microvasculature either de novo or from existing vessels. As a result, the 
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vasculature formed is of physiologically relevant dimensions. Only one hydrogel would be 
required which avoids problems adhering multiple gels. Limitations of this method include the 
process being time consuming, on the order of days, and as a result the vasculature cannot be 
perfused immediately. Since cells are required to create the vasculature, they themselves need 
vascularization to remain viable if the thickness of the construct is greater than 400 μm. Finally it 
was difficult to direct the formation of blood vessels to and have proper sealing at the input and 
output of a microfluidic chamber. 
An additional means of creating a microvascular network was via the bonding of pre-
vascularized hydrogels. Through the use of precise manufacturing processes such as silicon 
wafer photolithography, well-defined geometry within the hydrogel after network fabrication 
was maintained. Complex, small-scale geometries could be formed and these channels could be 
filled well via capillary action. A major drawback of this method was that it only allows for half-
channel formation. In order to complete the channel, an additional layer needs to be applied on 
top of the molded fibrin layer. This produces a number of issues to the method. Adhesion 
between two fully polymerized fibrin layers is a difficult process and often results in weak 
attachment. This means that the seals at the inlet, outlet, and around the channel walls were 
compromised and may have led to leakage. An additional complication arose from the need to 
align the inlet and outlet of the network with the bioreactor.  
Another method of creating a microvascular network was via cylindrical rod extraction in 
which a wire or needle is suspended and fibrin is cast around it. Once the fibrin polymerizes, the 
wire was then extracted, leaving behind a cylindrical channel. Of the means described here, this 
method had the simplest set-up and procedure for channel formation. Finally, it was possible to 
create multiple, parallel channels with an associated mold. Some limitations of the cylindrical 
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rod extraction method included being limited to applications of straight, non-bifurcated channels 
and non-uniform geometry or gel tearing due to adhesive interactions between the wire and 
hydrogel. 
A final method considered for creating a microvascular network involved making use of 
sacrificial materials. In this method, the channel was produced by a material, which was 
dissolved and flushed out, leaving a channel behind. One advantage over the photolithographic 
method was that the fibrin gel can be formed in one piece as opposed to two, which eliminated 
the problem of gel adhesion. Similar to photolithography, but contrary to the cylindrical rod 
extraction method, sacrificial molding could create more complex geometries than the cylindrical 
rod extraction method. One limitation, similar to photolithography, was the difficulty of aligning 
of the network with inlet and outlet of the bioreactor. Another drawback of this method was that 
it might leave unwanted residue along the channel.  
4.2.3.2 Sacrificial Mold Fabrication Methods 
Four sacrificial mold production methods were determined and advantages, 
disadvantages, were compiled as seen in Table 7. 
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Table 7: Analysis of sacrificial mold production method 
Production 
Method 
Advantages Disadvantages 
Free Extrusion Reproducible geometry 
Extrusion rate independent 
Cost effective 
Limited to single channel 
geometry 
Hand-Printed 
Extrusion 
Bifurcations possible 
Cost effective 
 
Less reproducible geometry 
Less reproducible extrusion rate 
Difficulty forming solid 
connections in bifurcations 
Cast in Mold Bifurcations possible, geometries 
only limited by reverse mold 
Reproducible geometry 
Can be cost effective 
Problems removing sacrificial 
material from mold 
 
3D Printed Complex possible 
Reproducible geometry 
Reproducible extrusion rate 
Most expensive 
Extrusion size constraint 
Limited material options for 
sacrificial mold method 
 
The first sacrificial mold production method was free extrusion in which a sacrificial 
material was extruded out of a syringe and needle. The advantages of this method were its 
reproducible geometry, process that was independent of extrusion rate, and cost effectiveness. 
The main disadvantage of extrusion was the limitation to production of single channel geometry. 
A similar production method was hand-printed extrusion. In this method, the user 
extrudes the sacrificial mold out of a syringe and lays down cylindrical material to build a more 
complicated structure such as a bifurcation. The main advantages of this method were being able 
to create materials with more complicated geometries than cylindrical extrusion and its cost 
effectiveness. Disadvantages of this method included difficulty maintaining regular thickness, 
forming solid connections in bifurcations, less reproducibility over the geometry, extrusion rate, 
and lateral printing speed. 
Another production method of sacrificial materials was to make a mold with a material 
such as PDMS in which the sacrificial material could be added and solidified. The advantages of 
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this method were reproducibility, vast number of geometries possible, limited only by what can 
be produced as a reverse mold on which to cast the PDMS, and potential cost effectiveness 
depending on the mold fabrication method. 
3D printing was another possible method to produce sacrificial materials. The advantages 
of this method were the potential for printing bifurcations and increased reproducibility in 
extrusion rate and lateral printing speed. The disadvantages of this method were the large 
extrusion size, limited sacrificial materials available and considerably greater expense when 
compared to other methods. 
4.2.3.2.1 Sacrificial Mold – Photolithography Feasibility Study 
Another feasibility of gelatin as a sacrificial material was assessed, this time using a 
PDMS mold created from a photolithographic silicon wafer. Liquid gelatin was added to the top 
of the PDMS mold and excess liquid was scraped off. The gelatin was cooled and allowed to gel 
at 4°C. The solidified this sacrificial material film was then peeled off the PDMS as seen in 
Figure 37, but the gelatin was somewhat damaged when removed with forceps. In the future, 1% 
bovine serum albumin (BSA) would be added in an attempt to help remove the film without 
causing damage. 
 
Figure 37: Gelatin on PDMS stamp with microvascular network pattern formed via photolithography. 
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 After successful formation and transport of the sacrificial material, it was placed 
in a PDMS mold and fibrin was cast around it. After polymerization, the mold in fibrin was 
imaged, the gelatin was melted at 37°C, and the resulting structure was imaged again, as seen in 
Figure 38.  
  
  
  
Figure 38: Sacrificial mold - photolithography feasibility study: gelatin sacrificial material formed and placed on fibrin. 
Top: Sacrificial material in PDMS mold before (left) and after (right) fibrin addition. Bottom: Gelatin sacrificial mold on 
top of fibrin (left) and pattern left on top of fibrin after gelatin melted.  Note: microvascular network is on top of fibrin 
gel. 
This feasibility study showed gelatin could be patterned on a PDMS surface, and could 
leave a pattern on fibrin after melting and removal. A limitation of this study was that the 
sacrificial material floated to the top of the fibrin so the pattern formed on the top of the fibrin 
gel. 
4.2.3.3 Sacrificial Mold Loading Mechanisms 
Part of the design of the microvascular network using a sacrificial mold included the 
loading mechanism of the mold into a microfluidic chamber. The loading mechanism refers to 
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the way the sacrificial mold is placed into the microfluidic chamber after production. 
Mechanisms were brainstormed and analyzed, as seen in Table 8. 
Table 8: Analysis of sacrificial mold production method 
Loading 
Method 
Advantages Disadvantages 
Semi-circle 
laying 
 Allows for complex geometries 
 Simple to “drop” sacrificial mold in 
place 
 Mold does not need to be 
transferred once in place 
Limits design of bioreactor inlet 
and outlet 
Lateral tube-
loading 
 Allows for complex geometries Mold needs to be placed in tube 
laterally 
Difficult to move if loaded outside 
of bioreactor 
Threading  Mold does not need to be 
transferred once in place 
Limited to straight, cylindrical 
sacrificial molds 
 
The semi-circle laying mechanism consisted of placing the sacrificial mold in a semi-
circular portion of a mold. One design, as seen in Figure 39, was to design the inlet and outlets as 
semi-circles on the top and bottom of the microfluidic chamber.  
  
Figure 39: "Semicircle laying" loading mechanism: sacrificial material is placed into semicircular grooves in the bottom 
portion of a mold before the top of the mold is dropped into place. 
The lateral tube-loading method consisted of placing a mold into a tube and then sliding 
the second tube into place over the other end of the mold, as seen in Figure 40. The main 
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advantage of this method was that molds with more complex geometries could be loaded into the 
bioreactor. Disadvantages included difficulty in loading the mold laterally and difficulty moving 
the tubes once the mold was in place. 
  
Figure 40: "Lateral tube-loading" loading mechanism: a) Sacrificial material is inserted into one tube and then b) the 
other tube is moved laterally into place over the other end of the cylinder. 
 The threading method consisted of pushing a cylindrical mold through the inlet, though 
the volume of the mold, and through the outlet, as seen in Figure 41. The advantage of this 
method was that the mold did not need to be transferred once it is put in place. The main 
disadvantage was that the mold must be cylindrical. 
  
Figure 41: "Thread" loading mechanism: a) Pluronic cylinder is inserted into the inlet needle and then b) pushed and 
inserted through the outlet needle. 
4.2.4 Final Design Selection 
To select a final design for the microengineered vascular network, the team assessed 
vascularization methods, materials and fabrication methods.  
4.2.4.1 Vascularization Method 
To select a vascularization method, a Pugh Method decision matrix was created as seen 
in Table 9.  
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Table 9: Pugh Method decision matrix for the selection of the vascularization method 
 
The selection criteria were avoiding damage due to fluid shear upon removal of the mold, 
the requirement of sealing multiple hydrogels, sample fabrication time, sealing at the fluid input 
and output, the possibility of creating bifurcated channels, and whether or not it was possible to 
begin perfusion immediately after adding cells. These criteria were created based on the 
previously mentioned, in Section 4.2.3.1 Microvascularization Strategies.  
The first step in the selection of the final vascularization method was to assign weights to 
the selection criteria with 6, sealing at input and output being the most important and 1, sample 
fabrication time, being the sixth most important. It was then determined if each method met the 
selection criteria as stated in the selection criteria specification in the second column.  
The sacrificial mold vascularization method was selected because it met five out of six 
criteria in full and ended with 20.5 out of a possible 21 points. The sacrificial mold method 
overcomes many key limitations of other methods. There is limited damage to the hydrogel due 
to shear since the mold is a liquid when it is removed from the mold. An entire hydrogel is cast 
around a pre-fabricated sacrificial mold which means that only one hydrogel would be needed 
and there is no need to adhere multiple gels. The sample fabrication time for the sacrificial mold 
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method was slightly longer than some others because there were two steps: fabricating the 
sacrificial mold and forming the vascularization. However this method, on the order of minutes, 
is still much faster than angiogenesis/vasculogenesis, on the order of days. Because the 
sacrificial mold could be integrated into the microfluidic chamber before hydrogel formation, 
there would be proper sealing at the input and output of the hydrogel. Finally, bifurcations were 
possible and perfusion would be possible after the addition of cells as soon as the mold was 
removed. 
4.2.4.2 Sacrificial Mold Material 
After the sacrificial mold vascularization method was chosen, the next aspect of the final 
design considered was the sacrificial mold material. The final material was selected after the 
creation of a decision matrix, seen in Table 10. 
Table 10: Pugh Method decision matrix for the selection of the sacrificial mold material 
 
The selection criteria were the sacrificial material fabrication ease of use, the ability to 
form a residue free channel, the ease of removal of the sacrificial material, reproducibility of 
geometry and extrusion rate, cost effectiveness, and ease of use with respect to removal of the 
produced sacrificial mold. These criteria were chosen based on the previously mentioned, in 
Section 2.3.3.2.4 Sacrificial Molds, as well as the sacrificial mold feasibility studies in Section 
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4.2.2 Feasibility studies. As in the previous section, weights were assigned to the selection 
criteria and total scores calculated.  
The sacrificial mold material chosen for the final design was gelatin since it received 6 
out of a possible 6 points. The mold fabrication was easy since it was done at room temperature, 
no visible residue remained in the channel in the feasibility studies, and the material was easy to 
remove by heating to 37°C in an incubator and flushing. 
4.2.4.3 Sacrificial Mold Fabrication Method 
After the sacrificial mold vascularization method and material were chosen, the sacrificial 
mold fabrication method was the next aspect of the final design for the microengineered vascular 
network. The final fabrication method was chosen after the creation of a decision matrix, seen in 
Table 11. 
Table 11: Pugh Method decision matrix for the selection of the sacrificial mold fabrication method 
 
The selection criteria were the ability to form bifurcations, reproducibility of geometry 
and extrusion rate, cost effectiveness, and ease of use with respect to removal of the produced 
sacrificial mold. These criteria were chosen based on the previously mentioned, in Section 
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4.2.3.1 Microvascularization Strategies. As in the previous section, weights were assigned to the 
selection criteria and total scores were calculated.  
The fabrication method chosen for the final design was free extrusion since it received 13 
out of a possible 15 points. The free extrusion method allowed for reproducible geometry and 
extrusion rate, was cost effective, and mold removal was easy. The free extrusion method was 
however limited to single channel molds. The strategy of this project was to take incremental 
steps and for this reason initial tests were planned to be conducted on single channel systems. 
The hand-printed extrusion method was selected as a secondary fabrication method for 
this project to form bifurcated channels. The 3D printed method, though it received the same 
score as the hand-printed extrusion method, was cost- and time-prohibitive for this project. 
4.2.4.4 Sacrificial Mold Loading Method 
After the sacrificial mold vascularization and fabrication methods were chosen, the next 
aspect of the final design for the microengineered vascular network was the sacrificial mold 
loading method. The final loading method was chosen after the creation of a decision matrix, 
seen in Table 12. 
Table 12: Pugh Method decision matrix for the selection of the sacrificial mold loading method 
 
The selection criteria were the ability to form bifurcations, ease of loading, and loading 
the sacrificial mold in place without having to transfer to another location. These criteria were 
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chosen based on the previously mentioned, in Section 4.2.3.1 Microvascularization Strategies. 
As in the previous sections, weights were assigned to the selection criteria and total scores were 
calculated.  
The loading method chosen for the final design was semicircle laying because it scored 6 
points out of a possible 6. This method allowed for loading of both single and bifurcated 
channels. It was easy as the mold was simply dropped into place, and did not need to be 
transferred after loading. To summarize, the final design for the microengineered vascular 
network was a gelatin sacrificial mold fabricated via free or hand-printed extrusion and loaded 
by semi-circle laying method. 
4.3 Bioreactor and Microfluidic Chamber 
The bioreactor and more specifically, the microfluidic chamber was designed to contain 
the fibrin layer and the cardiac scaffold during experimentation through perfusion. There are a 
series of functions that needed to be addressed in each microfluidic chamber design in order for 
the system to be effective. The functions are discussed in detail in Section 4.3.1 Needs analysis. 
4.3.1 Needs analysis 
Based on the objectives of the bioreactor system, the team determined what elements 
were necessary for the success for the project. It was determined that for the bioreactor to be 
successful, it needed to control and limit the gas permeability of the system and be reproducible. 
The control over gas permeability was necessary, because the users needed to be able evaluate 
the efficiency of the microvascular network in delivering nutrients and gases to cells seeded in 
the tissue scaffold. Along with that, the bioreactor needed to generate reproducible results under 
the same conditions, in order for the system to be a successful research tool. The bioreactor 
needed to have a fabrication protocol that would allow it to be accurately reproducible.  
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Wants determined by the set objectives on the bioreactor were for the system to allow for 
multiple samples to be sustained simultaneously, to be easy to use, and to be cost effective. If the 
bioreactor system was capable of sustaining a single tissue scaffold, maintaining multiple 
samples simultaneously would be a question of scaling up the components. According to the 
clients and the users, cost effectiveness and ease of use were secondary objectives. If the 
bioreactor system achieved all other objectives, it would already be considered a successful 
system.  
4.3.2 Functions & Means 
Based on the needs of the clients and users, a list of functions the device needed to 
perform was created. The functions are in no particular order. All needs and specifications that 
should be achieved to result in a successful bioreactor were listed in Section 3.8 Specifications. 
When design functions were determined, the team brainstormed different means of 
accomplishing the functions. In Table 13 below, a list of the functions and means for the 
bioreactor can be seen. After different means were determined, each was evaluated based on its 
capabilities of reaching the required specifications. 
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Table 13: Functions means chart for bioreactor 
Function Means 
Allow for 
continuous 
perfusion 
Peristaltic Pump Syringe Pump Gravity Fed 
Controlled gas 
exchange Permeable Coverslip 
Impermeable Lid of Closed 
Bioreactor 
Maintain 
sterility 
Gasket Tape Clips Screws & Gaskets 
Allow 
visualization Polyethylene Silicone PDMS 
Glass 
Coverslip 
Contain Fibrin 
Microvascular 
Network 
Rectangular 
Mold 
Two 
Piece 
Peg 
Mold 
Tongue 
& 
Groove 
Mold 
Box 
Mold 
Simple 
Mold 
Hinged 
Mold 
Insert 
Mold 
Tetris 
Mold 
 
One function of the microfluidic chamber is to allow for continuous perfusion throughout 
the microvascular network in the mold. Along with this function are the specifications of proving 
flow of 0.001 mL/min and maintaining that flow for up to three weeks. This could be achieved 
with the use of a peristaltic pump, syringe pump, or gravity fed system. The peristaltic pump 
could be beneficial because the rate of perfusion could be set prior to beginning an experiment 
and the pump is able to mimic pulsatile flow. A drawback to this pump is that the perfusion rate 
did not produce a consistent flow when the rate was at its lowest speeds around 0.14 mL/min. A 
specification explained in the previous chapter was that the pump must precisely reach flow rates 
between 0.0015 - 0.21 mL/min. Therefore, the peristaltic pump could not meet this specification. 
A benefit of the syringe pump was that the amount of fluid that will flow through the system 
could be predetermined. Additionally, the syringe pump allowed for rates of flow as low as 0.001 
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mL/min. Another advantage to the syringe pump was that the amount of fluid flowed through the 
system could be controlled with the size of the syringe used, meaning the length of the 
experiment can be modulated to the time needed. The gravity fed system removed the need for 
electricity to power the system but a drawback was the difficulty to maintain a constant flow 
rate. This was difficult because as the media was depleted, the force of gravity became less, 
decreasing the flow rate. In Table 14 below, the advantages and limitations of each method can 
be seen.  
Table 14: Advantages & limitations for continuous perfusion methods 
Function - Allow for controlled continuous perfusion 
Means Advantages Limitations 
Peristaltic 
pump 
 Mimics in vivo pulsatile flow  Does not reach low flow rates 
well 
 One sample 
 
Syringe pump 
 Continuous flow 
 Controlled lower flow rates 
 Volume modulation for long 
experiments 
 Multiple samples 
Large size 
Gravity fed  Does not require power  Hard to control flow rate 
 
Another function was to allow for controlled gas permeability. This allowed the team to 
control how the system and tissue was supplied with oxygen. The system must only allow the 
tissue to receive oxygen from the perfusion of media. This would mean the tissue was supported 
only by the microvascular network. Using two methods, one impermeable and one with oxygen, 
would give the most strict gas monitoring and allow for controlled gas exchange. Means for this 
include the use of impermeable coverslips and lids as seen in Table 15.  
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Table 15: Advantages & limitations for gas exchange methods 
Function - Controlled gas exchange 
Means Advantages Limitations 
Impermeable coverslip Not gas 
permeable 
Delicate; Easily broken 
Impermeable Lid of Closed 
Bioreactor 
Not gas 
permeable 
Difficult to find perfectly transparent 
material  
 
The system must also be tightly sealed to ensure a sterile environment.  This could be 
achieved by using screws, gaskets, or clips to provide a tight seal against gases and liquids. Each 
means created and ensured a tight seal from the outside environment by securing each piece of 
the microfluidic chamber, making the device airtight and fluid tight. The screws along with 
gaskets would be most efficient for ensuring an airtight seal since the screws would tighten and 
keep the entire system in place, also preventing air from entering the system around the gasket. 
This would also prevent fluid from leaking around each piece of the chamber. Clips could be 
applied to many of the designs which simply allow for a tight close between the lid and base. 
However, although this ensured the lid will remain in place on the chamber, this did not 
necessarily prevent air from entering the system if there were regions on the sides of the chamber 
where air could enter. Table 16 contains the advantages and limitations of the means to maintain 
sterility.  
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Table 16: Advantages & limitations for sterility methods 
Function - Maintain sterility 
Means Advantages Limitations 
Gasket  Airtight 
 Allows for separation of like 
materials 
Not always reusable 
Screws  Secures layers of bioreactor 
 Reusable 
Could be difficult to fabricate threads in 
device 
Clips  Cheap Bulky 
 
The fourth function was to allow for visualization. The bioreactor needed to allow for 
imaging with a microscope and observation throughout its use. This could be done with various 
materials such as glass coverslips, silicone, and polyethylene. Table 17 contains the advantages 
and limitations of the means to allow for visualization. In addition the height profile of the 
chamber has to be below 19.50 mm in order to obtain a clear image from the microscope.  
Table 17: Advantages & limitations for transparent materials 
Function - Allow for visualization 
Means Advantages Limitations 
 
Glass coverslip 
 Easily accessible 
 Rigid 
 Gas impermeable 
 Cheap 
Difficult to clean/reuse 
Fragile 
Silicone  Gas permeable 
 Cheap 
Flimsy/flexible 
PDMS  High gas permeability 
 Cheap 
Can be difficult to fabricate such a thin sample 
Soft & flexible 
Polyethylene  Cheap     Not very strong 
 
116 
The final function was to contain the microvascular network with a formation mold. This 
is where the fibrin is formed and what will hold the gel throughout testing. This mold needed to 
be easy to use for simple or complicated vascular networks and hold liquids and the hydrogel 
without leakage. It is the link between the microvascular network and the bioreactor as a whole. 
This mold could vary in design and alternatives can be found later in Table 19. The advantages 
and limitations for containing the microvascular network were categorized for each means of 
completion and can be seen in Table 18 below. 
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Table 18: Advantages & limitations for containing the microvascular network 
Function - Contain microvascular network 
Means Advantages Limitations 
Rectangular One Piece Mold 
 Easy to set up   Allows for only straight 
channels 
Rectangular One Piece Mold 
without Nozzles 
 Allows for use of needle tips  Movement of needle tips 
could occur 
Two Piece Peg Mold  Allows for bifurcated channels  Difficult to manufacture 
Two Piece Mold w/ Base 
 Allows for bifurcated channels  Must be held together with 
clips 
 Difficult to line up  
Tongue and Groove Mold 
 Easier to manufacture than peg 
mold 
 Allows for bifurcated channels 
 Top and bottom pieces 
could slide 
Box Mold 
 Allows for bifurcated channels 
 Assists in alignment 
 Top and bottom pieces 
could slide 
 Top piece can warp, 
releasing the seal 
Simple Mold 
 Allows for bifurcated channels  Poor alignment outside of 
bioreactor 
Hinged Mold 
 Allows for bifurcated channels 
 Assists in alignment 
 Top and bottom constantly 
attached 
 Difficult to manufacture 
 Difficult to accommodate in 
a chamber 
Insert Mold 
 Allows for bifurcated channels 
 Reduces axis of rotation during 
use 
 Fragile 
 Difficult to fabricate 
Tetris Mold 
 Allows for bifurcated channels 
 Assists in alignment 
 Fragile 
 Difficult to fabricate 
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4.3.3 Bioreactor Feasibility Studies 
4.3.3.1 Glass vs Transparent Material 
In order for visualization to be possible, either glass coverslips must be used or 
transparent materials such as polyethylene and silicone. The team spoke with professionals in the 
field of materials as well as manufacturing. After a few conversations, it became clear that glass 
would be the best option. Polyethylene and silicone are difficult to machine especially when the 
end result needs to be transparent and produce a clear image when viewing through a 
microscope. Machining any surface of these clear materials would leave microscopic scratches 
that leave a haze or uneven clarity on the material. This haze would be unacceptable because it 
would distort the image under a microscope. Polyethylene poses the highest chance of working 
compared to silicon because it is commonly machined for many products and can be almost 
100% transparent. The team looked at microscope images of machined polyethylene from 
literature. One study shows the following image (Figure 42) of polyethylene after being milled.  
 
Figure 42: Microscopic image of milled polyethylene (Carr & Feger, 1993) 
There are many imperfections in the material once machined. The high feed rate had 
great influence in the generation of the surfaces roughness. Glass coverslips and slides are used 
in imaging because of their transparency. Glass slides are also produced in multiple sizes and 
thicknesses so there is no need to machine it. Glass therefore is the best option for a viewing 
window.  
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4.3.3.2 Clips vs Screws  
To determine whether clips or screws would work best in keeping the microfluidic 
chamber closed tightly to ensure sterility, a feasibility test was performed. Clips were used to 
hold down a top and bottom piece of 3D printed PLA mold and filled with water which can be 
seen below in Figure 43. 
 
Figure 43: Using clips to hold PLA mold together 
The system was placed into the incubator for twenty-four hours. After the twenty-four 
hours, the system still had water remaining within the top and bottom pieces with no signs of 
leakage. Because of the humidity of the incubator, the clips oxidized leaving rust on the PLA 
which can be seen in the Figure 44 below.  
 
Figure 44: Corrosion buildup on binder clips. a) Rusty clips b) rust on mold 
The rust left from the clip would ruin the developed microfluidic chamber so screws 
would be the best option at keeping the system closed while maintaining sterility.  
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4.3.3.3 Inlet and Outlet  
Previous work in Pins Lab used needle tips as inlets and outlets that were not fused, for 
their mold designs. The needle tips could be pushed into or out of the system when attaching 
tubing, causing structural damage to the fibrin gel. Other options were looked into for inlet and 
outlets such as 3D printing inlet and outlet nozzles, infusing needle tips into our final design, or 
having only openings as opposed to extruded nozzles. Below, Figure 45 is shows a 3D printed 
mold made from PLA. 
 
Figure 45: Attempt to 3D print nozzle 
The pieces of material extruding out of the right side and bottom of the mold are the 
supports for the nozzles; the nozzles, however, themselves did not print, even though they were 
included in the CAD designs. 3D printing inlet and outlet nozzles when printing the molds 
proved to be extremely difficult, because the available 3D printer lacks the precision necessary to 
form the miniscule nozzles. In order to print the nozzles, the pieces needed structural support; 
however the support was still unsuccessful in allowing the nozzles to print.  
An alternative method to this was to design for holes as inlets and outlets as opposed to 
extruding nozzles where metal needle tips could be used. To prevent movement of the needles 
when attaching or detaching tubing, the metal tip could be heated to a temperature higher than 
the glass transition temperature of PLA, 60°C, and then fused into the holes of a 3D printed 
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mold. This would permanently secure the tips in place and not allow them to move during 
experimental testing. A feasibility study was performed to see if this method would be effective. 
First the tip was heated through an open flame as seen in Figure 46 below. 
 
Figure 46: Heating needle tip over flame 
Once the tip turned orange (800 - 900°C), it was removed from the flame and 
immediately placed into the two piece mold as seen below in Figure 47. Immediately, the PLA 
touching the heated metal began melting around the tip. As the PLA cooled, it solidified around 
the metal tip, securing it into place.  
   
Figure 47: Inserting needle tip into inlet 
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After letting it cool for a few minutes, pushing and pulling the needle tip with pliers 
resulted in no movement, proving to be very secure. Fusing the needle into the mold was an 
effective method of securing the nozzles. The fused needle tips can be seen in Figure 48 below. 
 
Figure 48: 3D printed mold with fused needle tips in inlets 
The issue with this method is that fusing both needles to be perfectly straight was 
extremely difficult by hand. It was very important for the needles to be straight for the creation 
of a linear channel through the mold. The third option was to just leave a hole for the inlet and 
outlet where tubing or full needles could be inserted to. As long as the tolerance between the 
tubing or needle and the holes were small enough, there would be enough resistance to ensure a 
secure fitting. Given the advantages and limitations of these methods, leaving a hole where a 
needle or tube could be inserted into seemed to be the most feasible option.  
4.3.4 Conceptual & Alternative Designs 
The team brainstormed a series of designs, both for the mold and the microfluidic 
chamber. A summary table of the conceptual and alternative designs for the mold piece can be 
seen in Table 19 below.  
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Table 19: Design alternatives of mold 
Design Stage Design Alternative Model 
Conceptual Designs 
Rectangular 
One Piece  
Mold 
 
Rectangular  
One Piece 
Mold without 
Nozzles  
Alternative Designs 
Two Piece 
Peg Mold 
 
Two Piece Mold with Base 
 
Tongue and Groove Mold 
 
Box Mold 
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Simple Mold 
 
Hinged Mold 
 
Insert Mold 
 
Tetris Mold 
 
 
Molds  
The following molds were designed to hold the team’s microvascular network. The mold 
is placed into the final bioreactor design and connected to tubing, allowing perfusion through the 
mold. The mold was not designed to be airtight itself because that function would be fulfilled by 
the microfluidic chamber. The size of the mold was designed to fit the myocardial layer being 
provided to the team to ensure a secure fit and no movement of the mold upon movement of the 
microfluidic chamber.  
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Rectangular One Piece Mold 
The Rectangular One Piece Mold design is the simplest of the mold designs. This mold 
has an inlet and outlet nozzle allowing tubing to be connected. The design is very robust because 
of the entirety of the mold being one piece. This contributes to why this mold is user friendly. 
Fabricating the nozzles could pose a challenge because of the small diameter. Defects within the 
inlet have potential to affect the perfusion, especially with an already very low flow rate. The 
external nozzles can be seen in the Figure 49 below. 
 
 
Figure 49: Rectangular One Piece Mold 
Rectangular One Piece Mold without Nozzles 
This design is a replica of the previous design with one modification. The nozzles were 
removed because of the difficulty to fabricate a nozzle with such a small diameter. Now, there is 
an inlet and outlet hole where tubes could be fed through or needles could be fused in. The inlets 
can be seen in Figure 50 below. 
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Figure 50: Rectangular One Piece Mold without Nozzles 
Two Piece Peg Mold 
This design uses pegs to align the top and bottom of the mold, seen in Figure 51.  
 
Figure 51: Two Piece Peg Mold 
The pegs ensure an accurate fit when stabilizing the mold. The flow inlets were designed 
so that tubing could easily be attached around them. Fabricating connectors and pegs are very 
difficult because of the small size of the mold. Manufacturing the pegs with the correct tolerance 
to fit tightly into the holes is a challenge at the millimeter scale. Manufacturing small diameter 
nozzles precisely with no defects is also difficult. Defects within the inlet could potentially affect 
the perfusion, especially at low flow rate.  
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Two Piece Mold with Base 
This mold was designed to be used only outside the bioreactor for testing. The mold has a 
bottom that cannot be imaged through, but the fibrin does not leak out the bottom when moved 
or when not in contact with a glass slide on the bench top, as seen in Figure 52. As in previous 
mold designs molds, the nozzles on the sides are hard to manufacture. 
 
Figure 52: Two Piece Mold with Base 
Tongue and Groove Mold 
This design is similar to the Two Piece Peg Mold, but for ease of fabrication, the pegs 
have been removed. They have been replaced with grooves in the top piece that are placed 
around extruded material on the bottom piece. In turn, this secures movement in one direction. 
With this design, the top still has a degree of movement in the y direction, front and back. To 
further simplify the fabrication of the mold, the inlet and outlet nozzles were removed seen in 
Figure 53. Now, there is an inlet and outlet hole where tubes could be fed through or needles 
could be fused.  
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Figure 53: Tongue and Groove Mold 
Box Mold 
This mold has a much simpler design than the Two Piece Peg Mold. There is a top and 
bottom that incorporates an inlet in the middle of the two, seen in Figure 54. This design 
removes the extruded nozzles and pegs, both features that are difficult to fabricate. These inlets 
allow tubing or needles to be inserted straight through both the microfluidic chamber and the 
mold, up to the microvascular network. The lip of the top piece wraps around the sides of the 
bottom piece to stabilize the mold and provide an accurate fitting and alignment. 
 
Figure 54: Box Mold 
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Simple Mold 
This is a simple design for a mold. A slight modification was made to the previous design 
to remove the lip from the lid, seen in Figure 55. This is because its only use would be inside the 
microfluidic chamber. It is difficult to align the top and bottom pieces of the mold outside the 
microfluidic chamber. While in the microfluidic chamber, the mold would be secured in place, 
therefore eliminating this issue. Tubing or needles could be placed inside the flow inlets on each 
end of the mold. 
 
Figure 55: Simple Mold 
Hinged Mold 
The Hinged Mold design uses a hinge for easier handling and alignment of the mold. 
With this connection between the top and bottom piece, the entire mold becomes only one piece. 
This concept disposes the need of any pegs or lip around the top piece to stabilize the mold. This 
design is very user friendly and simple. Similar to the previous design, tubing or a needle will be 
inserted straight through both the bioreactor and the mold right up to the microvascular network, 
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as seen in Figure 56. Fabricating the hinge could be a challenge because of how small and thin it 
is. The diameter of the hinge would allow a one millimeter pin to fit through it.  
 
Figure 56: Hinged Mold 
Insert Mold 
This mold was designed with a different way of ensuring stability. Here, pegs are used 
that would be pushed into the insert holes, securing the two halves of the mold. As opposed to 
having a top and bottom, this design has a left and right piece that come together, as seen in 
Figure 57. The flow inlet and outlet are through the center of the mold. Similar to the past 
designs, tubing or a needle will be inserted straight through both the bioreactor and the mold 
right up to the microvascular network. The tubing or needle would be secure in these holes 
because they are designed to fit a very specific diameter. Needles could be fused to the inlets of 
the mold to ensure a lesser chance of needle movement. Keeping the mold together and sealed in 
the middle where the two halves meet may pose a challenge.  
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Figure 57: Hinged Mold 
 
Tetris Mold 
This mold was designed similarly to the Insert Mold, but modified to simplify its 
fabrication. The Insert Mold can be seen in Figure 58. Manufacturing this mold would be less 
complicated than creating the pegs of the previous design. Though creating the mold would be 
simpler, this design is not as stable. Here, there is chance of rotation. Either side of the mold 
could bend up or down around the point of contact, unlike the Insert Mold where the pegs ensure 
there cannot be any movement in the vertical plane.  
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Figure 58: Tetris Mold 
Microfluidic Chamber 
The brainstorm process resulted in five alternative designs of a microfluidic chamber: 
three conceptual and two preliminary. The conceptual designs include the Petri Dish, Drawer, 
and Layered. The preliminary designs include the Pressure Square and the Boxed. The 
preliminary alternative designs can be seen in Table 20 below.  
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Table 20: Preliminary design alternatives of microfluidic chamber 
Design Stage 
Design 
Alternative 
Model 
Conceptual Designs 
Petri Dish  
 
Drawer 
 
Layered 
 
Alternative Designs 
Pressure Square 
 
Boxed  
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Petri Dish  
This design was created for its simplicity. Because Petri dishes are common items in 
laboratories, this design could be created by modifying an existing product. Holes where the 
nozzles would enter would be drilled into the sides of the base of the Petri dish as seen in Figure 
59. The external and internal nozzle is one piece that would be placed through the drilled hole on 
either side of the dish. The lid is a typical Petri dish hood which is transparent.  
 
Figure 59: Petri Dish Design 
The transparent cover and base allow for imaging with a microscope. The cover is easily 
removable if necessary. Each nozzle design involves an external and internal portion that both 
make one piece. The nozzle would be inserted into the separate mold containing the 
microvascular network to ensure that there is no gap where fluid flowing through the created 
channels could leak through. This ensures consistent input and output through the network. This 
design would be most convenient to manufacture, as it would simply involve drilling holes into 
the dish and inserting nozzles. Though it would be simple to manufacture, drilling holes into a 
Petri dish would not be ideal because the drilling process will most likely shred the material of 
the dish and make it difficult to re-seal, causing it to lose its sterility. Another problem with this 
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design is that it can only accommodate one of the molds which carry the microvascular network 
since there are no divisions or walls within the Petri Dish design. 
Drawer  
This concept was created to mimic a drawer with a removable container to allow for an 
easy and efficient means of mounting the mold, as shown in Figure 61. The outside of the drawer 
contains three external nozzles matching up with the three internal nozzles of the removable 
container, labeled in the Figure 60. This design can accommodate up to three molds and can be 
modified to allow for more or less samples. The mold designed to hold our samples would 
connect to the internal nozzles of the microfluidic chamber to allow for continuous isolated flow. 
Each sample is enclosed by a wall to ensure cross contamination does not occur. The top and 
bottom of both pieces are transparent to allow for visualization of the samples using a 
microscope. With proper insulation on all edges of the drawer, this design would be airtight, 
maintaining the sterility of the samples.  
 
Figure 60: Drawer design 
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This alternative design is beneficial because it is robust and sturdy. Accessing the 
samples would be simple and quick. Simple modifications to the CAD design would allow for as 
many samples as the user would like this microfluidic chamber to accommodate. This design 
could be difficult to manufacture in order to align the holes of the inside and outside 
compartments. The diameters of the nozzles are so small that aligning them precisely could be 
difficult. If not aligned, media could leak between the two parts during perfusion. In order to 
assure an airtight seal, the tolerance must be very small and manufacturing such a small product 
so accurately could be difficult.  
Layered Design 
This design was created utilizing screws to keep the system together and maintain 
sterility. The center opening in the top and bottom pieces each hold a coverslip to allow for 
visualization. The bottom piece has a cavity where the inner layers fit into. This allows the top 
and the bottom pieces to sit on each other and create a closed system when the screws are in 
place. This design also has a spacer for the myocardial layer to fit into allowing the top and 
bottom to sit flush. There are external nozzles for tubing to be connected allowing media to be 
perfused through the microvascular network. Each layer of the microfluidic chamber can be seen 
in Figure 61. 
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Figure 61: Layered design 
This design is airtight once sealed, maintaining the sterility of the microvascular network. 
Unlike the other conceptual designs, this design has many components that are all independent of 
each other. This makes it less user friendly because the user would need to manually place more 
parts into the chamber, leaving more room for human error. Another issue is the difficulty in 
fabricating the external nozzles. The nozzles are very small and finding a machine that could 
manufacture such a small diameter precisely has proven to be difficult.  
Pressure Square Design 
This design simplifies the previous Layered design by removing the scaffold spacer and 
using a different mold, as shown in Figure 62. Instead of using the scaffold spacer to create more 
space for the microvascular network, the client would use vellum paper surrounding the 
myocardial layer. This design also uses screws to tighten the top and bottom, creating an airtight, 
sterile environment. The holes on the sides of the bottom piece of the microfluidic chamber line 
up with the holes of the mold to allow for perfusion.  
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Figure 62: Pressure Square design 
This design is not very user friendly because it could be difficult to insert a sacrificial 
material into the mold when it is in the microfluidic chamber. Although this is the case, with use 
of the cylindrical rod extraction method for creating a channel, the setup could be completed in 
very few, simple steps. With this specific design, the user is restricted to only one sample though 
it can be easily modified to accommodate more samples. The inlet diameters have been increased 
in order to fabricate them more easily and accurately.  
Boxed Design 
This design seen in Figure 63 incorporates a lid with a lip which helps secure the entire 
microfluidic chamber. The setup is very similar to the Pressure Square design. What has been 
changed is that the top now has a lip that will wrap around the bottom piece; this can be better 
seen in Figure 64. Also, a different mold is used in this version. The sides have been extended to 
allow for easier handling of the microfluidic chamber.  
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Figure 63: Boxed microfluidic chamber top view 
 
Figure 64: Boxed microfluidic chamber bottom view 
This design incorporates all the aspects of the Pressure Square design. The addition of the 
lip is to provide increased stability and an accurate fitting. Also, the half circle inlet on the 
bottom piece is not a full circle to allow for tubing or a fused needle connected to the mold to 
easily fit into place by just lowering the entire part into the microfluidic chamber. The other half 
of the inlet was incorporated into the lid which would be lowered onto the bottom. 
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4.3.5 Final Bioreactor Selection 
4.3.5.1 Final Mold  
To select a final mold and microfluidic chamber design, a Pugh Method decision matrix 
was created as seen in Table 21 and Table 22. The Pugh Method is a decision-matrix that 
incorporates end-use applications of design objectives as the initial product specifications. This 
technique establishes a set of criteria options which are scored and summed to gain a total score. 
The higher the score, the better that design satisfies that selection criteria. This method is not 
weighted to provide a quick selection process, each design was discussed and analyzed prior to 
creating this matrix in order to properly score each (Thakker, Jarvis, Buggy, & Sahed, 2009). 
Table 21: Pugh Method decision matrix for the selection of the mold 
 
The selection criteria were ease of use, being able to secure the sample, allowing for 
visualization under a microscope, stability of the entire mold, allowing for ease of sacrificial 
mold loading, and ease of manufacturability. These criteria were created based on the advantages 
and limitations of the different molds presented in Section 4.3.4 Conceptual & Alternative 
Designs. In order to select a final mold design, each of the selection criteria were assigned 
weights 1 - 6. 6, being the most important, was assigned to visualization and 1, being the least 
important, was assigned to stability. It was then determined whether or not each mold design 
could meet the selection criteria.  
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The Box and Simple mold ranked highest, both with 20 out of 21 points. Both of these 
designs satisfied all of the selection criteria except for stability. The other molds have a 
mechanism that secures the top to the bottom whether a hinge or pegs. The Box and Simple 
molds do not provide any similar mechanism for stability but this was ranked lowest because a 
function of the microfluidic chamber is to secure the mold, providing the necessary stability. For 
further analysis, both of these molds were 3D printed and tested. After testing, it was determined 
the simple mold would satisfy the selection criteria best. Both are easy to use, but setup and 
cleanup of the simple mold was easier than the box mold because there were no edges or pockets 
to clean. Finally, the simple mold was much easier to manufacture solely because of its 
simplistic design.  
4.3.5.2 Final Microfluidic Chamber 
The selection criteria for the microfluidic chamber are shown in Table 22. 
Table 22: Pugh Method decision matrix for the selection of the microfluidic chamber 
 
The selection criteria included ease of use, being able to secure the mold, allowing for 
visualization under a microscope, stability of the entire system, ease of manufacturability, and 
being able to maintain a sterile environment. These criteria were created based on the advantages 
and limitations of the various microfluidic chamber designs as discussed in 4.3.4 Conceptual & 
Alternative Designs.  
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Weights were assigned to the selection criteria with 6 assigned to visualization of the 
sample to allow for imaging with a microscope being the most important and 1, stability of the 
system, being the least important. It was then determined if each method met the selection 
criteria as stated in the selection criteria specification in the second column.  
After completing the matrix, the Boxed chamber received a total score of 20 out of 21 
points and the Pressure Square chamber received a total of 21 out of 21. Both chambers and their 
respective molds were fabricated through 3D printing to help determine which design would 
prove to be most effective at completing the objectives and functions of the project.  
Pressure Square Design 
The 3D printed Pressure Square prototype made of PLA can be seen below in Figure 65. 
 
Figure 65: Pressure Square parts separated 
This design uses tubing that is fed through the inlet of the microfluidic chamber and sits 
on top of the mold inlet. The figure above shows the bottom piece of the mold already placed 
inside the microfluidic chamber and the tubing sitting above the bottom mold. A closer view of 
this setup can be seen below in Figure 66. 
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Figure 66: Pressure Square internal tubing 
Figure 67 below shows the top piece of the mold placed on top of the bottom piece, 
securing the tubing. Figure 68 shows the complete setup of the microfluidic chamber with the 
cover on top as well as the 23G needle inside of the tubing.  
 
Figure 67: Pressure Square with mold inside 
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Figure 68: Pressure Square with cover 
Boxed Design 
As opposed to the last microfluidic chamber, this design does not insert tubing directly 
into the inlets. Instead, 20G needles are fused into the mold. The mold with the attached needles 
is then placed into the microfluidic chamber. Below, in Figure 69, all pieces separated can be 
seen individually.  
 
Figure 69: Boxed Design parts separated 
Figure 70 below on the left shows the 20G needles fused into the mold and placed into 
the microfluidic chamber. Figure 71 on the right shows the mold with the fused needles after it 
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was placed into the microfluidic chamber. Instead of the chamber having a hole where the needle 
would go into, there are openings where the needles can be lowered into.  
 
Figure 70: Boxed with mold inside 
 
Figure 71: Needle in mold 
Figure 72 below shows the shows the complete setup of the microfluidic chamber with 
the cover on top as well as the 20G needle fused into the mold. 
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Figure 72: Boxed chamber with cover 
The Pressure Square chamber was selected because it met all six of the design criteria 
best. The Pressure Square chamber does not face the limitations of the other chamber designs. It 
is extremely easy to use with its intuitive design. It allows the mold to be secure and remain in 
place once the system is assembled. It allows for visualization so the sample can be imaged with 
a microscope. The system also has high stability because of the use of screws that ensure the 
system is secure. The Pressure Square chamber is easy to manufacture as it does not have 
nozzles or extensions that would be difficult to fabricate. Additionally, it is able to keep the 
entire system sterile as there is no way for contaminants to enter the closed system.  
It was chosen over the Boxed design, even though they ranked the same, partly because it 
is not as stable of a system when compared to the Pressure Square chamber. The method of 
placing the needle in the Boxed design and placing a cover over the top does not provide any 
means of sealing the needle nor does it provide a reliable way to close the system tightly. If you 
refer to Figure 71, the extra space above the needle can be seen. This extra space could 
potentially hinder the sterility of the microfluidic chamber. In addition, the lid of the Boxed 
design did not supply a proper seal of the microfluidic chamber, once again limiting the sterility 
of the system and allowing for possible leakage. It was decided regardless of the final design that 
it would need to incorporate screws to ensure a proper seal and maintain sterility during testing.  
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The Pressure Square design was selected as the final design for the microfluidic chamber 
and was then professionally fabricated because 3D printing was only for preliminary tests. 3D 
printing results in poor quality and would not suffice as a reliable device. Thomas Partington, the 
Lab Manager in Goddard Hall within the Chemical Engineering Department at Worcester 
Polytechnic Institute, fabricated the Pressure Square microfluidic chamber. The fabrication is 
further discussed in Chapter 6: Final Design and Validation. Below in Figure 73 is an image of 
the setup of the machined microfluidic chamber.  
 
Figure 73: Machined microfluidic chamber 
The chamber was made from PTFE. The PTFE was chosen because of its 
biocompatibility in addition to its hydrophobicity, which minimize resistance of flow through the 
system. Initial material options were PTFE, POM, and stainless steel. POM and stainless steel 
were both ruled out because of their rigidness and poor malleability. PTFE is more easily 
malleable which allows for a tighter seal between layers once the chamber is fully screwed and 
tightened into place. This is because the layers slightly adjust shape to fill in any micro gaps 
which reduces the chance fluid leakage.  
Figure 73 shows two 20G needles inside the input and output holes of the microfluidic 
chamber. The preliminary design used silicon tubing to flow media in and out of the chamber. 
Feeding the tubing through the inlet and outlet holes proved to be extremely difficult because the 
tubing and hole must be very similar in diameter to ensure a tight seal, preventing leakage and 
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maintaining sterility. To ensure an equally tight seal, the tubing was removed and only the 
needles were used as inlets and outlets. There is a very small tolerance between the diameters of 
the 20G needle and inlet and outlet holes. There is a lot of resistance between the holes and 
needles, exactly what was needed to prevent any leakage. The preliminary design used 23G 
needles, but the 20G were used in the final design because the sacrificial mold that created the 
channels through fibrin fit easier into the larger diameter. The diameter of the 23G needle was 
too small to allow the mold to sit within it.  
 
Figure 74: Microfluidic chamber components 
In Figure 74, the top and base of the chamber, two part simple mold, glass coverslip and 
screws are shown. The 4 - 40 screws, the 4 indicates the standard number of the screw and 40 
indicates the number of turns per inch, were used to ensure a tight seal between the top and 
bottom of the microfluidic chamber in order to maintain sterility of the system and prevent any 
leaking. The glass coverslips were placed above and below the simple mold which allowed for 
visualization and prevented contamination of the components within the microfluidic chamber. 
The depth of the pocket in the middle of the chamber accounts for the thickness of the two 
coverslips, the two part mold, and the 300 μm scaffold. After the initial fabrication of the 
microfluidic chamber, modifications and additions were made to better improve the functionality 
of the system. 
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To further prevent leakage and maintain sterility from occurring between the top and 
bottom of the microfluidic chamber, a groove was machined into the bottom face of the top piece 
of the microfluidic chamber. It was machined around the viewing window as seen below in 
Figure 75. However, adding a gasket to the PTFE top proved to be ineffective, as the PTFE was 
too smooth and the gasket would not remain in place. POM was then selected as an alternate 
material to make the top of the chamber. POM, as stated before, is not as malleable but having 
bottom of the chamber remain PTFE still ensures a tight seal because the PTFE slightly adjusts 
its shape when pressed against the POM. The groove was machined around the viewing window 
and the gasket remained in place. It can be seen in Figure 75 below.  
 
Figure 75: POM top with Silicone gasket in groove 
Although the silicone gasket helped eliminate leakage occurring from the sides of the 
microfluidic chamber, leakage still occurred around the needles at the inlet and outlet ports. 
During perfusion, it was noticed that if pressure was applied to the top of the microfluidic 
chamber above the inlet and outlet ports, leakage did not occur and fluid flowed completely 
through the chamber and into the reservoir. In order to apply uniform pressure to the system to 
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ensure a tight seal, the next alteration was the addition of stainless steel plates. Below in Figure 
76, the microfluidic chamber is seen with stainless steel plates in place.  
 
Figure 76:  Microfluidic chamber with Stainless Steel plates in place 
The stainless steel plates proved to be effective as they eliminate all leakage and prevent 
bowing within the layers of the chamber, by distributing the pressure created by the screws in the 
corners. Below in Figure 77, a side view of the chamber can be seen which shows the 
elimination of bowing within the component layers. 
 
Figure 77: Microfluidic chamber Stainless Steel plates prevent bowing 
All components of the finalized microfluidic chamber are seen in Figure 78 below.  
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Figure 78: Microfluidic chamber components 
An additional microfluidic chamber was fabricated to allow for testing multiple samples 
simultaneously. 
4.3.5.3 Pump Selection 
The last major component of the bioreactor system is the pump. The pump is used to 
perfuse media and nutrients through the microfluidic chamber. The gravity-fed pump, peristaltic 
pump, and syringe pump. After testing each of the options, it was determined that the syringe 
pump would be most suitable because it can precisely reach very low flow rates, especially flow 
rates of physiological relevance like 0.003 mL/min. The gravity fed pump was able to reach very 
low flow rates, but it was all dependent on the amount of media in the bag acting against gravity. 
Because of this, accuracy and precision were poor. The peristaltic pump would lose functionality 
when flow rates close to 0.003 mL/min were reached, making it unfeasible for this project. The 
syringe pump also has the ability to perfuse more than one sample at a time because multiple 
syringes can be connected unlike the other two options. The syringe pump was determined to be 
best suited because of its ability to precisely reach physiological flow rates and perfuse multiple 
samples simultaneously.  
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4.3.5.4 Complete Bioreactor 
Below in Figure 79, the entire bioreactor setup can be seen including the pump (left), 
microfluidic chamber (middle), and collection flask (right) with tubing that connects the syringe 
to the chamber and the chamber to the collection flask. 
 
Figure 79: Bioreactor setup with pump, microfluidic chamber, and reservoir 
The final components of the bioreactor system include a syringe pump, microfluidic 
chamber based off the Pressure Square alternative design, and a collection flask. The syringe 
pump was chosen because of its precision when operating at physiologically relevant flow rates 
such as 0.003 mL/min and its ability to perfuse multiple samples simultaneously. The 
microfluidic chamber was based off the Pressure Square design. This design was chosen because 
it is extremely easy to use with its intuitive nature. It allowed the mold to be secure and for 
visualization with a microscope. The Pressure Square design also allowed for the system to have 
high stability due to the screws which ensure a secure system. This design is easy to manufacture 
and is able to maintain a sterile environment through the use of a gasket, specific materials with 
low tolerances, and screws.  
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Chapter 5: Design Verification 
This chapter contains the results of this project which include all steps of the 
development of the microengineered vascular network protocol, establishment of continuous 
perfusion, and the findings of the diffusion assay. A cell viability assay was also designed and 
performed to verify the components of the bioreactor met the objectives and functions. 
5.1 Microengineered Vascular Network Development and Analysis 
A protocol was developed to fabricate the microengineered vascular network using a 
gelatin sacrificial mold. Steps of the protocol included production of both single cylinder and 
bifurcated gelatin sacrificial molds, transfer of the mold to a microfluidic chamber, addition and 
polymerization of fibrin, melting of the mold at 37°C, and flushing of the liquid gelatin.  
To validate the microengineered vascular network, continuous perfusion was shown to be 
established. Additionally, a diffusion assay was conducted to determine the diffusion rate of 
fluorescein isothiocyanate (FITC) from a single channel through fibrin.  
5.1.1 Gelatin Sacrificial Mold Method Development 
A summary of the process of forming microvasculature from a gelatin sacrificial mold is 
depicted in the Figure 80. The completed protocol is found in Appendix D: Protocols: Formation 
of Channels from Gelatin Sacrificial Materials. 
154 
 
Figure 80: Gelatin sacrificial mold to formation of microvasculature schematic. Extrude gelatin at 20°C (A), transfer to 
microfluidic chamber (B), add fibrin (C), liquefy gelatin at 37°C (D), flush gelatin out with warm PBS (E). 
5.1.1.1 Production 
The production of the 10% w/v gelatin sacrificial molds was initially adapted from a 
method from Golden & Tien (2007). For this project, free and hand-printed extrusion would be 
used to create single cylinders and bifurcated molds respectively. For both methods, gelatin was 
melted in a hot water bath before being drawn into a one milliliter syringe. In addition, for both 
methods, gelatin was extruded onto a non-coated PDMS surface which was found to be non-
stick, allowing for easy removal of the molds. To fit in the microfluidic chamber, the overall 
length of the channel had to be greater than 10 mm.  
5.1.1.1.1 Single Cylinder 
It was found that extruding the gelatin once it had been cooled for ten to fifteen minutes 
and had reformed as a gel resulted in successful production of single gelatin cylinders. Extruded 
single cylinder molds are later seen in the top of Figure 82. 
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5.1.1.1.2 Bifurcation 
When extruding gelatin cylinders, an interesting observation was made. Due to heat 
transferred to the solid gelatin from the extruder’s hand, the gelatin entered a liquid-like, gel-like 
state in its gel transition temperature, as seen in Figure 81.  
 
Figure 81: Gelatin phase diagram with 10 and w/v concentration used in this project and gel transition temperature 
range. Diagram adapted from Parker & Povey (2012). 
This gelatin flowed out of the needle without pressure being applied to the syringe. This 
property was taken advantage of to draw bifurcations. One of the problems of drawing 
bifurcations with Pluronic was connecting sides of the bifurcation. The Pluronic material would 
temporarily connect but as it dried would pull apart. Contrary to this, the gelatin in its gel 
transition state fully connected due to its liquid-like properties but still maintained shape due to 
its gel-like properties. Single cylinder, hand-printed single bifurcations, as well as double 
bifurcations, can be seen in below in Figure 82.  
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Figure 82: Different gelatin geometries. Top: Single cylinder gelatin sacrificial molds. Middle: Hand-printed single- and 
double-bifurcations before (left) and after (right) dehydration. Bottom: Magnified image of hand-printed double-
bifurcations (left) and 20X magnification image of bifurcation 
5.1.1.2 Transfer and Placement in Microfluidic Chamber 
Once the sacrificial mold was formed, the next problem to overcome was transferring it 
to the microfluidic chamber. Immediately after extrusion, the gelatin exists as a gel and cannot 
be easily lifted with forceps without inflicting damage. It was found that dehydration on the 
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benchtop at room temperature (20°C) for approximately thirty minutes resulted in sacrificial 
molds that could be handled with forceps without causing damage. Dehydration occurred 
automatically after extrusion. 
It was found that during dehydration, the channels decreased in diameter. This change in 
diameter was studied by extruding ten gelatin cylinders through a 20G needle which has an inner 
diameter of 603 μm so it is expected that the cylinders have an initial outer diameter of around 
600 μm. The cylinders were then dehydrated over multiple days then measured and an average 
diameter was calculated (three measurements per sample). Results of these measurements can be 
seen in Figure 83. The average diameter was determined to be 260 ± 32 μm, a 57% reduction in 
size.  
 
Figure 83: Measurements of the dry diameters of gelatin cylinders after dehydration over multiple days 
The next important design challenge was to overcome the low density of the gelatin 
cylinder. When fibrin components were added into the microfluidic chamber, the gelatin cylinder 
would rise to the top of the fibrin gel instead of remaining in the center. To overcome this 
problem, the ends of the sacrificial mold were inserted into the inlet or outlet needles as seen in 
Figure 84. This was sufficient to hold the mold in place. 
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Figure 84: Gelatin channel mold stabilization. Gelatin cylinder transferred to microfluidic chamber, inserted into both 
inlet and outlet needles to keep cylinder from rising to the top of the fibrin gel. 
5.1.1.3 Channel Formation 
To form a channel in a fibrin hydrogel, a sacrificial mold must maintain its shape during 
the process of fibrin polymerization. A gelatin cylinder was placed in a prototype microfluidic 
chamber, one insert mold and one simple mold, to attempt channel formation. After fibrin 
polymerization was complete, the samples were placed in the incubator to melt the gelatin and 
images were taken. As seen in Figure 85, the gelatin cylinders maintained their cylindrical shape 
during fibrin polymerization. Furthermore, to develop a relatively straight channel as opposed to 
one that ends up with a greater curvature, it was determined that adding fibrin slowly or 
dropwise on either side of the sacrificial mold prevented the curvature. 
   
Figure 85: Gelatin cylinders maintain geometry during fibrin polymerization. Microfluidic chamber with gelatin 
sacrificial mold immediately after fibrin component addition (left), after fibrin polymerization (middle), and microscope 
image of gelatin in fibrin (right) 
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Next, removal of the gelatin was attempted. The sample and a syringe with PBS were 
placed in the incubator to warm and then brought to the benchtop in an attempt to clear the 
gelatin. However, the flushing of the gelatin was unsuccessful as seen in the left part of Figure 
86. PBS with blue food coloring as a contrast agent was used to attempt to visualize the channel 
clearance of gelatin. The PBS did not flow through the channel and instead flowed into the fibrin 
and up through the top. When removing the fibrin, it was found that the gelatin cylinder was still 
in place, even though it had been melted in the incubator, as seen in the right image of Figure 86. 
It was determined that though the gelatin melted in the incubator, it must be flushed out in the 
incubator as well to ensure that the gelatin melts, and stays in liquid form until it is been 
completely removed. 
  
Figure 86: Gelatin solidification during channel fabrications. Perfusion unsuccessful (left) because the gelatin cylinders 
resolidified after melting as seen when the fibrin was being removed (right). 
After establishing the strategy of flushing the liquid gelatin out of the fibrin in the 
incubator, channel formation and gelatin flushing were successful, as seen in Figure 87. The left 
images show the gelatin sacrificial mold surrounded by the fibrin hydrogel. The right images 
show the channel formed after the gelatin was flushed out with PBS with a blue dye. To clear the 
gelatin, around 2.5 mL of PBS was perfused with a syringe pump at a flow rate of 0.1 mL/min.  
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Figure 87: Images of gelatin channel in fibrin gel before (left) and after (right) flushing with warm, blue, PBS with 2X 
(top) and 10X (bottom) objectives. 
5.1.1.4 Tunability of Channel Diameter 
The team’s goal was to be able to tune the dimensions of the microengineered vascular 
network based on initial sacrificial material dimensions during fabrication.  
To accomplish this goal and to characterize the change in size of the gelatin cylinders, 
measurements of gelatin sacrificial mold diameter immediately after extrusion, after 25 minutes 
of dehydration, after 3 days of dehydration, after encasing in fibrin, and final channel diameter 
were measured, as seen in Figure 88. 
 
Figure 88: Measurements of sacrificial mold diameters, extruded from 20G and 23G needles and final channel diameter 
at different stages of the protocol. From left to right: gelatin sacrificial mold diameter immediately after extrusion, after 
25 minutes of dehydration, after 3 days of dehydration, after encasing in fibrin, and final channel diameter. 
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The initial sacrificial mold diameter relative to the inner diameter of the extrusion needle 
was first assessed as seen in Figure 89.  
 
Figure 89: Comparison of predicted vs actual initial diameters of gelatin cylinders. 
To determine if there was a significant difference between the predicted and actual initial 
diameters of the sacrificial molds, a two-sample t-test was run for each. It was found that there 
was no significant difference between the predicted diameter (the inner diameter of the extrusion 
needle) and the actual outer diameter of sacrificial molds extruded through 20G (n = 3, p = 
0.2929) nor 23G (n = 3, p = 0.1409) needles.  
 
Figure 90: Comparison of initial diameter of gelatin cylinder and final channel diameter. 
To determine if there was a significant difference between the initial diameter of gelatin 
cylinders and final channel diameters, a t-test was run. There was found to a significant 
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difference between the initial mold extruded out of 23G needles and final channel diameter (n = 
3, p = 4.23E-9, *), seen in Figure 90. A limitation of this experiment is that only one 20G sample 
of the original three successfully formed a channel, but the data does suggest that there is a 
difference between the initial mold formed from a 20G needle and the final channel diameter. 
The goal was to predict the ultimate channel diameter and the initial diameter of the 
sacrificial material was found to be equal to the inner diameter of the extrusion needle. A 
relationship between the initial sacrificial mold diameter and ultimate channel diameter was 
sought.  
To determine the tunability of the microengineered vascular network, diameter 
measurements were first made of gelatin cylinders immediately after extrusion through 20G and 
23G needles. It was previously shown that the initial diameters were not significantly different 
than the inner diameter of the extrusion needle. Diameter measurements were also taken of the 
final channel formed from each of the cylinders. These relationship between these measurements 
was modeled linearly and the slope was determined to be 1.41 μm/μm. As a result, the 
dimensions of the microengineered vascular network were determined to be tunable based on the 
initial sacrificial mold dimensions during fabrication. By varying the inner diameter of the 
extrusion needle, the initial sacrificial mold diameter (𝑑𝑠𝑚) and subsequently final channel 
diameter (𝑑𝑐) could be controlled. The final channel diameter was modeled by the linear 
relationship  
(1)   𝑑𝑐  =  (1.41) 𝑑𝑠𝑚 
which was used to predict the ultimate channel diameter based on various extrusion needles, as 
seen in Table 23. 
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Table 23: Needle gauge and inner diameter with associated predicted channel diameter based on the channel diameter 
equation (Sigma-Aldrich, 2016). 
Needle Gauge Needle Inner Diameter Predicted Channel Diameter 
20G 603 μm 850 μm 
22G 410 μm 578 μm 
24G 310 μm 437 μm 
26G 260 μm 367 μm 
28G 180 μm 254 μm 
30G 160 μm 226 μm 
 
5.1.1.5 Reproducibility of Sacrificial Mold Production 
Finally, the reproducibility of the production of gelatin sacrificial molds was assessed. 
Using the same data above, the average diameter of the molds immediately after extrusion (0 
min), twenty-five minutes after extrusion, and seventy-five hours after extrusion was measured 
for molds extruded through 20G and 23G needles, as seen in Table 24. 
Table 24: Reproducibility of gelatin sacrificial mold production at various time points in the dehydration process 
 0 minutes 25 minutes 75 hours  
20G 615 μm ± 4% 453 μm ± 8% 435 μm ± 9% n=9 
23G 350 μm ± 10% 270 μm ± 8% 265 μm ± 8% n=18 
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5.2 Bioreactor Verification Studies 
5.2.1 Perfusion Test  
Tests were performed to verify if the amount of liquid perfused into the microfluidic 
chamber was equal to the amount perfused out. First, a syringe pump was set up and connected 
to the microfluidic chamber. A syringe filled with 1 mL of water was connected to the pump 
which can be seen below in Figure 91.  
 
Figure 91: Setup of perfusion test 
Three separate flow rates were chosen: 0.01 mL/min, 0.1 mL/min, and 1 mL/min. The 
inside of the microfluidic chamber was first filled with water before perfusion began. Once it 
was full, the syringe pump was turned on and the water perfused through, coming out the other 
side into a collection flask. There was no difference between the input and output amounts of 
water. 1 mL was perfused into the chamber and 1 mL was collected once the syringe had fully 
emptied all water into the chamber. All water perfused into the microfluidic chamber flowed into 
the collection flask. To further test this observation, a sealing test with constant perfusion for 
twenty-four hours was conducted which is described in the next section. 
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To verify the perfusion rates of the syringe pump, a syringe was loaded with 1 mL of 
water. The water was perfused through the microfluidic chamber at a programed rate of 0.005 
mL/min. The process was timed and the end time was recorded at 200 min. Using the equation:  
(2) Q = C / t 
In the above equation Q is the flow rate, in mL/min, C is the capacity (Volume), in mL, 
and t is time, in minutes. Using the equation, the perfused volume and resulting time was used to 
calculate a flow rate of 0.005 mL/min. Thus, verifying the programed flow rates of the syringe 
pump were accurate.  
5.2.2 Sealing Test  
This test was performed to verify that the microfluidic chamber did not leak while media 
was being perfused. First, a syringe pump was set up and connected to the microfluidic chamber. 
Next, a syringe was filled with three milliliters of C2C12 media and was connected to the pump. 
The setup was identical to the previous test, which can be seen in Figure 91 above. The media 
was perfused at a rate of 0.003 mL/min in order to mimic physiological flow for twenty-four 
hours. This test resulted in no leaked media and all media that perfused through the system was 
collected in the collection flask. This was verified by measuring the volume of media in the 
collection flask and comparing it to the starting volume. The measured volume of media in the 
collection flask was 2.7 mL. The missing media can be accounted for because the chamber of the 
microfluidic chamber holds 0.3 mL of media. The media inside the chamber was withdrawn 
using a syringe and exactly 0.3 mL was retrieved, proving all media that was perfused into the 
microfluidic chamber came out the outlet or remained inside the system.  
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5.2.3 Setup Time of Microfluidic Chamber 
For the purpose of determining the setup time of the chamber, the team determined how 
long it would take to setup the microfluidic chamber components. The chamber was assembled 
with all of its components three times and the time to complete was averaged. During each 
assembly, the base was first placed on the benchtop. Vacuum grease was then applied to the 
bottom of the mold and an 18 mm x 18 mm glass coverslip was placed onto it. The bottom piece 
of the simple mold was then placed into the base of the chamber and the top part of the mold was 
then placed on top of that, aligning the mold channels. A coverslip and the top of the chamber 
were placed next. Then the stainless steel plates were screwed into place. Last, the needles were 
inserted into the inlet and outlet ports. The duration of each setup time trial is seen below in 
Table 25.  
Table 25: Setup time trials & durations 
Trial (#) Duration (s) 
1 84.32 
2 80.00 
3 75.77 
Average 80.03 
 
As seen above in Table 25, the average of the three trials took 80.03 seconds to complete. 
Additionally, the duration to complete the setup of the microfluidic chamber decreased with each 
trial.  
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5.2.4 Dimension Validation 
To determine the accuracy of the fabrication method of the microfluidic chamber, a 
dimension validation test was performed following the Dimension Validation protocol in 
Appendix D: Protocols. Images of components of the chamber were taken and were then 
analyzed using ImageJ. These measurements were averaged and compared to the desired length 
within the CAD drawing prior to fabrication. The mean measured length and desired length of 
chamber components can be found in Table 26 below.  
Table 26: Microfluidic chamber component measurements 
 
In Table 26 above, the average length of similar measurements, desired length of 
dimensions, error, percent error, and standard deviation can be seen. The dimensions with 
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corresponding numbers are shown below in Figure 92 along with a clear representation of what 
was measured.  
 
Figure 92: Corresponding numbers and measurements 
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The specific measurements were selected to validate as many dimensions of the 
microfluidic chamber pieces as possible.  
5.2.5 Sterility Testing 
In order to test the microfluidic chamber’s ability to maintain an aseptic environment, a 
sterility test was completed. This test analyzed the bacterial growth on the microfluidic chamber 
by sterilizing it then filling it with media and letting the chamber sit in the incubator for five 
days. First, all components of the bioreactor were sterilized using 70% ethanol inside a biosafety 
cabinet (Refer to Appendix D: Protocols: Cell Viability). Once all parts were submerged in 
ethanol for 1.5 hours, the microfluidic chamber was rinsed with deionized water, assembled, and 
filled with C2C12 complete media, the protocol for making the media can be seen in Appendix 
C: Client Meetings. The entire system was transported in a sterile Petri dish into the incubator 
and left for five days. On day five, the coverslips from the chamber were taken out. Below is an 
image taken with an upright bright-field microscope at 10x magnification.  
 
Figure 93: Top of lower coverslip from chamber prior to staining with Methylene Blue. Imaged at 10x with an upright 
bright field microscope. 
As can be seen above in Figure 93, no bacteria were present on the coverslip. The streak 
marks show evidence of scratches but no bacteria. Next, each coverslip was placed in a separate 
well and stained with a mixture of 0.05% Methylene Blue. After one minute of staining, the 
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coverslips were washed with water and imaged under a microscope to look for bacterial growth. 
Figure 94 below shows an image of the stained coverslip.  
 
Figure 94: Top of the bottom coverslip of the chamber after staining with 0.05% Methylene Blue. Imaged at 10x with an 
inverted fluorescent microscope of the Rolle Lab. 
No growth was found anywhere inside the chamber. All images did not detect any 
presence of live culture. In the image above, specs of dust can be seen as well as a smudge which 
can be attributed to the vacuum grease that was in between the base of the chamber and glass 
coverslip. The resulting media was not inspected for contamination, only the inside of the 
chamber was inspected. This test was done once due to time restrictions.  
5.3 Continuous Perfusion 
Once the sacrificial mold protocol was developed, and a microengineered vascular 
network could be created, the team worked to validate the process by attempting continuous 
perfusion through the channel. 
The final design challenge to overcome before establishing continuous perfusion was to 
get flow out the outlet needle of the microfluidic chamber. Many attempts were performed 
before it was determined that the needle needed to be primed with fluid before starting perfusion 
to promote flow out of the microfluidic chamber. The setup can be seen in Figure 95. 
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Figure 95: Continuous perfusion of a microengineered vascular network in a microfluidic chamber with a primed outlet 
needle, pre-filled with fluid to promote flow. 
Continuous perfusion of a single channel was initially shown at a flow rate 0.01 mL/min 
for around 2.5 hours. The perfusion set-up and sample after the 2.5 hours of perfusion are seen in 
Figure 96.  
 
Figure 96: Microvascular network perfusion. Perfusion set-up (left) of channel perfused at a lower flow rate of 0.01 
mL/min for 2.5 hours; arrow points to microfluidic chamber. The gel (middle); arrow points to the formed channel. The 
channel (right) was imaged at the end of the experiment; arrow points to the channel. Note in the middle image the 
diffusion of blue PBS throughout the fibrin. 
A bifurcated channel was created to be perfused. As previously mentioned, the ends of 
the sacrificial molds are placed inside the inlet and outlet needles but the drawn bifurcations 
were too large for this to occur. For this reason and due to its low density, the bifurcation rose 
toward the top of the fibrin surface. The bifurcation was pushed down to try to get it below the 
surface. This contact damaged the gelatin since it had already begun hydrating and forming a gel 
again. However continuous perfusion through the bifurcation was still successful, as seen in 
Figure 97. 
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Figure 97: Bifurcated channels in fibrin gels. Top row: Bifurcated gelatin sacrificial material in PTFE bioreactor before 
addition of fibrin (left), after the addition of fibrin (right) and after flushing and perfusion (middle). Bottom row: 
Microscope images of bifurcated channel at damaged site (left) and one of the bifurcations at 20X (middle) and 40X 
(right) magnifications. 
Continuous perfusion through the microengineered vascular network was conducted for 
as long as twenty-four hours at flow rates ranging from 0.001 mL/min to 0.1 mL/min. These 
flow rates are within the range found in vivo through arterioles. 
5.4 Diffusion Assay 
Analyzing the diffusion of molecules through the gel was the next element of the project 
strategy. The diffusion subsequently influences the scaffold’s ability to sustain cell viability. In 
order to characterize the diffusion, diffusion was observed through a single channel using a 
fluorescent dye. This allowed the diffusion to be observed in real time, and thus gave more 
precise data. We were interested in what the diffusion rate and distance were, since these 
properties affect the nutrient delivery to the seeded cells in an adjacent layer. The diffusion 
distance was going to tell us if the microvascular network increased the diffusion limit enough to 
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reach the furthest point of the adjacent cell layer. The diffusion rate was crucial to determine the 
time necessary for the nutrients in the channel to reach the seeded cells.  
The dye chosen for this diffusion assay was fluorescein isothiocyanate (FITC). The 
molecular weight of FITC is 389.4 g/mol. Even though the molecular weight (MW) of glucose is 
half that of a FITC molecule, the molecular weights of the two molecules would not significantly 
change the diffusion. At such small molecular weights, the difference between the MW of 
glucose and FITC would have negligible effects on the diffusion rate and diffusion coefficient, 
so FITC can be used as a glucose analog. FITC was chosen because it is a fluorescent dye, can 
be used to replace glucose, and is readily available.  
For the experiment, microvascular networks were first fabricated. 0.0625% w/v FITC 
solution was loaded into a syringe and perfused at 0.005 mL/min through the fabricated channel 
system. For the first thirty seconds, using screen capture software and the live image on the 
computer, video of the diffusion was recorded in real time. The initial diffusion was rapid due to 
the large concentration gradient between the solution inside the channel and the solution in the 
gel around the channel. After the initial thirty seconds, images were periodically gathered for 
fifteen minutes because by that point the diffusion had reached the mold’s wall and was reaching 
equilibrium. To repeat the data collection process, the assay was run two times. A detailed 
protocol of the experiment can be found in Appendix D: Protocols: Fibrin Gel Diffusion Assay.  
Once all the images were gathered, the team determined the diffusion distance from the 
channel wall. First, the channel wall was defined. The second step was to set a grey scale 
threshold which would define the diffusion boundary. The darkest areas, where the FITC had not 
reached, ImageJ measured a grey scale value of 5, while the inside the channel, where FITC 
solution concentration was the highest, ImageJ measured an average grayscale value of 75. 
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Based on those grey scale values and the standard deviation, which was 3, a grey scale threshold 
of 10 was defined to indicate the boundary of diffusion. Using ImageJ, as demonstrated in Figure 
98, the distance between the diffusion boundary and the channel wall was measured. Based on 
the gathered data, the team modeled the relationship between the diffusion distance and time.  
 
Figure 98: FITC Diffusion. Images gathered from fluorescent imaging of FITC diffusion.  
The team found out that in the initial ten seconds of the diffusion, the model was 
logarithmic. This can be explained by the concentration gradient between the solution inside and 
outside of the channel. After the initial ten seconds, the slope stabilized and remained linear until 
the final data point is reached. This can be explained as the system had reached a steady state, 
where the concentration has a linear slope based on the distance from the channel. As Figure 99 
demonstrates, the diffusion of FITC reached 1600 μm, while remaining at a constant rate. The 
equation which describes the linear relationship between diffusion distance (μm) and time (s) is: 
(3) d=2.31*t+235.5.  
 
Figure 99: Model graphs of the diffusion of FITC. The left graph shows the logarithmic model for the first 10 seconds, 
while the right graph shows the steady state diffusion model, which matches a linear slope. 
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The calculated R-squared value was 96.25% for the linear curve fit, which indicated that 
the model is a good fit to measured data points.  
5.5 Cell Viability Assays 
One of the high level objectives is for the microvascular network to maintain the viability 
of cells. The experimental setup aims to imitate physiological conditions. The only source of 
oxygen, nutrients, and serum molecules was from the fluid perfusing through the channel. In 
order for all the seeded cells to survive, the diffusion rate of the molecules through the gel 
needed to be high enough to reach the furthest cells before they no longer remained viable. To 
develop these assays a preliminary cell survivability study was conducted. Two types of cell 
viability were performed, the first of which was cells seeded directly on top of a perfused 
microengineered vascular network and the second of which consisted of a cell-seeded fibrin 
hydrogel placed adjacent to a perfused microengineered vascular network. 
5.5.1 Preliminary C2C12 Survivability Study 
For this project, C2C12, mouse myoblasts were used for each cell viability experiment 
due to their skeletal muscle cell type which is one of the closest cell types to cardiac muscle, ease 
of culture, and availability in the lab. In order to develop cell viability assays for the 
microengineered vascular network, the C2C12 cell viability was initially characterized in 
standard culture. Unfavorable conditions in which C2C12 cells cannot survive or cell viability is 
not maintained were tested. In the experiment, three conditions were tested, C2C12 in media, 
C2C12 in PBS, and C2C12 in air. The cells were seeded in well plates and sampled at three 
different time points: four, eight, and twenty-four hours. At each time point, the cells were 
stained with a LIVE/DEAD stain, calcein and ethidium homodimer. Fluorescent images were 
gathered at different locations of the sample wells and qualitatively studied to determine the cell 
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culture survivability, which can be seen in Figure 100, Figure 101, and Figure 102. A detailed 
protocol of the assay can be found in Appendix D: Protocols: C2C12 Survival Assay. 
 
Figure 100: Fluorescent images at 4 hours. Taken from the top left corner of the well. Row 1 is C2C12 cells in air, row 2 is 
C2C12 in media, and row 3 is C2C12 in PBS. 
 
Figure 101: Fluorescent images at 8 hours. Taken from the middle of the well. Row 1 is C2C12 cells in air, row 2 is C2C12 
in media, and row 3 is C2C12 in PBS. 
. 
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Figure 102: Fluorescent images at 24 hours. Taken from the middle of the well. Row 1 is C2C12 cells in air, row 2 is 
C2C12 in media, and row 3 is C2C12 in PBS.  
Based on the gathered fluorescent images, the team drew conclusion about the cell 
viability of C2C12 in the different experimental conditions. The purpose of this preliminary 
study was to determine the minimal amount of time necessary to study C2C12 cell viability. The 
qualitative data showed after four hours, a number of cells in the PBS condition and air condition 
survived at the edge of the well, where there was hypothesized to be media residue. At 4 hours, 
C2C12 cells in the media condition remained viable. The images also demonstrated that after 8 
hours, C2C12 in PBS and in air are all dead, determined by the lack of green fluorescence and 
rounded morphology of the cells. At eight hours, it can be seen that the C2C12 in cell media 
maintained their viability. At twenty-four hours, it seemed only the cells in media were remained 
viable.  
5.5.2 Cells on Top of Perfused Single Channel Viability Assay 
The objective of these experiments was to determine if perfusion through a single 
channel in a fibrin hydrogel could maintain cell viability of cells seeded on top of the hydrogel. 
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The schematic for this assay can be seen in Figure 103. C2C12 cells were seeded directly on top 
of the perfused microengineered vascular network fibrin hydrogel. The distance from the edge of 
the channel to cells directly over the channel was approximately 1200 μm and the horizontal 
distance to the cells furthest from the channel was approximately 4700 μm. 
 
Figure 103: Cells on top of perfused single channel viability assay schematic. The distance from the edge of the channel to 
cells directly over the channel was ~1200 μm and to the furthest cells was a horizontal distance of 4700 μm. 
5.5.2.1 Cell-Seeded Coverslip 
The first experimental set-up had cells seeded on top of a coverslip and then placed 
upside-down on a perfused gel. This set-up was chosen because of the ease of imaging at the end 
of the twenty four hour experiment. The coverslip was removed from the microengineered 
vascular network, washed, and stained with a LIVE/DEAD stain.  
However, because the top of the gel was concave, an air bubble formed between the gel 
and coverslip. Even though perfusion through the gel was successful, the cells did not come in 
contact with the media and subsequently died as seen in Figure 104. The curvature of cells seen 
corresponds to the edge of the air bubble under the coverslip. To adjust for this problem, the cells 
were seeded directly on top of the gel in the next cell viability experiment. 
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Figure 104: Coverslip fluorescent staining for cell viability assay. Image of cells stained with ethidium homodimer to show 
dead cells on coverslip. Note the curved line of cells which corresponds to the location of the air bubble between the 
coverslip and the perfused gel. 
5.5.2.2 Cells Seeded Directly on Top of Gel 
The next cell viability experiment set-up included a positive (+) control of cells in media 
(n=3), negative (-) control of cells in PBS (n=3), and (-) control of cells on a gel with a non-
perfused channel (n=1). There were also two experimental groups of media perfused (n=1, PTFE 
bioreactor) and PBS perfused (n=2, PLA molds).  
The experiment lasted twenty-two hours (Perfusion rates: two hours at 0.01 mL/min, 
seven hours at 0.001mL/min, eleven hours with no perfusion, 0.5 hours at 0.01 mL/min). A rate 
of 0.01 mL/min was initially used to ensure gelatin has been thoroughly flushed out. Because 
there was an extended period of time in which group members could not be in the lab to refill 
syringes, the flow rate was dropped to 0.001 mL/min. When one group member refilled the 
syringes, the “run” button was not pressed on the syringe pump. As a result the samples were not 
perfused for eleven hours overnight. Upon arrival in the morning the samples were perfused for 
0.5 hours at 0.01 mL/min to flush out waste and supply nutrients to cells. 
As seen in Figure 105, the positive control stained for living cells had healthy, elongated 
morphology. The sample perfused with PBS showed no living cells after twenty-two hours as 
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seen by the rounded morphology and solely red stain on the merged images. To note, a gel that 
was not perfused dried out over the course of the twenty-two hours while gels perfused with 
either PBS or media remained fully hydrated. 
There is some background fluorescence in the perfusion with media images because all of 
the media in the gels was not able to be washed out. There are esterases in the serum that react 
with the calcein, just as the esterases in live cells do. However it is clear the gel is covered with 
living cells with healthy morphology like the positive control. Images are included of two 
regions of the gel, one at the edge of the sample and another directly over the channel. There 
does not seem to be a difference in cell viability between the two locations. 
 
Figure 105: Results from cell viability experiment with cells on top of perfused gel with a single channel. All are merged 
images of LIVE/DEAD stain. Top row: Positive control of cells cultured in media (left) and cells on top of 
microengineered vascular network perfused with media both directly over a channel (left) and at the end of the hydrogel 
(right). White lines depict location of channel walls below cells. 
Once cells were shown to be maintained on the surface of fibrin gel containing a 
microengineered vascular network, the cell viability in an adjacent fibrin layer was assessed. 
5.5.3 Adjacent Layer Cell Viability Assay 
The application of the work in this project in the Pins Lab is the creation of stacked, 
alternating myocardial and microvascular fibrin hydrogels. A cell viability assay of a fibrin 
hydrogel adjacent to the vascular network would indicate the effectiveness of this system. Once 
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it was shown that the perfused microengineered vascular network and bioreactor system 
maintained viability of cells seeded directly on top of the fibrin microvascular network, the 
viability of cells in adjacent layers was assessed using the protocol found in Appendix D: 
Protocols: Cell Viability in an Adjacent Layer on Top of Perfused Single-Channel Gels. 
5.5.3.1 Trial 1 
In this trial of cell viability of an adjacent layer to the perfused microengineered vascular 
network, the adjacent layer was added to the microfluidic chamber and then perfusion was 
initiated at 0.002 mL/min. This flow rate was maintained for twenty-four hours. 
As seen in Figure 106, all cells were dead. The green seen in the image is background, 
base-level fluorescence.  
 
Figure 106: LIVE/DEAD merged image of cell-seeded fibrin hydrogel adjacent to perfused microengineered vascular 
network. 
5.5.3.2 Trial 2 
Trial 1 cell viability assay of an adjacent layer was unsuccessful as adjacent gels 
contained only dead cells. It was hypothesized this was because it took too long for media to 
reach the cells in the adjacent layer before they died. 
182 
In this trial of cell viability of an adjacent layer to the perfused microengineered vascular 
network, the adjacent layer was added to the microfluidic chamber and then perfusion was 
initiated at 0.01 mL/min for thirty-five minutes before lowering the flow rate to 0.002 mL/min 
for the rest of the twenty-four hours.  
As seen in Figure 107, all cells in the adjacent layer were not viable. 
 
Figure 107: LIVE/DEAD merged image of cell-seeded fibrin hydrogel adjacent to perfused microengineered vascular 
network.  
5.5.3.3 Trial 3 
Trials 1 and 2 were unsuccessful and this was hypothesized to be because it took too long 
for media to reach the adjacent layer before cells died. 
In this trial of cell viability of an adjacent layer to the perfused microengineered vascular 
network, the microengineered vascular network hydrogel was pre-perfused with media at 0.01 
mL/min for one hour in an attempt to have media close to the top of the hydrogel when the 
adjacent layer was added. The adjacent layer was then added to the microfluidic chamber and 
then perfusion was lowered to 0.003 mL/min. This flow rate was maintained for the remained of 
the twenty-four hours. 
As seen in Figure 108, all cells in the adjacent layer were dead.  
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Figure 108: LIVE/DEAD merged image of cell-seeded fibrin hydrogel adjacent to perfused microengineered vascular 
network. 
5.5.3.4 Trial 4 
Trials 1, 2, and 3 failed and it was hypothesized that the low cell viability was not due to 
lack of media, but lack of oxygen. 
In this trial of cell viability of an adjacent layer to the perfused microengineered vascular 
network, there were a few changes made. Cells were seeded not only in the adjacent layer, but 
throughout the microvascular hydrogel. The gelatin channel was flushed with media instead of 
PBS to “pre-load” the fibrin with some media. Gelatin flushing always is completed with a flow 
rate of 0.01 mL/min. Finally, one microfluidic chamber did not have the top coverslip viewing 
window in place while the other was sealed as usual. The adjacent layer was added to the 
microfluidic chamber and then perfusion was initiated at 0.002 mL/min. This flow rate was 
maintained for twenty-four hours.  
As seen in Figure 109, cells remained viable after twenty-four hours in the positive 
control in which the cell-seeded gel was immersed in a well with media, and in a cell-seeded gel 
adjacent to a microengineered vascular network in an open microfluidic chamber. Cells did not 
remain viable in the negative control in which the cell-seeded gel was immersed in a well with 
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PBS and in a cell-seeded gel adjacent to a vascular network in a fully sealed microfluidic 
chamber. 
 
Figure 109: LIVE/DEAD merged images. Top row: Positive control of cells in hydrogel in well with media (left) and 
negative control of cells in hydrogel with PBS (right). Bottom row: Cells in adjacent layer in open microfluidic chamber 
(left) and cells in adjacent layer in sealed microfluidic chamber (right). 
As seen in one representative image in Figure 110, cells throughout the full thickness 
vascular network hydrogel did remain viable in the open microfluidic chamber while cells in the 
vascular hydrogel in the fully sealed bioreactor had little to no viability. 
  
Figure 110: LIVE/DEAD merged images. Cells seeded within vascular network hydrogel in open microfluidic chamber 
(left) and fully sealed microfluidic chamber (right). 
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Chapter 6: Final Design and Validation 
The purpose of this project was to design, develop, and characterize a bioreactor that 
provides continuous flow through a thin hydrogel scaffold containing a microengineered 
vascular network. Through the verification experiments performed in Chapter 5: Design 
Verification, the final designs of the microvascular network and bioreactor were selected, and the 
fabrication process was finalized. The team then validated the final design through a new set of 
experiments. These tests were set to evaluate the device along the objectives and functions 
defined in Chapter 3: Project Strategy.  
In terms of the microvascular network, the qualitative assessment was based on the 
network’s ability to sustain physiologically relevant flow and the fabrication method’s ability to 
form channels of physiologically relevant diameters. Along with that, the assessment evaluated 
the network's ability to be stacked and the reproducibility of the microvascular network. It also 
assessed the network’s endothelialization and the cost effectiveness of network fabrication.  
The following sections discuss the qualitative assessment of the bioreactor design’s 
ability to limit gas permeability, to allow for reproducibility, the use of multiple samples, ease of 
use and manufacturing, material cost, and cost effectiveness. Along with the objectives, the 
constraints and functions were taken into account. The team was able to successfully meet all of 
the defined constraints. The team was able to fabricate a microvascular network which 
maintained its patency and was able to sustain a physiologically relevant flow rate. The 
engineered vasculature also showed potential capacity to supporting an adjacent cell seeded 
layer. The team additionally developed a bioreactor system that can maintain viability of a small 
tissue construct through the use of a microfluidic chamber component. The chamber assists in 
the microvascular network fabrication and holds the tissue construct in a sterile environment 
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over an extended period of time. The team was able to complete the project in twenty-eight 
weeks and remain within the given budget of $780. In this chapter, the team described the final 
designs and how the project’s objectives were achieved. Along with that, the limitations of the 
tests performed are discussed in addition to the relationship between the project and topics 
including economics, environmental impact, societal influence, political ramifications, ethical 
concern, health and safety issues, manufacturability, and sustainability. 
6.1 Final Design 
The gelatin sacrificial method was selected as the final fabrication method for the 
microvascular network. Based on the studies described in Chapter 5: Design Verification, this 
final design achieved most of the objectives and all functions described in Chapter 3: Project 
Strategy, while following the set constraints and specifications. The detailed protocol for 
microvascular network fabrication using the gelatin sacrificial material approach can be found in 
Appendix D: Protocols.  
The Pressure Square Microfluidic Chamber, as described in Chapter 4: Design Process, 
was machined by Thomas Partington in Goddard Hall’s machining shop of Worcester 
Polytechnic Institute. The base of the microfluidic chamber and the simple mold components 
were made out of PTFE. The top of the microfluidic chamber was made of POM and used a 
silicone gasket to improve the sealing between the microfluidic chamber parts. In addition the 
stainless steel plates allowed for distributed pressure improving the sealing and stability. The 
protocol for machining the microfluidic chamber can be found in detail in Appendix D: 
Protocols: Microfluidic chamber fabrication process. 
When using the machined Pressure Square Bioreactor, all pieces needed be sterilized 
prior to use. When casting fibrin within the bioreactor mold, the following steps should be taken. 
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First, an 18 mm x 18 mm glass coverslip should be placed in the pocket of the base. As described 
in Section 5.3 Continuous Perfusion, the gelatin mold, either single or bifurcated, should be 
placed within the two pieces of the mold. The plugged needles are next inserted into the inlet and 
outlet holes, and the fibrin is cast. Once the fibrin has polymerized, another 18 mm x 18 mm 
coverslip is placed on top of the mold sealing the fibrin gel system. The top half of the bioreactor 
is placed and the screws are screwed in to ensure a tight fit so that leakage cannot occur. The 
final CAD drawings can be seen in Appendix E: Final Design. Figure 115 shows the exploded 
view of the microfluidic chamber. Figure 116 - Figure 120 show the 2D drawings of the 
machined pieces. In addition the parts list for the chamber is located in Appendix E: Final 
Design. The plugged needles are replaced with new needles, and the system is moved into the 
incubator in order to melt the gelatin hydrogel. Using warm PBS, the gelatin is flushed out, and a 
patent channel is formed.  
6.2 Objectives Achieved 
The following section describes how the final designs achieved the objectives determined 
in Chapter 3: Project Strategy. The section includes details on how the microvascular network 
and bioreactor follow the set specifications and remained within the design space limited by the 
constraints.  
6.2.1 Microvascular Network 
6.2.1.1 Physiologically Relevant Dimensions and Flow 
The defined objective was that the fabricated microvascular network needed to have a 
diameter ranging between 11 and 1000 μm and be able to sustain a flow rate ranging between 
0.0015 and 0.21 mL/min. Using the gelatin sacrificial method and the available gauge needles, 
the team was able to fabricate channels which mimic the sizes of arterioles. The system was also 
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able to sustain its patency, when perfused at flow rates between 0.001 and 0.005 mL/min for an 
extended period of time.  
6.2.1.2 Stackable 
One objective of this project was to create a system that would allow for the stacking of 
fibrin hydrogels. In its simplest form, one gel containing a microengineered vascular network 
and another containing cells would be able to be stacked. This objective was accomplished as 
seen in Section 5.5.3 Adjacent Layer Cell Viability Assay. The ultimate goal of stacking cell-
seeded layers adjacent to the microvascular network was to maintain cell viability. This was 
shown, at least preliminarily, in Trial 4 of the Adjacent Layer Cell Viability Assay in which cell 
seeded in the adjacent layer remained viable. Though the top of the microfluidic chamber 
remained open since no glass coverslip was added, because cells remained viable after twenty-
four hours, the system perfused media through the microengineered vascular network hydrogel 
into the cell-seeded adjacent hydrogel. In conclusion, this project developed a system that 
allowed for the stacking of two fibrin hydrogels and produced preliminary data that cell viability 
in the adjacent layer was able to be maintained. 
6.2.1.3 Reproducible 
From the tunability study and reproducibility analysis, described in Chapter 5: Design 
Verification, the team demonstrated that the fabrication method created microvascular networks 
of similar diameters. For example, the average diameters of gelatin sacrificial molds after 25 
minutes of dehydration for 20G and 23G needles were 453 μm ± 8% and 270 μm ± 8% 
respectively. Additionally, the team showed that the final diameter of the channel is dependent 
on the initial size of the sacrificial mold. This would allow the user to adjust the final resulting 
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microvascular network dimensions based on the extrusion needle used to create the sacrificial 
mold.  
6.2.1.4 Endothelializible 
After the client meetings and discussions, the endothelialization objective of the 
microvascular network was ranked second to last. As such, this want was addressed last in the 
project strategy. Due to the time constraint on the team, endothelialization of the microvascular 
network was not achieved. This could be potentially addressed in future work on the project. 
6.2.1.5 Cost Efficient 
The average cost of the materials necessary to fabricate a single microvascular network is 
$ 0.0672, calculated based on the components in Table 27. These values were calculated based 
on the cost of the raw stock materials from providers and the amount used in the fabrication of 
the designed microvascular network. The finalized microvascular network fabrication protocol, 
as written in Appendix D: Protocols, minimizes any possible waste of materials. The protocol 
allows for any excess materials to be frozen for later use, which significantly reduces the amount 
of waste. 
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Table 27: Cost of materials necessary for the fabrication of a single microvascular network 
Material Cost per one microvascular network fabrication ($) 
Fibrinogen 64.4*10-3 
Thrombin 2.02*10-3 
PBS 0.106*10-3 
CaCl2 38.3*10
-6 
Gelatin 0.255*10-3 
HEPES Buffered Solution 0.404*10-3 
NaCl 0.426*10-6 
Total 0.0672 
 
6.2.2 Bioreactor 
6.2.2.1 Controlled Gas Permeability 
Through the sealing test described in Chapter 5: Design Verification, the results 
suggested that a sealed microfluidic chamber is gas impermeable. By analyzing the cell viability 
of an open microfluidic system and a completely sealed microfluidic system, the team 
hypothesized that by sealing the chamber, the only oxygen that could be delivered to the system 
came from the media. Cells died much faster when in the sealed chamber, compared to being in 
an open chamber with no coverslip. When a closed chamber was perfused through, the cells 
remained alive, proving that the cells were receiving enough oxygen and nutrients from media.  
6.2.2.2 Maintain Sterility 
The microfluidic chamber maintained sterility over a five day period. The silicone gasket, 
stainless steel plates, and screws successfully seal the chamber. Using all three provided a tight 
seal of the chamber; it proved to be more effective than using one or two methods alone. The 
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chamber was sterilized in 70% ethanol for ninety minutes, rinsed with distilled water three times, 
and then filled with media. This setup remained in the incubator for five days and resulted in no 
microbial growth, proving the method of sterilization to be successful.  
6.2.2.3 Reproducible 
The dimensions of the microfluidic chamber are intricate and the small scale of the 
features can be difficult to reproduce. However, with the correct tools and experience, the 
dimensions could be reproduced easily. The flow through the chamber is subject to no change 
between experiments because there is no change in the dimensions of the chamber between uses. 
The only modulation in the flow would come from any size differences in the microvascular 
channel during the channel formation process. 
6.2.2.4 Multiple Samples 
Currently the microfluidic chamber is self-contained for a single fibrin gel with a single 
cell scaffold. This means cross contamination is avoided by isolation of each sample to its own 
chamber. Future versions may be designed to accommodate multiple samples. This design would 
simply need to extend the length of the current chamber and create multiple slots for the mold to 
sit into, as opposed to only one. There would be some features that must be determined before 
designing a microfluidic chamber that can accommodate multiple samples such as whether or not 
each sample needs its own perfusion system or if all samples would be perfused at the same time 
with one pump. Another consideration would be whether each slot would be growing tissue with 
the same properties or not. 
6.2.2.5 Ease of Use 
The microfluidic chamber is a very small device making it simple for the user to set up, 
transport, and perform experimentation. The average set up time for the chamber is about 
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twenty-two seconds when not using vacuum grease. However, when vacuum grease is being 
used in between all layers, the average time increased to one minute and forty-three seconds. The 
chamber must be transported from the lab bench where set up occurs, to the incubator where it 
would be attached to the whole bioreactor system. The microfluidic chamber is small enough to 
transport it with one hand, easily. Currently, the most time consuming step is cleanup. The 
vacuum grease can be messy and difficult to remove off the chamber. Cleanup takes about four 
minutes to ensure all the grease has been washed off. The chamber is washed with warm water 
and soap.   
6.2.2.6 Cost Effective 
The microfluidic chamber cost $0 to produce. This was because only little material was 
required to manufacture the part, so scrap from the machine shop in Goddard Hall was used. 
Glass coverslips cost close to $0.03 per piece and two are used in the chamber totaling $0.06. 
Also, two 20G needles are used which costs $0.10 per needle, totaling $0.20 if the chamber were 
to be manufactured. The materials used, POM and PTFE, could be purchased in bulk and the 
same could be done for the slides and needles. Producing this microfluidic chamber at large 
quantities would cost very little for the material and associated parts. Also, the chamber is 
reusable, minimizing costs to the user.  
6.3 Impact of Device 
The overall purpose of the following sections is to discuss the impacts the device has in 
areas including economics, environment, health and safety, society, politics, ethics, 
manufacturing, and sustainability. 
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6.3.1 Economics  
By designing a microvascularization method, the team helped advance the development 
of the cardiac patch in the Pins Lab towards reaching clinically relevant sizes. A cardiac patch 
could offer a regenerative treatment for myocardial infarcts, which is readily available and 
regenerates the patient’s myocardium, restoring function to the damaged site. By creating a 
bioreactor system that could assist in the fabrication of and sustain the multilayered cardiac 
scaffold, the team created a non-expensive method to create the replacement cardiac patches. If 
FDA approved, it is possible that this treatment could become the industry gold standard, as it 
overcomes many limitations of current treatments. Another possible advantage is that this 
approach would make the treatment more available, which would increase the number of treated 
patients while increasing the standard of living. If implemented, this treatment could increase the 
cost of fibrinogen, since there would be larger demand for tissue constructs. This in turn would 
promote the creation of companies that focus on providing this treatment and its required 
materials. Major challenges that need to be overcome to reach that stage are the development and 
finalization of the cardiac patch design, scaling up the design, FDA regulatory approval with 
animal testing and clinical trials, and finally the marketing and distribution of the treatment.  
6.3.2 Environmental Impact 
The designed bioreactor system and the engineered microfluidic network could have an 
impact on the environment. The microvascular network is made using gelatin, natural protein, 
fibrin, and natural polymers, all of which would be disposed of as a biohazard waste. Once 
biohazard waste is brought to the appropriate facility, it is incinerated and dumped into landfills. 
Incinerators release mercury and dioxins into the environment. Biohazard waste incinerators are 
one of the country’s leading emissions sources of toxic and bioaccumulative pollutants. Also, the 
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diesel trucks which travel far distances to deliver the medical waste to incinerators also emit 
toxic pollutants. The pollutants that are released into the atmosphere threaten the public’s health 
(Wormer et al., 2013). Since the final design involves cell culture, the supplies needed to 
maintain these cultures would follow safe biohazard disposal protocols, which would ensure that 
the materials would be discarded safely into the environment.  
Currently, the chamber top is made from polyoxymethylene (POM). In regards to 
polyoxymethylene, there are no environmental impacts that exist. The material is not dangerous 
or of any harm to nature. However, the melting point of polyoxymethylene is 167°C and if this 
temperature is reached or surpassed, the generation of formaldehyde gas could occur. Since the 
steam autoclave temperature reaches 121°C, the polyoxymethylene should not reach its melting 
point (Council on Dental Materials, 1991). Because the difference between the melting of 
polyoxymethylene and the temperature of the steam autoclave is only 46°C, it may be a safer 
option to sterilize with ethanol.  
The base of the bioreactor is made up of polytetrafluoroethylene (PTFE). PTFE has been 
shown to release toxic chemicals that could potentially be carcinogenic (Ellis DA, 2001). PTFE 
will endure temperatures up to 230°C for about 2.3 years before degradation occurs and toxic 
chemicals begin to be released (Simon, 1998). Regardless, for this project, the designed 
microfluidic chamber does not expect to reach temperatures that high. If it is decided that 
components of the bioreactor need to be disposed of, the user must follow appropriate solid 
biohazard disposal procedures. Since PTFE is a stable material, once cleared of biologicals, it 
can be disposed to a landfill or recycled. Most of the components of the whole bioreactor system 
are recyclable and reusable, which reduces the risk of waste accumulation.  
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6.3.3 Societal Influence  
As discussed previously, the project aims to assist in the research and development of a 
cardiac patch, which is still in its early stages. If the overarching research project is successful in 
creating a cardiac patch as a treatment for heart failure, the need for heart donors would decrease 
and the cost for treatment could be reduced, making it more affordable for more people. One 
drawback of this is that there is may be a chance that the number of organ donors would actually 
decrease. This could be due to the public perception that tissue scaffold treatments have nullified 
the need for organ donors. However, by offering a more affordable treatment, which has lower 
associated risks than whole heart transplant, the standard of living of patients could improve. 
Based on the AHA statistics, the average cost of a heart transplant is approximately 1.2 million 
dollars. The team expects the cardiac patch treatment to cost a fraction of a heart transplant 
because the fabrication cost would be lower than the cost of finding and transporting an available 
live heart.  
6.3.4 Political Ramifications  
This project has insignificant political ramifications, as there would no direct effects on 
the industry or commercial market. If commercialized, it is possible that well developed 
countries would implement these treatments first, since these countries would have access to the 
research, materials, and funding to provide them. The increase in standard of living would likely 
make these countries more favorable, which could potentially lead to migration of people from 
less developed countries. The bioreactor system design and microvascular network design are in 
the initial stages of research and development, which means significant work, needs to be done 
before the engineered cardiac patch becomes marketable and accessible to the public.  
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If the device were to include embryonic stem cells, there would be perceived political 
issues. In 2001, President George W. Bush banned federal funding for embryonic stem cell lines 
that were recently created. This left only twenty-one cell lines fit for research using federal 
funding. In 2009, President Barack Obama introduced an Executive order that lifted the ban 
Bush executed and allowed the National Institutes of Health (NIH) to introduce new criteria for 
stem cell research. The new criteria allowed for hundreds of embryonic stem cell lines to be 
studied through federal funding. However, difficulties with stem cell studies still exist as the 
Dickey-Wicker amendment is still in place. This prevents federally funded scientists from 
creating new embryonic stem cell lines as they are not allowed to create or cause harm to 
embryos (Murugan, 2009). This would prove to be an issue with this project if scientists choose 
to use embryonic stem cells for the creation of the cardiac patch, since private funding would be 
required.  
6.3.5 Ethical Concerns 
For the scope of this project, there are few ethical concerns. One ethical concern is the 
isolation of proteins from animals used in the design. Fibrinogen, thrombin, and gelatin are 
proteins acquired from animal sources, two bovine and porcine sources respectively. If demand 
for tissue engineered cardiac patches increased, the need for these animals could increase as well. 
The designs from the project are going to be contained within the lab space, where ethical 
norms are overseen by the Institutional Animal Care and Use Committee (IACUC). Ethical 
concerns could arise when the bioreactor system and microvascular network are used to fabricate 
a cardiac patch for an actual patient. There would need to be oversight that would control the 
patient’s biopsied cells from being used for any other purpose than agreed on by the patient.  
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Tissue engineering includes the ethical concern of potential abuse of the regenerative 
approach. By regenerating tissue, researchers try to improve the function and structure of 
damaged tissue. This could, however, be used to create enhanced humans, which is similar to the 
ethical concern with embryonic gene therapy. The only way to regulate this and prevent this 
extreme from becoming reality is to strictly regulate who has access to the tools and materials 
necessary. These concerns, however, relate to the finalized and implemented treatment.  
6.3.6 Health and Safety Issues 
In terms of the bioreactor, it is safe for the user to use. None of the components of the 
bioreactor system produce harmful chemical fumes because they are all made of stable materials 
that are not reactive at room temperature, 22°C, and incubator temperature, 37°C. The device 
does not produce any harmful chemical byproducts. The main two cautions that must be taken is 
using glass coverslips because they are easy to break if not handled carefully and handling the 
input and output needles. Mishandling of these could potentially cause injury by punctures and 
cuts. The user must follow proper procedures for disposal of sharps, as well as follow standard 
procedures for working with blood-borne pathogens. In terms of the vascular network, because it 
is still within the initial phases of design, more tests will need to be completed to understand its 
safety and reliability. None of the materials used to fabricate the microvascular network are 
toxic, so the user is at low risk, as long as he or she follows proper lab safety procedures and 
protocols.  
In order for the researched cardiac patch to be FDA approved, the designed system needs 
to go through thorough inspections and regulatory tests, as this treatment approach would most 
likely be treated as a 510k device. There is a chance that the fibrin sourcing will need to change, 
since currently for research bovine fibrinogen is used, which may not be the best option for 
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human implantation. Since fibrinogen and thrombin are blood derived, they must be screened for 
viral prions prior to use. 
6.3.7 Manufacturability  
The casing that is considered the “microfluidic chamber” can be manufactured simply 
with appropriate tools. The chamber needs to be manufactured with precision so that the system 
ensures proper sealing of the chamber. The screw holes must be drilled with a small enough 
tolerance to ensure the inlet and outlets fit tightly to avoid leakage. Manufacturing the inside 
corners of the bottom piece can be very challenging, since the machining device does not allow 
for sharp corner precision. A possible approach to this would be using a milling device to make 
the well initially, and then using a sawing device to cut the corners, making precise sharp corner 
which match to the mold edge. Besides these few components that require more precaution and 
attention, the microfluidic chamber is simple to manufacture and many could be reproduced 
quickly. The current prototype has been manufactured by hand at WPI. With appropriate CAD 
drawings, the part could be outsourced to professional medical device manufacturing companies, 
which have access to the materials necessary for the fabrication and machines with micrometer 
precision milling and cutting,  
6.3.8 Sustainability  
In order to achieve the fibrin microvascular network, significant amounts of 
unrecoverable energy is necessary. The network is fabricated using natural polymers and 
proteins which need to be isolated from animal sources. In order to purify and separate the 
desired materials, large amount of energy is necessary. Large amounts of energy is used to create 
the purified solutions necessary for cell media. During the fabrication process, energy is 
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expended to keep the biosafety cabinet and incubator functional, which are necessary for the 
sterile fabrication of the microvascular network. 
Significant energy is needed to manufacture the bioreactor components. The syringe 
pump system required energy to fabricate, since energy would be expended to build the device 
from raw materials, and then to fabricate the pieces to the right size and dimensions. After that, 
addition energy is needed to assemble the system precisely. For the microfluidic chamber, 
significant energy would be expended to make the initial raw materials, and then to machine 
them to into the proper dimension to fit together.  
For sustaining a tissue construct, energy would be expended to autoclave the microfluidic 
chamber, and to keep the syringe pump functional, as it runs on electricity. Additional energy 
would be expended by the incubator, which sustains conditions favorable for cell growth. The 
current bioreactor design allows for repeated use of the system, which means the energy 
necessary to fabricate the components is only once over extended periods of time. This is also 
true for the isolation and purification processes of the materials needed for microvascular 
network fabrication. The largest amount of energy would be consumed by the repeated 
sterilization of the bioreactor components, and the continuous function of the incubator to keep 
favorable conditions and of the biosafety cabinet to maintain a sterile environment for cell work.  
6.4 ISO Standards 
ISO International Standards ensure that products are safe, reliable and of good quality. 
The most important standard for the team's application is ISO 10993: Assessing the 
biocompatibility of medical devices and materials. This was examined by testing the 
biocompatibility of the material used through multiple experiments (ISO 10993, 2009). When 
cells were placed into the bioreactor system with constant perfusion, no death occurred, proving 
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the material to be biocompatible. Next is ISO 11737: Sterilization of Medical Devices. This 
standard is in place to determine what population of microorganisms might be on the product, 
test the sterility, and validate/maintain the sterilization process (ISO 11737, 2006). Tests were 
completed to analyze the sterility of the microfluidic chamber using 70% ethanol. The tests 
yielded no microbial growth, proving the sterility of the system. ISO 13022: Medical products 
containing viable human cells are the next standard that team must adhere to. (ISO 13022, 2012). 
This standard was not implemented during this project, but if the design were to be manufactured 
for clinical use, this standard must be implemented. The final standard that applies is ISO 16792: 
Technical product documentation using CAD. Computer-Aided-Design was used to design the 
microfluidic chamber and this standard was followed to ensure proper dimensioning, labeling, 
and documentation (ISO 16792, 2015). 
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Chapter 7: Discussion 
Heart disease is the leading cause of death in the United States and the most common 
form is a myocardial infarction. A myocardial infarction causes the death of myocardium which 
is then replaced by scar tissue reducing the functionality of the heart because no healing occurs. 
Current treatments either are not readily available or are only used to prevent further damage. 
Most importantly, no treatments regenerate the patient's myocardium. There is a clear need for an 
off-the-shelf solution that regenerates functional tissue (Emmert, Hitchcock, Hoerstrup, 2013). 
The team was able to design and develop a bioreactor system as well as microvasculature that 
sustained the viability of C2C12 cells. This consisted of two main components: the microfluidic 
chamber and the microengineered vascular network in a fibrin hydrogel.  
7.1 Discussion of Results 
The purpose of this project was to design, develop, and characterize a microengineered 
vascular network in a fibrin hydrogel and a bioreactor that provides continuous perfusion. Once 
continuous perfusion was established, the diffusion of nutrients through the hydrogel and the 
viability of cells were to be assessed. As described in earlier portions of this report, through 
interviews and meetings with the client and users, the design team developed a list of objectives 
and constraints. Some of the high-level objectives for the project were being reproducible, of 
physiologically relevant dimensions, stackable, easy to use, and cost effective. From the list of 
objectives, the team developed functions which included providing continuous perfusion, 
maintaining sterility, allowing for visualization, providing diffusion of nutrients, and maintaining 
cell viability. Over the course of the project, each of these functions were achieved.  
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7.1.1 Microengineered Vascular Network 
A microengineered vascular network was designed and developed using 10% gelatin in 
PBS as a sacrificial mold.  
7.1.1.1 Gelatin Sacrificial Mold Method Development 
A method to produce both a single cylinder and a sacrificial mold with one or two 
bifurcations, transfer to a microfluidic chamber, maintain structure in fibrin, and form a 
perfusable channel was designed and developed. To develop this method, much iteration was 
attempted to solve problems as they arose. 
The method of loading liquid gelatin into a syringe, cooling to form a gel, extrusion 
through a needle onto a PDMS surface enabled rapid production of single sacrificial mold 
cylinders. To create bifurcated channels, a method was developed in which the solid gelatin was 
heated to its gel transition temperature, between 25℃ and 30℃ for a concentration of 10%, and 
printed. This method allowed for the production of single- and double-bifurcations in a user-
friendly, non-time-consuming way.  
7.1.1.2 Transfer and Placement in Microfluidic Chamber 
Unless the sacrificial mold was to be produced in the microfluidic chamber, it would 
have to be transferred to the chamber. Immediately after extrusion, it was not possible to handle 
the mold. The dehydration process on the benchtop for thirty minutes enabled the mold to be 
lifted, cut, and maneuvered into the microfluidic chamber. 
To overcome the low density of gelatin relative to water, it was critical to hold the mold 
in place to prevent it from rising to the top of the fibrin solution. The developed method includes 
inserting the mold into the inlet and outlet needles of the microfluidic chamber. This kept the 
sacrificial mold in the center of the fibrin throughout the polymerization process. The final 
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design in this project has a relatively thick microengineered vascular network hydrogel of around 
3000 μm. The ultimate goal is to create thin microvascularized hydrogel. This method of keeping 
the sacrificial mold straight and in the plane of the inlet and outlet needles would be critical as 
the microvascular network hydrogel is scaled down in thickness to ensure the mold does not 
bend and reach the surface of the fibrin gel,  
7.1.1.3 Channel Formation 
The ultimate goal of forming sacrificial mold in microvascular engineering is to remove 
it and form a channel. The team developed a method of forming a channel by warming the entire 
sample in an incubator for ten to fifteen minutes to fully melt the gelatin and then perfusing with 
warm PBS for more than ten minutes at a flow rate of 0.1 mL/min to ensure full gelatin removal. 
This same process was able to be used for the fabrication of single and bifurcated channels.  
7.1.1.4 Tunability of Channel Diameter 
It was first determined that the initial sacrificial mold had an outer diameter not 
significantly different than the inner diameter of the corresponding extrusion needle. It was then 
shown that there was a significant difference between this initial mold diameter and final 
diameter of the formed channel. It was determine that the final channel diameter could be 
predicted through a linear relationship with the initial mold diameter immediately after 
fabrication. The implication of this is that one could tune the desired channel diameter by 
changing the needle through which the sacrificial mold is extruded. Additionally, using needles 
of gauges smaller than 19G would result in channels with physiologically relevant diameters on 
the scale of arterioles.  
204 
7.1.1.5 Reproducibility of Sacrificial Mold Production 
It was shown that the fabrication of cylindrical sacrificial molds in this project was 
reproducible with respect to the diameter of the molds. The average diameter and percent 
standard deviation of gelatin cylinders were measured and calculated at three time points, zero 
minutes (immediately after extrusion), twenty-five minutes, and seventy-five hours for two 
different gauge needles, 20G and 23G. As seen previously in Chapter 5: Design Verification, the 
average diameter immediately after extrusion is approximately equal to the inner needle 
diameter. At all-time points for both needle sizes tested, the percent standard deviation was 10% 
or less. The team concluded this showed sufficient reproducibility. Also important to note is that 
there is little difference between the diameters at twenty-five minutes and seventy-five hours. 
From this it can be concluded that the gelatin sacrificial molds decreasing of size is mostly 
complete by twenty-five minutes after extrusion and that this is a sufficient amount of time for 
dehydration.  
The ability to form reproducible, tunable, perfusable channels in fibrin within a 
biomaterial has implications to tissue engineering. Through the implementation of the 
microengineered vascular network process designed in this project, it was hypothesized the 
passive diffusion limit of oxygen and nutrients could be overcome. By overcoming this 
limitation, scaffold development can continue to produce tissues constructs of clinically relevant 
sizes, for example a one centimeter thick cardiac patch (Kawel et al., 2013). 
7.1.2 Bioreactor System 
The team designed and developed a microfluidic chamber in a perfusion bioreactor 
system that successfully provided continuous perfusion of a physiological rate for twenty-four 
hours. The bioreactor system includes the microfluidic chamber, a syringe pump, and collection 
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flask. In addition, the team designed and developed a microvasculature in a fibrin gel that 
sustained C2C12 cells 1200 μm above the network. In the following sections the results and 
limitations of the design testing is discussed.  
7.1.2.1 Perfusion Testing 
One of the functions of the bioreactor was to allow for continuous perfusion. During the 
perfusion test it was shown that the bioreactor system was able to continuously perfuse one 
milliliter of liquid through the microfluidic chamber successfully at flow rates of 0.01 mL/min, 
0.1 mL/min, and 1 mL/min. The system allowed for the perfusion of water in and out without 
disruption. This means the system can sustain perfusion through the microfluidic chamber to 
provide the sample with the necessary nutrients for growth. The longest the team perfused 
through the microfluidic chamber was twenty-four hours. A limitation of this test is that the 
duration was only one day and therefore does not prove the ability to perfuse over the original 
desired length of three weeks.  
7.1.2.2 Leakage Testing 
The leakage test resulted in no leaked fluid. This means the system is sealed and can 
sustain perfusion over the course of experimentation. The bioreactor system can both perfuse 
liquid through and not leak, showing the system is properly sealed. This proves that the 
microfluidic chamber can contain fibrin before and after polymerization without compromising 
the structure of the gel. Because of this, the chamber can be used without losing volume in the 
experimentation area or contaminating the sample for up to twenty-four hours. The limitation of 
this test is that it was only performed for twenty-four hours. Future experiments should perform 
leakage tests for longer periods of times to understand the microfluidic chambers ability to 
remain properly sealed. 
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7.1.2.3 Setup Time 
An objective of the bioreactor was ease of use. If the setup time for the microfluidic 
chamber is minimal, it contributes to the ease of use of the entire system. As seen in Section 
5.2.3 Setup Time of Microfluidic Chamber, the average of the three trials took 98.43 seconds to 
complete. The duration of the setup decreased with each trial. This shows that after becoming 
familiar with the system and the process becomes more fluid, the time it takes to complete is 
reduced. Overall, a setup time of approximately 100 seconds requires a minimal time 
contribution to the setup of the system which lightens the burden on the user and demonstrates its 
ease of use. A limitation of this experiment includes that it did not include the time it takes to 
create the gelatin sacrificial mold, place the sacrificial mold, allow for diluted thrombin and 
fibrinogen aliquots from the freezer to thaw, create the fibrin scaffold, etc. because these steps 
can greatly vary in set-up time depending on different conditions. The setup time calculation 
strictly applies to the setup of the microfluidic chamber itself and does not include any of the 
microengineered vascular network components or the other components of the bioreactor system 
as a whole.  
7.1.2.4 Dimension Validation 
By validating the dimensions of the microfluidic chamber, the accuracy of the machining 
process can be tested. Based on the results, the highest percent error that occurred for any 
measurement was with the silicone gasket, which had a percent error of -6.000%. This is because 
the gasket is stretched when it sits in the grove of the POM top piece of the chamber which 
causes stretching and for the width of the gasket to decrease in size. The next highest percent 
error occurred with the PTFE chamber top viewing window length, which had a percent error of 
3.47%. Overall, since the percent error for all fabricated components is less than 4%, the 
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machining process proved to be effective. A limitation of this experiment includes that it was 
only performed on one fabricated microfluidic chamber. Although two were made, the 
dimension validation test was only performed on one. Another limitation is that this dimension 
validation was performed after the microfluidic chamber was used a few times. Because of the 
malleable material used, there could be slight variation in dimensions after each use, especially 
screw holes.  
7.1.2.5 Sterility 
A function of the bioreactor was to maintain a sterile environment. The sterility test ran 
on the microfluidic chamber resulted in no microbial growth as seen in Figure 93 and Figure 94 
in Section 5.2.5 Sterility Testing and suggested the completion of this objective. Over the five 
day incubation period, no bacteria was able to enter the chamber and grow. This suggests the 
sterilization technique of 70% ethanol was successful. This also shows the chamber successfully 
remains sealed and can maintain an aseptic environment during experimentation. This was 
successfully completed with the use of a silicone gasket and screws that compressed the 
microfluidic chamber. A limitation of this test is that the duration was only five days and 
therefore does not show sterility over the original desired length of three weeks. In order to prove 
the completion of the objective, a bioburden assay should be performed according to the FDA 
and ISO 11737 standards (ISO 11737, 2006).  
7.1.3 Continuous Perfusion 
Previous work in the Pins Lab focused on developing a microengineered vascular 
network using the bonding of a pre-vascularized hydrogel to a single flat hydrogel (Bornstein, 
Gagnon, Moutinho, & Reyer, 2015). Continuous perfusion was not able to be established due to 
improper sealing of the two hydrogels as well as at the input and output of the network. This 
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design of the microengineered vascular network presents solutions to these problems and as a 
result, continuous perfusion was shown to be possible. The vascularized hydrogel in the current 
method is formed in one piece which eliminates the need to bond hydrogels together.  
These two strategies subsequently allowed for continuous perfusion after removal of the 
sacrificial mold. Perfusion was accomplished at physiologically relevant flow rates within the 
ranges of arterioles in vivo. 
7.1.4 Diffusion Assay 
Based on the gathered images, the team was able to measure the diffusion distance from 
the channel wall. From the data gathered, the relationship between the diffusion distance and 
times was modeled. A linear curve fit was used, since the team expected that the diffusion 
through the gel system would be at a steady state.  
The team found out that in the initial ten seconds of the diffusion, the model was 
logarithmic. This can be explained by the concentration gradient between the solution inside and 
outside of the channel. After the initial ten seconds, the slope stabilized and remained linear until 
the final data point reached when the assay was completed after forty minutes. This time limit 
was selected, because at thirty minutes, the diffusion boundary had reached the wall of the mold. 
Because of the manner that the FITC spread out of the channel, this lead the team to believe that 
rather than simple diffusion, the FITC molecule was actually perfusing through the system, being 
carried with the solution away out from the channel. Because of that, the FITC diffusion 
boundary was able to reach 1600 μm. This lead the team to conclude that the fabricated 
microvascular network could potentially sustain the cell viability of an adjacent cell-seeded gel.  
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7.1.5 Cell Viability Assays 
7.1.5.1 Preliminary C2C12 Survivability 
From the gathered data from the experiment, a few conclusions were drawn. The first is 
that PBS is effective and sufficient as a negative control in cell viability experiments as 
determined by loss of cell viability after four and eight hours at all areas outside of the edge of 
the wells. It was hypothesized that residual media remained at the edge of the wells in which 
cells retained viability. By comparing Figure 100 and Figure 101, it can be seen that the air and 
PBS have similar effects on cell culture, as a significant portion of the cell culture died in both 
conditions. The second conclusion that was drawn is about the time length of the cell viability 
experiments. By comparing Figure 101 and Figure 102, there is little to no change in the air and 
PBS conditions. The cell culture in the cell media seems to have increased between the eight 
hour time point and twenty-four hour time point. This means that either amount of hours is 
sufficient time to determine C2C12 cell viability relative to PBS or air negative controls.  
It is important to note a drawback to our analysis. The wells in the plate used for the 
experiment have a slight curvature upward toward the center. This creates a small groove at the 
edge of the wells. Because of this depression, it was difficult to completely remove the cell 
media from the systems. It is for this reason it is believed living cells were observed in the air 
wells at later time points. Media was not completely aspirated and this residual media allowed 
some cells to survive. In order to avoid this, we recommend using flat wells, thoroughly rinsing 
the non-media systems with PBS, and / or carefully aspirating all fluid along the edge of the 
wells.  
210 
7.1.5.2 Cells on Top of Perfused Single Channel Viability Assay 
The cell viability assay on top of a perfused microengineered vascular network was a 
critical validation of the bioreactor and microengineered vascular network designs.  
Various flow rates were used in this assay for different reasons. A flow rate of 0.01 
mL/min is always used to clear the liquid gelatin. Once the gelatin was cleared and to mimic 
physiological flow rates for arterioles, a flow rate of 0.001 mL/min was selected. Due to an error 
by a team member, neither the media perfused or PBS perfused samples were perfused 
overnight. Because cells remained viable, the team concluded that continuous perfusion of the 
system was not actually a requirement to maintain cell viability.  Even though the flow rates 
varied throughout the experiment, though not a continuous perfusion experiment, this is still a 
controlled experiment because all perfused samples received the same variable flow rates. 
This assay showed that media perfused microengineered vascular networks maintained 
cell viability of C2C12 cells on top of the hydrogel 1200 μm from the top of the perfused 
channel, a distance six times the 200 μm static diffusion limit of oxygen. Additionally, cells at 
the edge of the hydrogel, at a distance of around 4700 μm remained viable. The implications of 
this are that a perfusable microengineered vascular network has the capability of maintaining cell 
viability at distances greater than the passive diffusion limit of oxygen.  
The next step, which is more directly relevant toward the goal of creating a stackable 
alternating microvascular, myocardial layered cardiac patch, would be to assess cell viability of a 
layer adjacent to the vascular network. 
7.1.5.3 Adjacent Layer Cell Viability Assays 
Through multiple trials of the cell viability assay of a cell-seeded fibrin hydrogel adjacent 
to a perfused vascular network, it was hypothesized that the cells were not remaining viable, not 
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due to lack of nutrients media, but due to lack of oxygen. It seemed that the microfluidic 
chamber was so well sealed that the amount of oxygen entering the system in the media was not 
sufficient.  
Trial 4 tested to see whether this hypothesis was correct. The results suggested that in the 
microfluidic chamber without the top coverslip, allowing oxygen to access the top of the gel, 
cells in both the adjacent layer and throughout the 3400 μm thick vascular network hydrogel 
remained alive. These results raise some interesting points. It seems in a sealed microfluidic 
chamber, there is not sufficient oxygen to keep any cells alive. In a microfluidic chamber that is 
open on the top, cells remain viable throughout the entire thickness of the microvascular network 
and adjacent layers so there is sufficient oxygen for all cells to survive. The cell viability in the 
adjacent layer did seem higher than within the vascular network hydrogel. Based on the 
literature, oxygen should only passively diffuse 200 μm into the hydrogel so oxygen delivered to 
the rest of the hydrogel should come from the perfused media.  
Future tests of this system would include the use of a gas permeable membrane, such as a 
thin silicone sheet, on top of the microfluidic chamber that would allow for gas exchange in 
addition maintenance of sterility with just the microfluidic chamber. 
7.2 Comparison to Other Studies 
7.2.1 Microengineered Vascular Network 
The design of the microengineered vascular network presented in this project report is 
created using a novel, tunable method of extruded sacrificial molds made of 10% gelatin. As 
described in detail in Chapter 2: Literature Review and Chapter 4: Design Process there are 
multiple methods for developing in vitro vascularization including angiogenesis and 
vasculogenesis, the formation of new blood vessels by endothelial cells from existing vessels or 
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de novo respectively, bonding of pre-vascularized hydrogels, and cylindrical rod extraction 
(Hasan et al., 2014; Lovett, Lee, Edwards, & Kaplan, 2009). Each of these methods, however, 
has distinct limitations. Vascularization by angiogenesis or vasculogenesis is a time-consuming 
process and it can be days or weeks before vasculature is formed (Laschke et al., 2006). In this 
time, the development of thick scaffolds is difficult because perfusion is not yet possible. In 
addition, it is difficult to control the formation of vascularization (Laschke et al., 2006). The 
method of bonding pre-vascularized hydrogels is limited by inadequate sealing of the two gels as 
well as difficulty sealing the inlet and outlet (Bornstein, Gagnon, Moutinho, Reyer, 2015). The 
cylindrical rod extraction method is limited by the possibility of damage to the hydrogel due to 
shear upon rod removal and lack of geometry options since it is only possible to create a single, 
non-bifurcated channel based on feasibility studies in this report. The sacrificial mold method 
developed in this project overcomes each of these limitations. Compared to the days or weeks 
with the angiogenesis method, the time required from formation of a gelatin sacrificial mold to 
channel fabrication is vastly decreased to around an hour. There is also much greater control over 
the formation of the microvasculature since the resultant channels are of the approximate size 
and geometry of the mold.  
Compared to the method of bonding pre-vascularized hydrogels, the method developed in 
this project avoids the problems of bonding two hydrogels together and improper sealing at the 
input and output of the network. The sacrificial mold is placed in the microfluidic chamber 
before adding the fibrin components and the gel is created in one piece. This eliminates the need 
to even consider bonding hydrogels together. The method in this project includes placing the 
sacrificial mold into the inlet and outlet needles of the microfluidic chamber which integrates the 
formed channel into the microfluidic chamber. The sacrificial mold method also has distinct 
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advantages over cylindrical rod extraction. In this project there was no evidence of damage to the 
fibrin hydrogel due to shear upon removal of the sacrificial mold as opposed to common damage 
with the rod extraction. Additionally bifurcations are possible with the sacrificial method as 
opposed to only being able to form single channels with rod extraction. 
7.2.2 Bioreactor   
The team’s final bioreactor system included a syringe pump, microfluidic chamber, and 
collection flask. A similar bioreactor system was created by Warren Grayson et al. (2008).  Their 
bioreactor system focused on using tissue engineering of bone to allow 6 tissue constructs to be 
maintained at the same time, while allowing for continuous perfusion and imaging with a 
microscope. This system is similar to the team’s bioreactor in that both included a pump and 
microfluidic chamber; however the bioreactor system of Grayson et al. did not have a collection 
flask. Instead, the media continued to flow through a loop. Another difference is that the team’s 
bioreactor made use of a syringe pump while that of Grayson used a peristaltic pump.  
An additional difference between the two designs is that the microfluidic chamber of 
Grayson used the same media for six tissue samples. With the team’s design, a different chamber 
would be used for each sample, thus making use of a different input media syringe for each 
chamber. The chamber of Grayson was entirely transparent, as it was made with polycarbonate 
plastic, while the only part of the team’s chamber that was transparent was the glass coverslip 
viewing window; the rest of the team’s chamber was made of materials including PTFE and 
POM. Both designs, however, made use of silicone gaskets. The team’s bioreactor used a 
silicone gasket between the top lid of the chamber and the top glass coverslip. The chamber of 
Grayson used silicone gaskets to separate the parts of their microfluidic chamber. Additionally, 
both could be imaged with a microscope as they both had a large enough transparent portion to 
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allow for viewing of the sample and also both adhered to a height profile appropriate for 
imaging. The team used stainless steel plates and 4 - 40 screws to secure the system and maintain 
sterility, while the other chamber makes use of a Petri dish lid, which can easily be removed. 
This could also be seen as a benefit, however, to allow for easy access to the samples when 
desired.  
Another similar microfluidic chamber was created by Mirjam Fröhlich and focused on 
the perfusion of 3D tissue scaffolds (Fröhlich et al., 2010). Their system used a peristaltic pump, 
microfluidic chamber and a media reservoir. The system flows from the reservoir, through the 
pump, into the microfluidic chamber, then back to the reservoir. The team’s system flows one 
way, starting in the syringe pump and ending in the collecting flask. Their microfluidic chamber 
used a silicone gasket as well; however, it was a sheet gasket rather than a gasket. They also used 
a layer that contained pre-made channels for the media to be perfused through. This layer 
restricts the number of tissue samples the device can sustain at one time. The team’s microfluidic 
chamber has space for a hydrogel, whereas the chamber created by Mirjam Fröhlich only 
contained a glass slide with a tissue scaffold on top. The other microfluidic chamber utilized 
threaded nozzles to allow for the addition of tubing to be secured. Both the team’s and Fröhlich’s 
chamber take advantage of the rigidity stainless steel to provide structure and pressure to 
maintain the sterility of the chamber. Both microfluidic chambers kept the height profiles low to 
allow for imaging under a microscope. 
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Chapter 8: Conclusions and Recommendations 
8.1 Conclusions 
The challenge presented to the team was to design a bioreactor system and a novel 
microvascular network for the growth and vascularization of a cardiac patch. The current 
methods of cardiac repair are non-regenerative methods such as coronary artery bypass, 
percutaneous coronary intervention, and heart transplant. An engineered cardiac patch would 
fulfill this need with an off-the-shelf regenerative treatment. The major challenge is creating 
vasculature which would efficiently deliver nutrients and gases necessary to sustain cell viability 
throughout the scaffold. 
The team designed a microvascular network using a sacrificial material protocol and a 
bioreactor system with a custom designed microfluidic chamber to hold the tissue construct. The 
team developed a fabrication procedure for the microvascular network, which allows for the 
formation of channels with diameters similar to arterioles. The fabrication protocol also allows 
the user to tune the diameter of the final fabricated channel in a reproducible manner. Using this 
method, the vascularization formed maintained its integrity and patency. 
The team also designed, developed, and tested a bioreactor system that would sustain the 
microengineered vascular network and an adjacent cell-seeded layer. The components of the 
bioreactor are a syringe pump that allows for precise control over a physiologically relevant flow 
rate, a custom microfluidic chamber, which is compatible with the microvascular network 
fabrication process, and a collection flask. The designed system was able to sustain cell viability 
of fibrin construct seeded with cells over twenty-four hours.  
Once the bioreactor system and microvascular network were designed, the team studied 
the perfusion through the system, characterized the diffusion through the microvascular network, 
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and performed a cell viability assay to assess the effectiveness of the designs. The team 
determined that the bioreactor can provide continuous perfusion at a constant flow rate. After 
that the team studied the microvascular network’s ability to sustain the provided perfusion. Both 
of these experiments showed positive results, as the bioreactor pump allowed the user to 
precisely control the flow rate and that the engineered microfluidic chamber was able to 
withstand the flow without losing its integrity or patency. Once continuous perfusion was 
successfully established through the microvascular network, it was necessary to characterize the 
diffusion through the system. Using a fluorescent dye, the team hypothesized that the 
microvascular network would be able to deliver nutrients to and sustain an adjacent layer. 
Perfusion of the microengineered vascular network successfully maintained cell viability of 
C2C12 cells on top of the perfused hydrogel. The cell viability of an adjacent layer showed that 
bioreactor system and the microvascular system are able to sufficiently deliver nutrients to the 
cells of the adjacent layer, but the bioreactor system as design may be unable to provide 
sufficient oxygen to sustain the cell viability.  
In summary, the team designed a functional microvascular system with channels 
mimicking the size of arterioles and a bioreactor system that can sustain continuous perfusion 
and hold the construct in an aseptic environment. A number of recommendations are made to the 
designs to improve their functionality and efficiency.  
8.2 Recommendations 
8.2.1 Microvascular Network Design 
8.2.1.1 Using a Permeable Cover Cell Viability 
The first recommendation the team has for future work on the microvascular network is 
to test cell viability of an adjacent layer on top of the microvascular network in a microfluidic 
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chamber with a gas permeable cover. The team tested the cell viability of an adjacent layer in an 
open microfluidic system, and the assay showed promising results with high percentage of cells 
remaining alive both in the adjacent layer and throughout the entire 3400 µm thick hydrogel. 
This, however, made it more difficult to maintain an aseptic environment. The team recommends 
testing the use of a clear, gas permeable materials such silicone in place of the glass coverslips, 
improving the cell viability of the adjacent layer, while retaining an aseptic environment.  
8.2.1.2 Scaling Down the Microvascular Network Channel Diameter  
In this project, the team aimed to achieve a microengineered vascular network channels 
which have diameters within the range of arteriole diameters. In order to mimic in vivo 
vasculature at the lowest level, the next step would be to scale down the microvasculature to 
capillary diameter ranges. This would allow for more complex microvascular geometries to be 
created as well as increase the network’s efficiency in delivering nutrients and gases throughout 
the finalized fibrin construct.  
8.2.1.3 Developing and Designing More Complex Network Geometries 
In addition to scaling down the microengineered vascular network’s size, it would also be 
important to scale up the complexity of the network. This project developed channels that were 
either a single lumen or had one bifurcation. The team recommends increasing the complexity to 
better mimic a capillary bed and to bring the vascularization closer to cells within the hydrogel. 
The gelatin sacrificial material was shown to be molded in PDMS as single cylinders, 
single-bifurcations, and multi-bifurcations as seen in the Sacrificial Mold - Photolithography 
Feasibility Study. Forming a mold, introducing liquid gelatin, allowing to cool, and removing 
gelatin remains a very promising solution to forming more complex and smaller network 
geometries. 
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8.2.1.4 Endothelialization of Microvascular Network 
Endothelialization of the microvascular network, the lowest ranked objective, was the 
only objective the team was unable to achieve due to the time constraint. By endothelialization 
the microvascular network, two major aspects would be improved. The in vitro system would 
mimic in vivo even closer since the channels would be structurally closer to actual blood vessels. 
The second aspect is that by successfully endothelializing the microvasculature, the system has 
the potential to sustain blood perfusion.  
8.2.1.5 Perfusing and Sustaining a Multilayered Construct 
The next step in the development of a multilayered cardiac patch would be to perfuse and 
sustain multiple microvascular and myocardial layers respectively. This would require some 
adjustment to the bioreactor to be able to hold the multilayered system, as well as some possible 
changes to the microvascular layer fabrication method so that the gel can retain its patency even 
with the addition layer weight.  
8.2.2 Bioreactor System Design 
8.2.2.1 Microfluidic Chamber 
The current model of the microfluidic chamber is able to achieve each of the objectives 
and functions of the system. However, there is always room for improvement. Below, different 
aspects of the current design are further discussed and recommendations are made on how they 
can be improved. 
8.2.2.1.1 Chamber Shape  
The current shape of the chamber creates the need for the stainless steel plates to 
distribute the pressure across the surface area of the device. Having a hexagonal design with 
more screws evenly placed around the perimeter would eliminate the need for the plate because 
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the pressure would be distributed better. Also, the reduction in pieces would make the device 
easier to use during setup.  
8.2.2.1.2 Viewing Window 
The current viewing window on the top most portion of the microfluidic chamber is 10 
mm x 10 mm. However, these dimensions could be wider to allow the user to see more of the 
sample during testing in addition to allowing more of the sample to be imaged with a 
microscope. Glass coverslips come in a variety of dimensions, making the integration of a larger 
coverslip into a modified microfluidic chamber simple. 
8.2.2.1.3 Screw System 
Currently the system uses four 4 - 40 stainless steel screws to keep all components of the 
chamber in place. However, this system requires the use of an Allen wrench and can seem 
tedious when setting up more than one microfluidic chamber. An alternate approach could be the 
use of quarter turn fasteners that require one turn each before they are secured in place and 
ensure the system is tightened. 
8.2.2.1.4 Simple Mold Thickness 
The simple mold is three millimeters thick. However, this demands a thick fibrin layer 
which requires the media to diffuse further to reach the cells on top of it. By reducing the 
thickness of the mold, a thinner fibrin layer could be made which would reduce the distance the 
media needs to perfuse to reach the cells on the system and provide them nutrients.  
8.2.2.1.5 Input & Output Hole Stops  
Currently, it is difficult for the user to determine when to stop pushing the 20G needles 
into the input and output holes of the chamber. This can lead to damaging the fibrin layer that 
has been created if the needles are inserted too far. Even if they are inserted carefully, they could 
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potentially move when transporting the system as well. To prevent this altogether, small stops 
could be integrated into the input and output holes that would allow the needle to reach its 
intended place and would prevent it from moving further into the system. 
8.2.2.2 Media Oxygenation 
One alteration to the bioreactor system would be the addition of an oxygenator. This 
component would increase the oxygen concentration in the perfused media, which would mimic 
the blood. Using a the completely sealed microfluidic chamber, the user would be able to 
evaluate the microvascular network’s effectiveness in delivering oxygen and nutrients to cells in 
an adjacent fibrin layer, which would closely mimic the conditions in vivo. 
8.2.2.3 Chamber Testing 
A few recommendations can be made to further validate the microfluidic chamber, 
discussed in Chapter 7: Discussion. When validating the dimensions of the chamber, the 
measurements should be made immediately following fabrication before any testing is done. 
This would eliminate any changes to the dimensions that could be caused by sterilization or 
experimentation. The sterility testing performed on the chamber only suggested the completion 
of the objective. In order to prove this, a bioburden assay should be performed according to the 
FDA and ISO 11737 standards (ISO 11737, 2006). Additionally, long-term sealing tests should 
be run on the microfluidic chamber to ensure the device remains sealed and sterile.  
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Appendix A: Timelines 
 
Figure 111: Year-long MQP Gantt chart 
 
Figure 112: B Term MQP Gantt chart 
 
Figure 113: C Term MQP Gantt chart 
 
Figure 114: D Term MQP Gantt chart 
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Appendix B: Decision Matrices  
Table 28: Team PCC for bioreactor 
 
 
Table 29: Team PCC for microvascular network 
 
 
Table 30: Client PCC for bioreactor 
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Table 31: Client PCC for microvascular network 
 
 
Table 32: User 1 PCC for bioreactor 
 
 
  
235 
Table 33: User 1 PCC for mirovascular network 
 
 
Table 34: User 2 PCC for bioreactor 
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Table 35: User 2 PCC for microvascular network 
 
 
Table 36: Pairwise comparison chart of sub-objectives of “Ease of Use” 
 
 
Table 37: Pairwise comparison chart of sub-objectives of “Reproducible” 
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Appendix C: Client Meetings 
Client Meeting - 9/2/15  
We met with our clients, Meg & Megan. The following is the information we gathered.  
● The dimensions of the fibrin scaffold should at largest be: 
o Length: 2cm 
o Width: 1 cm 
o Height usually 300 µm 
● The longest duration the scaffold would need to survive in storage is 3 weeks, most often 
is 2 weeks. 
o 3 weeks is the longest cells need to be able to survive 
● Media needs to be changed every other day 
● The only financial budget/limitation is the team budget 
● Other needs: 
o Ease of use 
o Short setup time 
o Maintenance, sterilization 
▪ Autoclave 
▪ Fits in incubator 
▪ Pulsatile flow 
▪ Secure layers - reproducible stacking method for multiple layers 
▪ Closed and breathable 
o Incubator dimensions: 
o 18 in tall, 18.5 in wide, 18.5 inch deep 
o Hood: 15 in deep 
● Reviewed Gantt chart 
 
Client Meeting - 11/6/15 
● After grant rewrite, endothelialization has become a low priority 
● Stay away from zinc, use stainless steel 
● Non-uniform diameters of tubes in fibrin/thrombin does not matter as long as they are 
straight 
● Use a syringe pump, not a peristaltic pump  
● For vascular network instead of doing small branches try 2 bigger ones or 4 media ones 
● Agaros might be good for the sacrificial mold 
● Try casting fibrin around the tube 
● Does the fibrin gel go straight up against the Pluronic or does the Pluronic have some 
area that it cannot let material get close to 
● Call tech support and ask if Pluronic sticks to the material we are using 
● Pins Lab has biocompatible screws 
● Make sure material does not corrode in incubator 
238 
● Concerned 3D printing will not allow for a tihgt seal 
● PTFE tape or binder clips 
● Proved can form fibrin gel in one piece with complex geometries 
● Cons: more difficulty aligning channel with the inlet and outlets 
● Pro: no attachment or adhesion problems 
 
Client meeting - 11/13/15 
During meeting, we presented the alternative bioreactor designs and received feedback 
Tray/dish concept 
● Maybe instead of building the interior tubes and inlets, make the designs with just the 
holes so an inlet/tube could be inserted throughout the hole when needed 
● There might be “cross-talk” currently so design to have walls that can separate each 
sample 
● Look into ways that ensure an airtight seal. Maybe gasket tape? 
● For transparent material, look into using silicon, which is also gas permeable 
 
Petri Dish Concept 
● Same idea; make it so you can insert tube/inlet separately 
● Probably not easy to machine with holes 
● Maybe use a drill...not best option 
● Not airtight. DIfficult to make it 
 
Pressure Square 
● Only issue was 60 degree turn of vascular and graft and Meg’s layer. But Meg proposed 
that all layers be oriented in the same way and she can orient her threads onto the layer in 
a 60 degree fashion instead 
 
Mold 
● Instead of having a bottom, can we make the side walls a little thicker to maintain 
integrity and stability 
● Might be hard to machine or print such a small sized piece 
● Make sure all parts and materials of this mold are biocompatible 
 
Problish with lab testing: cylindrical rod extraction method tears the gel and when being perfused 
causes buildup of liquid 
● Look into other methods of cutting the wire or polishing the end to make it smooth 
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● Contact machine shop to see what might be available 
o Laser cutting 
o Polishing 
o Filing down ends 
 
Client Meeting - 12/4/15 
After a conversation about the meanings of each objective for both the bioreactor and the 
vascular network, there was a lot of confusion about the definitions of each objective. 
Bioreactor PCC 
Ease of Use 1 
Cost Effective 0 
Controlled Gas Permeability 4 
Reproducible 3 
Multiple Samples 2 
 
These new scores are based off unanimous agreement between the advisor, clients, and 
teammates 
Vascular Network PCC 
Reproducible 3 
Cost Effective 0 
Physiologically Relevant Flow 4.5 
Endothelializable 1 
Stackable 4.5 
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Review on molds: Clients favorite mold is the insert mold. This mold is most user friendly when 
it comes to the use of a sacrificial material. Also, because of its alignment ability, it is the most 
secure mold. 
We then spoke about next tests we should do with molds and bioreactor. 
Needle infusion 
Perfusion 
Leakage tests 
 
Client Meeting - 2/8/16 
● Clients were updated on progress 
● Manufacturing of bioreactor is in progress with Tom Partington in Goddard Hall 
● Channels continue to be successfully formed 
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Appendix D: Protocols 
Solution Preparation Protocols 
CaCl2 Solution Preparation (40 mM) 
Objective: To make a CaCl2 solution, which is used to activate the thrombin 
Materials: 
CaCl2 (MW = 110.98) 
diH2O 
Conical tube 
Beaker 
Pipetter 
 
Procedure: 
1. Add 0.1776 g of CaCl2 to 40 mL of diH2O to a small beaker 
2. Mix well and transfer to conical tube 
3. Store at 4℃ 
HEPES Buffered Saline (HBS) Solution Preparation 
Objective: To make HBS solution, which is used in fibrinogen and thrombin aliquot preparation 
NOTE: HBS has 20 mM HEPES and 0.9% (w/v) NaCl 
Materials: 
diH2O 
NaCl (MW = 58.44) 
HEPES (MW = 238.34) 
Beaker 
Capped bottle 
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Graduated cylinder 
 
Procedure: 
1. Add the following reagents to 200 mL of diH2O in a beaker 
a. 2.25 g of NaCl 
b. 1.1915 g of HEPES 
2. pH the solution to 7.4 using NaOH and HCl 
3. Bring the volume of solution to 250 mL with diH2O 
4. Transfer the solution to the bottle and store at room temperature 
1X Phostpage-buffered saline (PBS) Solution Preparation 
Objective: To make 1X PBS solution, which is used in fibrin gel formation and as an 
experimental negative control. 
Materials: 
diH2O 
10X PBS solution 
Graduated cylinder 
Capped bottle 
Stir bar 
 
Procedure: 
1. Measure 400 mLof diH2O 
2. Add 50 mLof 10X PBS to the solution 
3. Add 50 mLof diH2O and bring the final volume to 500 mL 
4. Mix well and pH the solution to 7.4 
5. Store at room temperature 
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C2C12 Complete Media Preparation Protocol 
Objective: Make C2C12 complete proliferation media, which is used to sustain the cells, while 
in culture 
Materials: 
Ham’s F12 
DMEM 
FBS 
Pen/Strep 
(Amphotericin B) 
Beaker 
Capped Bottle 
Pipetter 
 
Procedure: 
NOTE: Since this is cell culture media, the whole process needs to be done in a clean biosafety 
cabinet with sterile tools and containers, otherwise you risk contamination 
1. (day prior) Sterilize a capped bottle to contain the complete media 
2. Bring all materials into the biosafety cabinet 
3. Mix the following solutions in the prepared sterile bottle 
a. 220 mLof Ham/s F12 
b. 220 mLof DMEM 
c. 50 mLof FBS 
d. 5 mLof Pen/Strep 
e. (5 mLof Amphotericin B) 
NOTE: We add amphotericin B at gateway, because we have had fungal problems in the past 
4. Mix the solution well, label, and store in the 4°C fridge 
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0.05% w/v Fluorescein isothiocyanate (FITC) Staining Solution Preparation  
Objective: To make FITC, which is an auto-fluorescent dye. In our particular project, this was 
used to image diffusion through the microvascular network. 
Materials: 
FITC(solid) 
Sterile diH2O 
50 mLconical tube 
Pipetter 
 
Procedure: 
NOTE: the recommended solution concentration is 1 mg/mL, but this can be adjusted to match 
the experiment’s need 
1. Mix 0.05 g of FITC(s) into 45 mLof diH2O into the conical tube 
·Make sure to protect the solution from light, so that the dye does not 
photo bleach 
2. Add another 5 mLof diH2O, washing the weighting boat 
3. Mix well 
4.     Store in the 4°C fridge 
5.     Dilute if necessary 
Fibrinogen and Thrombin Aliquot Preparation 
Objective: Preparing fibrinogen and thrombin stock aliquots, which are used for dilution and 
fibrin thread creation. 
Materials: 
Fibrinogen (82022, MP) 
Thrombin (T4648, Sigma) 
CaCl2 (MW = 110.99) 
NaCl (MW = 58.44) 
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HPS 
Micropipette 
Conical tubes 
Eppendorf tubes 
 
Procedure: 
NOTE: Not all fibrinogen in product is clottable. This needs to be taken into account. Previous 
optimization of results was done with product from Sigma Aldrich (SA) 
NOTE: Current product is from MP Biomedicals 
NOTE: To get the % protein and % clottable, review the certificate of analysis, which comes in 
with the product. It might be different for each batch 
Originally, the aliquots are made to concentration of 70 mg/mL, based on SA’s procedure. Using 
that, determine the concentration of the new product needed to have an equivalent concentration 
of effective protein (EP) as SA’s aliquots. 
To dissolve 1000 mg: 
Fibrinogen Aliquot (70mg/mL) 
1. Weigh 1.00 g of fibrinogen and pour in conical tube. 
2. Measure X (specifically calculated for each batch) of Hepes buffered saline (HBS) and add 
to fibrinogen in conical tube 
3. Place conical tube on rocker plate, adjusting position every 30 - 40 min until fibrinogen is 
no longer visible on the inside of the tube 
NOTE: There may be clumps visible in the solution, which is OK 
4. Measure 1 mLaliquots in eppendorf tubes and store at -20℃ 
Thrombin Aliquot (40U/mL) 
1. Add 25 mLHBS to bottle of 1 KU thrombin 
2. Mix well 
3. Aliquot 200 μl into eppendorf tubes and store in -20℃ 
NOTE: Final concentration should be 8 U/ 200 μl  
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Fibrinogen and Thrombin Diluted Aliquot Preparation 
Objective: Preparing diluted fibrinogen and diluted thrombin aliquots for fibrin gel scaffolds 
Materials: 
Fibrinogen (82022, MP) Stock Solution 
Thrombin (T4648, Sigma) Stock Solution  
HBS 
40 mM CaCl2 
PBS (can be substituted with cell media if using cells) 
PDMS - curing agent & elastomer base 
Eppendorf tubes 
Centrifuge tubes 
 
Procedure: 
Diluted fibrinogen solution (2X solution) (dFb solution) 
1. Pipette 137.8 μL of fibrinogen stock solution into a centrifuge tube 
2. Add 862.2 μL of HBS into centrifuge tube 
3. Mix carefully 
4. Split in 200 μL aliquots of dilute Fb 
5. Final concentration = 11 mg/mL 
NOTE: Mix gently to avoid polymerization 
 
Diluted thrombin solution (2.35 U/mL) (dTh solution) 
1. Pipette 58.75μL of Thrombin stock solution into centrifuge tube 
2. Add 941.25μL HBS to the tub 
3. Mix (triturate) 
4. Split into aliquots of 50 μL of dilute Th 
 
Pluronic F127 Sacrificial Material 
Adapted from (Müller, Becher, Schnabelrauch, & Zenobi-Wong, 2013) 
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If available, perform the preparation of the poloxamer solution in a cold room (4 °C). If not 
available, place a glass bottle in a beaker filled with ice-cold water. At higher temperatures the 
poloxamer will be above the gel point and will not dissolve properly. 
Procedure: 
1. Add 15 mL of ice cold PBS solution into a glass bottle and stir vigorously using a 
magnetic stirrer. (Note: for Pluronic F127 in DI water, replace all PBS with DI water). 
2. Weigh 6.125 grams of poloxamer and add it in small amounts to the cold PBS. Wait until 
the poloxamer has partially dissolved before adding more. 
3. Stir the solution until all poloxamer has dissolved. 
4. Add cold PBS until a final volume of 25 mL is reached. The final concentration will be 
24.5% w/v. 
5. Stop stirring the solution and let it rest at 4 °C until bubbles and foam in the solution have 
disappeared. Bubbles that are trapped within the gel will be transferred to the printer 
cartridge and will lead to defects in the printed sacrificial molds. 
6. Keep the solution at 4 °C until 30 min before the experiment.  
 
Fibrin Gel Preparation Protocol 
Objective: Fabricate a fibrin hydrogel. 
Materials: 
Diluted Fibrinogen (dFb) 
Phosphate Buffered Saline (PBS) 
 or cell media 
 or cell suspension 
Diluted Thrombin (dTh) 
40 mM CaCl2 
 
Procedure: 
1. Thaw frozen dFb and dTh in hot water bath (5 - 10 minutes) to ensure complete melting. 
2. To make 1 mL of fibrin gel 
a. Add 150 μL of PBS, cell media, or cell suspension to 335 μL of dFb. Mix 
thoroughly (10 - 15 times with micropipette) Handle dFb with care to avoid 
polymerization before desired.  
b. Add 80 μL CaC1 to 100 μL dTh. Mix thoroughly. 
c. Add two solutions together, mix thoroughly, and add to desired location. 
3. Let polymerize for 30 minutes. 
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Vascularization Protocols 
Cylindrical Rod Extrusion  
Objective: Fabricate a single straight channel in fibrin gel using the cylindrical rod extraction 
method (for more information look in Chapter 5: Design Verification) 
Materials: 
40 mM CaCl2 
Diluted Thrombin (dTh) 
Non - sterile PBS 
Diluted Fibrinogen (dFb) 
0.02% Pluronic F127 solution 
Micropipette 
Eppendorf tubes 
Fibrin well/mold 
Steel wires 
Perfusion polyethylene tube 
 
Procedure: 
Wire Fabrication 
1. Measure needed length of the wires 
2. Cut the wires to length using wire cutters or saw 
Note: Cutting with these techniques results in defects on the tip of the wires 
3. Using a fine file, smoothen out the edges on the wire tips to remove any defects and sharp 
edges.  
 
Fibrin Channel Fabrication 
1. Coat the wire tips with Pluronic F127. 
1. Put the wire tips, which are going to be used, in a small beaker 
2. Pour 0.02% Pluronic solution into the beaker, until all tips are submerged 
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3. Leave the tips in the solution for 10 - 15 min 
4. Aspirate Pluronic, remove the wire tips, and leave to air dry before usage 
2. Prepare solutions for fibrin gel (for 500μL of final gel) 
1. Once the fibrinogen and thrombin are taken out of the freezer, thaw for 5 - 12 min 
1. Put the fibrinogen aliquot to thaw in the hot water bath (the water bath will 
ensure that all of the fibrinogen is completely thawed) 
2. Leave the thrombin aliquot to thaw on the lab bench 
2. Mix 335μL fibrinogen with 75μL cell media using micropipette in an Eppendorf 
tube (handle the fibrinogen with care to prevent polymerization) 
3. Mix 50μLof the thrombin with 40μL CaCl2 in another Eppendorf tube 
 
3. Making the fibrin gel 
1. Place the wire tip through the perfusion well 
2. Using a micropipette, transfer and mix the thrombin+CaCl2 solution to the 
fibrinogen+cell media tube 
3. Using the same micropipette, quickly transfer the new solution to the prepared 
well (speed is essential to prevent the fibrinogen from polymerizing) 
4. Leave the fibrinogen mixture to polymerize in the well for at least 30 min 
4. Fabricating the channel 
1. Once the fibrin is fully polymerized, slowly remove the wire 
2. Clean the wires to remove any residual protein 
 
Formation of Channels from Gelatin Sacrificial Materials 
Objective: To fabricate a microvascular channel using gelatin as a sacrificial material 
Materials: 
Microfluidic system 
Dilute fibrinogen 
Dilute thrombin 
CaCl2 (40 mM) 
1X PBS 
Syringe pump 
Syringe 
Tubing 
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Gelatin Sacrificial Mold Fabrication 
Solution preparation initially adapted from (Golden & Tien, 2007). 
Formation of gelatin cylinders (for a single channel) 
1.   Prepare a 10% w/v (g/100 mL) solution of porcine gelatin in (1X) PBS. 
2.   Heat gelatin to 37°C in hot water bath to liquefy. 
3.   Pull appropriate volume of liquid gelatin into 1 mL syringe. 
4.   Let reform gel (10 - 15 minutes). 
5.   Attach needle with desired diameter (ex: 20G needle = 603 μm inner diameter ~= initial gelatin 
cylinder outer diameter) 
6.   Extrude cylinders to desired length (~1.5 cm) onto PDMS (found to be a non-stick surface). 
7.   Dehydrate cylinders for 30 minutes. They can then be handled and moved into the mold. 
Formation of gelatin bifurcations (for a bifurcated channel) 
1.   Heat the syringe to 25 - 30°C, which is the range of the gelatin gel transition temperature. The 
gelatin will exist in a part liquid-like, part gel-like state. This allows the user to print a 
bifurcation that maintains its shape (gel-like property) yet forms connections (liquid-like 
property). 
2.   Heating can be done with the hand. Heat until gelatin leaving needle begins to flow without 
being extruded. 
3.   Draw bifurcation while slowly extruding. 
 
Channel Formation via Sacrificial Mold 
Formation of channels from gelatin sacrificial materials. 
1.   Place sacrificial mold into in microfluidic chamber mold. 
2.   Insert “plug” needles into inlet and outlet of bioreactor so that gelatin inserts into the needles. 
(This will hold the cylinder in place and prevent it from floating to the top of the fibrin.) 
3.   Add top of the inner mold, binder clips to hold pieces tightly together, and add appropriate 
volume of fibrin components. Add 340 µL of fibrin solution slowly or even dropwise to avoid 
“pushing” the gelatin mold in one direction. If fibrin is added only to one side, the gelatin mold 
will end up curving away from that side and the channel will have a high curvature. 
4.   Allow fibrin to polymerize for 30 minutes. 
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5.   Construct remainder of microfluidic chamber. Remove binder clips, 
6.   Heat sample to 37°C to melt gelatin for 10 - 15 minutes. Warning: Perfusion to flush gelatin 
before complete melting can damage the gel and channel. 
7.    Flush liquid gelatin with 1X PBS sufficiently (>10 minutes) at a flow rate of 0.1 mL/min. 
Fibrin Gel Diffusion Assay 
Objective: To characterize the diffusion rate, the diffusion limit, and the diffusion coefficient 
through a single-channel gel. 
Set up: 4 samples prepared 
Materials:  
1x PBS 
0.25% Pluronic 
Diluted fibrinogen aliquot (11 mg/mL) 
Diluted thrombin aliquot (2.35 U/mL) 
FITC stain (0.625 mg/mL) 
Channel fabrication mold on glass slide 
Steel wires 
1cc and 3cc Syringe 
Tubing and 20G needles 
 
Procedure: 
Preparation 
1.      Prepare the FITC stain 
2.      Mix the 0.2% Pluronic stock solution 
3.      Take out a small amount with a 1cc syringe 
4.      Put the steel needles into the syringe to coat (15 min) 
5.      Take out dTh and dFb to thaw (5 min) 
6.      Prepare the molds 
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·        Clear the inlet and outlet tube 
·        Check for leaks 
Casting the Gel 
1.      Fill the tubing with 1x PBS 
2.      Place the steel wire into the molds 
3.      Mix the solutions (650 μl total = 4 sample) 
·        dFb – 435.5 μl 
·        PBS – 97.5 μl 
 
·        dTh - 65 μl 
·        CaCl2- 52 μl 
4.      Leave the mixture to polymerize (30 min) 
5.      Extract the needle 
·        Needs to be done rapidly so there is no tearing in the gels 
6.      Perfuse a small amount of PBS to test the channel’s integrity 
Diffusion Testing 
1.      (30 min prior) Turn on the fluorescent mercury lamp 
2.      Load a 3cc syringe with FITC solution 
·        Keep in the dark to prevent photo bleaching 
3.      Setup the syringe pump to the microscope 
4.      Replace the PBS syringe with the FITC syringe and place onto the syringe pump 
5.      Start perfusion initially at a high rate, until the dye reaches the inlet, then drop it off to the     
desired perfusion rate (eg. 0.005 mL/min) 
6.      Image and collect data 
·        The initial 10 seconds, if possible collect a video 
·        After that image every 30 - 60 seconds 
7.      Clean up everything 
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8.      Analyze the images based in ImageJ 
 
C2C12 Survival Assay 
Objective: To study the C2C12 cell viability in unfavorable conditions for cell proliferation 
Materials: 
12 well plates 
0.25% Trypsin 
Complete c2c12 cell media 
1X PBS 
Pipette 
Centrifuge tube 
 
Procedure: 
1.      Check the C2C12 culture for contamination 
2.      Bring the flask into the hood and aspirate the media 
3.      Trypsinize the cells for 5 mins 
4.      Add 5 mL of media to deactivate the trypsin 
5.      Move the cell suspension to a centrifuge tube 
6.      Using a hemocytometer, determine the cell count 
7.      Centrifuge the cell suspension 
8.      Aspirate the solution, leaving behind the cell pallet 
9.      Add media amount to desired cell density 
10.   Add desired cell seeding to each well 
a.      3 wells for media condition 
b.      3 wells for PBS condition 
c.      3 wells for air condition 
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11.   Leave the cells to attach to the well bottom (2 hours) 
12.   Aspirate media from all wells 
13.   Add corresponding solution to each well 
14.   Leave in the incubator 
15.   Using a live/dead stain, collect fluorescent imaging 
a.      At 4 hours 
b.      At 8 hours 
c.      At 24 hours 
16.   Analyze cell viability by calculating percent cell survival 
 
Cell Viability on Top of Perfused Single-Channel Gels 
Purpose: To determine cell viability on top of perfused single-channel gels. 
Set Up: 
·       6 samples prepared 
● Experimental: Media Perfusion (n = 3) 
● Control: PBS Perfusion (n = 3) 
Materials: 
C2C12 full media 
·     219 mL F12 (1X) 
·     219 mL DMEM (1X) 
·     50 mL Fetal Bovine Serum 
·     5 mL Penicillin Streptomycin (Pen Strep) 
·     5 mL Amphotericin B 
·     2 mL Aprotinin 
70% Ethanol 
Diluted fibrinogen aliquot 
·     137.8 µL fibrinogen stock solution 
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·     862.2 µL HEPES Buffered Saline (HBS) 
Diluted thrombin aliquot 
·     58.75 µL thrombin stock solution 
·     941.25 µL HBS 
·     Calcium chloride (CaCl2) (40 mM) 
Cell culture devices on glass slides 
Glass coverslips 
~2.5 in. steel wire (279 μm diameter) 
C2C12 cells – Mus musculus myoblasts 
5 mL Trypsin (0.25%) 
LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells 
·     Calcein AM (Live-Green) 
● Live cells: ubiquitous intracellular esterase activity converts calcein AM to calcein. 
·     Ethidium homodimer-1 (EthD-1) (Dead-Red) 
● Enters through damaged membranes, binds to nucleic acids 
 
Sterilization: 
NOTE: Before starting the ethanol submersion, check for clots and blockages in the tubing and 
needles using a syringe 
·       Sterilize all components via submersion 70% ethanol for 90 minutes. Components include: 
● Cell culture devices on glass slides 
● Tubing 
● Needles 
● Steel wire 
● Adaptors 
● Coverslips 
·      Rinse tubing with DI water to ensure all ethanol is removed. 
·      Aspirate ethanol and allow to air dry overnight or rinse in DI water three time for 5 minutes. 
·     “Sterilize” or clean as best as possible the K210 Syringe Pump with 70% ethanol prior to use  
using a spray and wipe method. 
·     Sterile filter all fibrin gel reagents using a 0.2 µm filter. 
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Perfusion Preparation: 
·     Remove top shelf from the incubator. If the syringe pump is placed on the top shelf, it is too  
close to the temperature sensor and the incubator will alarm. 
·     Replace the plug from the bottom incubator with the one from the top, unused incubator (and 
place the bottom plug into the top incubator). 
·     Stay and watch the outputs on the incubator to ensure no CO2 and heat are escaping. 
·     Place “sterilized” syringe pump on left side of incubator so it is as far away from the 
thermometer as possible. 
·     Coat portion of steel wires that will be pulled through the gel with Pluronic F127 for 10 - 15 
minutes 
·     With tubing connected on both sides, put steel wire through tubing and across cell culture 
device. 
 
Cast Gels (All steps should be completed in biosafety cabinet): 
·     Prepare a new thrombin solution on the bench by mixing 200 µL of 40 mM CaCl2 with 250 µL 
of diluted thrombin aliquot.  This is the approximate amount needed for 1 mL of fibrin gel 
because some volume is lost during sterile filtering. 
·     Use a 0.2 µm sterile filter to filter the new thrombin solution and diluted fibrinogen aliquot into 
sterile 2 mL centrifuge tubes. 
·     Make one set of gels for each condition 
● Add 75 µL of PBS to 335 µL of fibrinogen.  
● Mix 90 µL of thrombin - CaCl2 and fibrinogen - PBS solutions and add 150 (or 120 µL) 
µL into each cell culture device.  
·      Let gels polymerize for 30 minutes. 
 
Cell Culture (All steps should be completed in biosafety cabinet): 
·     Culture C2C12 mouse myoblasts in C2C12 full media. 
·     When sufficient cells are available add 5 mL of 0.25% Trypsin and incubate at 37°C and 5% 
CO2 for 5 minutes or until cells have detached from the bottom of the flask. 
·     Neutralize trypsin with 5 mL of media and move cell suspension to a 15 mL conical tube. 
·     Remove a 10 µL sample and obtain a cell count. 
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·     Centrifuge cell suspension at 1000 RPM for 5 minutes in IEC Centra CL2. 
·     Resuspend in appropriate volume to establish a concentration of 1 million cells / mL. 
 
Cell Seeding: 
·     Add 100 µL of cell suspension to the top of the gel in each cell culture device 
·     Incubate for 4 hours at 37°C and 5% CO2 to allow cells to adhere to fibrin gel 
 
Perfusion: 
·     Attach needles and tubing to cell culture devices 
·     Prepare syringes with either media or PBS and attach to tubing. 
·     Place syringes in syringe pump and prime the tubing by running the pump until fluid fills all 
tubes and all air has been expelled. 
·     Aspirate media on top of fibrin gels. 
·     Cover each device with a glass coverslip to maintain sterility and prevent oxygen diffusion. 
·     Move all devices to the incubator, attach to tubing, and begin perfusion at a flow rate of 0.001 
mL/min or 60 μL / hour. 
·     Perfuse for 20 hours at 37°C and 5% CO2. 
NOTE: Make sure to take the tubing’s volume into account when preparing syringes for the 
perfusion 
 
LIVE/DEAD Cell Staining: 
·     This staining protocol is from Jon Grasman’s work with C2C12 cells and is similar to the 
example dilution protocol from Invitrogen.  
·     Thaw and centrifuge the reagents briefly. 
·     Add 4 µL of supplied 2 mM EthD-1 stock solution and 1 µL of supplied 4 mM  calcein AM 
stock solution to 2 mL of sterile D-PBS (I used PBS since cells were not later being trypsinized).  
Vortex to ensure thorough mixing.  Note: this represents 1/5 size batch of live/dead stain. 
·     Remove all media from the devices since media can react with Calcein AM causing high 
background fluorescence.  Wash with PBS. 
·     Add 100 µL of PBS staining solution to each device. 
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·     Incubate samples for 30 minutes. 
 
Imaging – Leica inverted fluorescence microscope (Rolle scope): 
·     Insert the correct fluorescence cubes prior to imaging. 
·     Turn on the mercury lamp 15 - 30 minutes prior to imaging. 
·     Keep shutter closed whenever possible to avoid photobleaching of the samples. 
·     Appropriate images were obtained by taking six images total, two above the channel, two at the 
inlet and outlet, and two below the channel using the 10X objective. 
·     After imaging, merge images using ImageJ and perform analyses. 
 
Cell Viability in an Adjacent Layer on Top of Perfused Single-Channel Gels 
Purpose: To determine cell viability in an adjacent layer on top of perfused single-channel gels. 
Set Up: 
·       6 samples prepared 
● Experimental: Bioreactor samples perfused with media (n = 2) 
● Positive Control: Cell-seeded fibrin hydrogel in media (n = 2) 
● Negative Control: Cell-seeded fibrin hydrogel in PBS solution(n = 2) 
 
Materials: 
Bioreactor system 
C2C12 full media 
● 219 mL F12 (1X) 
● 219 mL DMEM (1X) 
● 50 mL Fetal Bovine Serum 
● 5 mL Penicillin Streptomycin (Pen Strep) 
● 5 mL Amphotericin  
70% Ethanol 
Diluted fibrinogen aliquot (11 mg/mL) 
● 137.8 µL fibrinogen stock solution 
● 862.2 µL HEPES Buffered Saline (HBS) 
Diluted thrombin aliquot (2.35 U/mL) 
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● 58.75 µL thrombin stock solution 
● 941.25 µL HBS 
Calcium chloride (CaCl2) (40 mM) 
Thrombin aliquot (40 U/mL) 
Cell culture devices on glass slides 
Glass coverslips 
Gelatin hydrogel 
C2C12 cells – Mus musculus myoblasts 
5 mL Trypsin (0.25%) 
LIVE/DEAD Viability/Cytotoxicity Kit for mammalian cells 
Calcein AM (Live-Green) 
● Live cells: ubiquitous intracellular esterase activity converts calcein AM to calcein. 
Ethidium homodimer-1 (EthD-1) (Dead-Red) 
● Enters through damaged membranes, binds to nucleic acids 
 
Sterilization: 
NOTE: Before starting the ethanol submersion, check for clots and blockages in the tubing and 
needles using a syringe 
1.     Sterilize all components via submersion 70% ethanol for 90 minutes. Components include: 
·       Bioreactor Elements 
·       Tubing 
·       Needles 
·       Adaptors 
·       Coverslips 
·       Beakers 
2.     Rinse tubing with DI water to ensure all ethanol is removed. 
3.     Aspirate ethanol and allow to air dry overnight or rinse in DI water three time for 5 minutes. 
4.      “Sterilize” or clean as best as possible the K210 Syringe Pump with 70% ethanol prior to use 
using a spray and wipe method. 
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5.     Sterile filter all fibrin gel reagents using a 0.2 µm filter. 
 
Formation of gelatin cylinders 
1.     See Gelatin Sacrificial Mold Fabrication protocol 
 
Perfusion Preparation 
1.     Remove top shelf from the incubator. If the syringe pump is placed on the top shelf, it is too 
close to the temperature sensor and the incubator will alarm. 
2.  Replace the plug from the bottom incubator with the one from the top, unused incubator (and 
place the bottom plug into the top incubator). 
3.  Stay and watch the outputs on the incubator to ensure no CO2 and heat are escaping. 
4.     Place “sterilized” syringe pump on left side of incubator so it is as far away from the 
thermometer as possible. 
NOTE: It’s possible that the incubator will overheat due to the syringe pump running. Leave the 
door ajar with a note informing the other students why it’s open. If the alarm sounds just silence 
it. 
 
Formation of channels from gelatin sacrificial materials. 
1.     See Channel Formation Via Sacrificial Mold protocol. 
2.     Only proceed to the next step once the channel has been formed so that as soon as cells are 
ready to be added, they can be placed in the microfluidic chamber and perfused. 
 
Cell Culture (All steps should be completed in biosafety cabinet) 
1.     Culture C2C12 mouse myoblasts in C2C12 full media. 
2.     When sufficient cells are available add 5 mL of 0.25% Trypsin and incubate at 37°C and 5% 
CO2 for 5 minutes or until cells have detached from the bottom of the flask. 
3.     Neutralize trypsin with 5 mL of media and move cell suspension to a 15 mL conical tube. 
4.     Remove a 10 µL sample and obtain a cell count. 
5.     Centrifuge cell suspension at 1000 RPM for 5 minutes in IEC Centra CL2. 
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6.     Resuspend in appropriate volume of PBS to establish a concentration of 1 million cells/mL. Use 
PBS if validating the microengineered vascular network – bioreactor system so that the only 
media the cells obtain is from the media perfused through the network. 
 
Cell Seeding 
·       Create vellum paper frames with an inner square of 1 cm x 1 cm with side thickness of 0.15 cm. 
·       Add 105 µL of cell suspension (300,000 cell/mL) to each vellum frame.   
 
Perfusion 
1.     Prepare syringes with media and attach to tubing. 
2.     Place syringes in syringe pump and prime the tubing by running the pump until fluid fills all 
tubes and all air has been expelled. 
3.     Move all microfluidic chambers to the incubator, attach to tubing, and begin perfusion at a flow 
rate of 0.003 mL/min. 
4.     Perfuse for 24 hours at 37°C and 5% CO2. 
5.     Depending on the size of the syringe, it may be necessary to refill before the 24 hours are 
complete. When refilling, make sure outlet tubing is at the height of the microfluidic chamber so 
that when the inlet tubing is removed, fluid does not drain out of the channel and microfluidic 
chamber. 
NOTE: Make sure to take the tubing’s volume into account when preparing syringes for the 
perfusion 
 
LIVE/DEAD Cell Staining 
      This staining protocol is from Jon Grasman’s work with C2C12 cells and is similar to the 
example dilution protocol from Invitrogen.  
      Thaw and centrifuge the reagents briefly. 
      Add 6 µL of supplied 2 mM EthD-1 stock solution and 1.5 µL of supplied 4 mM  calcein AM 
stock solution to 3 mL of sterile D-PBS (I used PBS since cells were not later being trypsinized). 
Vortex to ensure thorough mixing.  
NOTE: Adjust the final solution volume to the amount needed for each sample. 
      Remove samples from wells and the bioreactor devices. Wash with PBS to remove any residue 
media! 
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      Add 0.5 mL of PBS staining solution to each sample. 
      Incubate samples for 30 minutes. 
 
Imaging – Leica inverted fluorescence microscope (Rolle scope) 
     Insert the correct fluorescence cubes prior to imaging.   
     Turn on the mercury lamp 15-30 minutes prior to imaging. 
     Keep shutter closed whenever possible to avoid photobleaching of the samples. 
   After imaging, through ImageJ perform analyses. 
 
Cell Viability in an Adjacent Layer on Top of Perfused Single-Channel Gels in an Open 
System and Seal System 
Purpose: To determine cell viability in an adjacent layer on top of perfused single-channel gels 
in an open system, which has no top coverslip, and a sealed system, where the microfluidic 
chamber is completely closed. 
* For this assay, the team used the protocol from Cell Viability in an Adjacent Layer on Top of 
Perfused Single-Channel Gels, with adjustments to improve the cell viability while preparing the 
samples. 
The first adjustment was the gelatin was flushed out warm media over 40 minutes, in order to 
preload the microvascular network gel with media before the adjacent layer is placed on top.  
The second adjustment was that the perfusion flow rate was 0.002 mL/min over 24 hours. 
 
All other elements of the protocol were kept the same. 
 
Microfluidic chamber fabrication process 
Objective: To fabricate the pieces for the microfluidic chamber 
Materials: 
PTFE block 
Stainless Steel block 
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POM 
Silicon Gaskets 
4 - 40 Screws 
 
Procedure: 
Microfluidic Chamber Bottom 
1. Start with desired raw material. 
2. Use band saw to cut the raw material to oversized dimensions of the desired piece. 
3. Secure oversized piece into a vice on a Bridgeport 3 axis mill.  
4. Cut the piece to the proper dimension on each side by using sets of parallel positioning 
bars.  
5. To cut the center window, find the center of the piece using an edge finder. When the 
spring loaded edge finder kicks out slightly, it is on the edge. Set the digital display to 
zero. Repeat on perpendicular side.  
6. Using a 3/8 in. mill bit, line up the center of the piece and begin to mill the window out. 
To determine the distance in one dimension needed use half the desired width and 
subtract the radius of the bit. Use the digital read out to determine depth of the cut.  
7. To drill holes for the screws, based on drawing, again use the edge finder to find the 
proper spacing. 
8. To drill inlet and outlet holes place the piece side up in the vice. Use the edge finder to 
determine the middle of the side and mill out the hole into the cutout window. Repeat on 
opposite side.  
 
Microfluidic Chamber Top 
1. Repeat steps 1 - 7 from bioreactor bottom. Use a square blank in the vice to secure piece 
due to the thickness of the desired piece.  
 
Mold Piece 
1. Start with raw material. 
2. Use band saw to cut the raw material to oversized dimensions of the desired piece. 
3. Secure oversized piece into a vice on a Bridgeport 3 axis mill. Use a square blank like 
when milling the bioreactor top.  
4. Cut the piece to twice the thickness of the final desired piece. Leave extra material 
around piece for easier handling because the small dimension of the final mold.  
5. Repeat steps 5, 6, and 8 from bioreactor bottom to cut out the window and inlet and outlet 
holes. 
6. Next, mill away the top half of the whole piece to leave the desired height and semicircle 
inlet and outlet channels. 
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7. Mill the outer diameter to correct size. 
8. Repeats steps 1 - 7 for second mold piece.  
 
Stainless Steel Plate 
1. Start with raw material.  
2. Repeat steps 2 - 7 from Bioreactor Bottom. Use a square blank in the vice to secure piece 
due to the thickness of the desired piece. 
 
20G Needles 
1. 4 20G needles were cut and filed down to make the endings blunt instead of sharp. 
 
Perfusion Test 
Objective: To ensure different flow rates could perfuse through the chamber without the loss of 
liquid while using the appropriate amount of volume and expected time frame.  
 
Materials: 
Syringe pump 
1 mL syringe 
Water 
Two pieces of 12 inch tubing 
Two 20G needles 
Microfluidic chamber 
Parafilm 
Collection flask  
Pin 
 
Procedure: 
1. Plug in syringe pump and set the flow rate to 0.01 mL/min.  
2. Fill syringe with 1 mL of water 
3. Attach tubing to syringe 
4. Attach other end of tubing to 20G needle 
265 
5. Assemble microfluidic chamber 
6. Insert the needle with tubing attached to syringe into the inlet hole of the microfluidic 
chamber 
7. Insert a second needle to outlet of microfluidic chamber 
8. Attach tubing to that needle 
9. Place parafilm over a collection flask and pierce a hole with a pin with the same diameter 
as the tubing 
10. Place the end of the tubing into the hole in the parafilm so the water can perfuse into the 
collection flask once it has perfused through the system 
11. Hit start on the syringe pump 
12. Wait until the syringe is empty 
13. Remove output tubing from collection flask and remove parafilm from top of collection 
flask 
14. Measure the volume of water in the collection flask 
15. Compare volume of water in collection flask to 1 mL 
16. Empty collection flask 
17. Fill a syringe with 1 mL of water 
18. Attach to inlet tubing of system 
19. Set flow rate of syringe pump to 0.1 mL/min 
20. Repeat steps 12 - 19 
21. Set flow rate of syringe pump to 1 mL/min 
22. Repeat steps 12 - 16 
 
Sealing Test 
Objective: To ensure the microfluidic chamber creates a tight seal to prevent contamination.  
Materials: 
70% ethanol 
Microfluidic chamber components 
Syringe pump 
CaCl2 solution 
2 mL syringe 
C2C12 media 
Fibrinogen 
Thrombin 
Gelatin 
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Two 20G needles 
Collection flask 
Parafilm 
Two pieces of 12 inch tubing 
Media 
 
Procedure: 
1. Sterilize components of microfluidic chamber through ethanol submersion. Submerge in 
70% ethanol for 90 minutes 
2. Remove components from ethanol after 90 minutes 
3. Set up syringe pump and plug in 
4. Prepare CaCl2 solution following CaCl2 Solution Preparation protocol 
5. Fill a 3 mL syringe with complete C2C12 media 
6. Prepare fibrinogen and thrombin following the Fibrinogen and Thrombin Diluted Aliquot 
Preparation 
7. Create gelatin sacrificial mold fabrication following the Gelatin Sacrificial Mold 
Fabrication protocol 
8. Create a channel within a fibrin scaffold following the Channel Formation Via Sacrificial 
Mold protocol 
9. Set flow rate on syringe pump to 0.003 mL/min 
10. Attach one end of tubing to 3 mL syringe containing media and other end to 20G needle 
of microfluidic chamber 
11. Attach another 20G needle to outlet end of microfluidic chamber 
12. Prepare collection flask by sealing with parafilm and piercing small hole 
13. Place tubing into hole of collection flask 
14. Hit start on syringe pump 
15. When syringe is empty fill with another 3 mL of media 
16. Set flow rate on syringe pump to 0.003 mL/min 
17. Hit start 
18. Run for 24 hours 
 
Setup Time of Microfluidic Chamber 
Objective: To ensure ease of use in order to not inhibit the users during experimentation 
Materials:  
Microfluidic chamber components 
Timer 
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Procedure: 
1. Separate all microfluidic chamber components 
2. Hit start on timer 
3. Place the PTFE base on the benchtop 
4. Apply vacuum grease to an 18 mm x 18 mm glass coverslip 
5. Place coverslip on PTFE mold bottom 
6. Place PTFE mold bottom into base of PTFE chamber 
7. Place PTFE mold top onto PTFE mold bottom 
8. Place a glass coverslip on top of PTFE mold top 
9. Place POM top of chamber onto assembly 
10. Place stainless steel base plate beneath assembly 
11. Place stainless steel top plate above assembly 
12. Place screws in holes on four corners of the chamber 
13. Use an Allen wrench to screw holes in place 
14. Tighten system 
15. Insert a 20G needle into the inlet hole of microfluidic chamber 
16. Insert a 20G needle into the outlet hole of microfluidic chamber 
17. Hit stop on timer 
18. Disassemble entire system 
19. Repeat steps 1 - 18 two more times 
20. Take the average of three trials 
 
Dimension Validation 
Objective: To ensure the manufacturing process is accurate and reproducible 
Materials:  
Microfluidic chamber components 
Microscope 
Ruler 
 
Procedure: 
1. *Take images of various components of the microfluidic chamber including: 
a. Indentation in POM chamber top for silicone gasket 
b. Silicone gasket 
c. PTFE mold indentation 
d. Screw hole in POM 
e. Top view of bottom part of microfluidic chamber 
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f. Side view of PTFE bottom part of microfluidic chamber 
g. Top view of POM top of microfluidic chamber 
h. Side view of POM top of microfluidic chamber 
i. Top view of Stainless Steel Top Plate 
j. Side view of Stainless Steel Top Plate 
k. Top view of Stainless Steel Bottom Plate 
l. Side view of Stainless Steel Bottom Plate 
m. Half of Simple Mold 
*take photo from top view unless otherwise noted 
1. For each measurement, make sure to measure it 3 times and to average the measurements 
2. For a, measure the diameter of the indentation in 3 different places 
3. For b, measure the diameter of the gasket in 3 different places 
4. For c, measure the diameter of the indentation in 5 different places 
5. For d, measure the diameter of the screw hole in 3 different places 
6. For e, measure the full PTFE chamber base length on the right, top, left, and bottom 
7. For e, also measure the PTFE chamber base pocket length on the right, top, left, and 
bottom 
8. For e, also measure the PTFE chamber base viewing window length on the right, top, left, 
and bottom 
9. For f, measure the PTFE chamber base height 
10. For g, measure the PTFE chamber top length on the right, top, left, and bottom 
11. For g, also measure the PTFE chamber top viewing window length on the right, top, left, 
and bottom 
12. For h, measure the POM chamber top height 
13. For i, measure the Stainless Steel top plate length on the right, top, left, and bottom 
14. For j, measure the height of the Stainless Steel top plate  
15. For k, measure the length of the Stainless Steel bottom plate 
16. For l, measure the height of the Stainless Steel bottom plate 
17. For m, measure the outer length of the PTFE mold on the right, top, left, and bottom 
18. For n, measure the length of the viewing window of the PTFE mold on the right, top, left, 
and bottom  
19. Ensure each set of similar measurements are averaged 
20. Compare average to the length that was desired before machining 
21. Calculate the error by subtracting the desired length from the average length 
22. Convert those values to percentages 
23. Calculate the standard deviation of the measurements 
 
Sterility Testing 
Objective: To ensure the microfluidic chamber can maintain a sterile environment of an 
extended time within incubator conditions 
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Materials:  
 
70% ethanol 
Microfluidic chamber  
Media 
Petri dish 
Microscope 
0.05% Methylene Blue 
Distilled water 
 
Procedure: 
1. Sterilize components of microfluidic chamber through ethanol submersion. Submerge in 
70% ethanol for 90 minutes 
2. Remove components from ethanol after 90 minutes 
3. Rinse with distilled water 3 times 
4. Assemble the microfluidic chamber while remaining inside the biosafety cabinet with 
needles attached 
5. Fill the chamber with media 
6. Place chamber into a Petri dish and cover with lid 
7. Transport Petri dish to incubator and let sit for 5 days 
8. Once the 5 days have passed, remove the Petri dish, disassemble the microfluidic 
chamber and remove the bottom coverslip  
9. Place coverslip under an upright bright - field microscope at 10x magnification 
10. Image for bacteria 
11. After imaging, place coverslip into a well and stained with 0.05% Methylene Blue 
12. After 1 minute, wash the coverslip 
13. Image washed coverslip under a microscope for bacteria 
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Appendix E: Final Design 
 
 
Figure 115: Exploded view of microfluidic chamber. a) Two Piece Mold, b) Glass coverslips, c) Chamber bottom, d) 
Chamber top, e) Stainless Steel top, f) Stainless Steel bottom, g) 4 - 40 screws 
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Figure 116: 2D drawing of one half of Two part Mold 
 
Figure 117: 2D drawing of chamber bottom 
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Figure 118: 2D drawing of chamber top 
 
Figure 119: 2D drawing of Stainless Steel top plate 
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Figure 120: 2D Drawing of Stainless Steel bottom plate 
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Microfluidic Chamber Parts List 
Table 38: Microfluidic chamber parts list 
Material Supplier Product Number Quantity Description 
PTFE McMaster-Carr 8545K1 1 sheet 6’’ x 6’’, 1/4’’ 
thick 
POM McMaster-Carr 8738K49 1 sheet 0.093’’ Thick, 
5ft 
Stainless Steel McMaster-Carr 9090K15 1 sheet 316 Stainless 
Steel, 2’’ x 12’’ 
Screws McMaster-Carr 91735A105 1 pkg. 316 Stainless 
Steel, 7/16’’ 
Length, 4 - 40 
Gasket McMaster-Carr 5233T19 1 pkg. 1mm wide, 11 
mm ID, Silicone 
Glass Coverslips Capitol Brand M3453 - 1818 1 Box. 18 x 18 mm #1 
Thickness 
 
